,Article,Date,Symbol,Time,Title,Url,compound,neg,neu,pos
0,"  Jan 22 Medical device maker St. Jude Medical Inc  reported a higher fourth-quarter profit on Wednesday, as it had expected, and forecast growth in both earnings and revenue in 2014.St. Jude said it expected 2014 revenue in the range of $5.6 billion to $5.75 billion, and earnings of $3.94 to $3.99 per share. That compares with sales of $5.5 billion and earnings excluding charges of $3.76 per share in 2013. For 2014, analysts had expected earnings of $3.98 per share and revenue of $5.64 billion, according to Thomson Reuters I/B/E/S. St. Jude said on Jan. 13 its fourth quarter had been better than expected and that it would report earnings of 97 cents to 99 cents per share, excluding restructuring costs and charges. Excluding special items, the company reported a profit of $294 million, or 99 cents per share, up from $285 million, or 92 cents a share, a year earlier.The company reported fourth-quarter revenue of $1.42 billion. Analysts had forecast adjusted earnings of 97 cents per share and revenue of $1.38 billion.",2014-01-22,STJ,"Wed Jan 22, 2014 | 7:59am EST",UPDATE 1-St. Jude forecasts 2014 growth in sales and revenue,http://www.reuters.com//article/stjude-results-idUSL2N0KW0IO20140122?type=companyNews,0.969,0.022,0.822,0.156
1,"  Jan 22 St. Jude Medical Inc on Wednesday reported a higher fourth-quarter profit, as it had indicated it would, and forecast growth in both earnings and revenue in 2014.St. Jude on Jan. 13 said that the fourth quarter had been better than expected and that it would report earnings of 97 cents to 99 cents per share, excluding restructuring costs and charges.  Excluding special items, the company reported a profit of $294 million, or 99 cents per share, up from $285 million, or 92 cents a share, a year earlier. ",2014-01-22,STJ,"Wed Jan 22, 2014 | 7:42am EST",St. Jude forecasts 2014 growth in sales and revenue,http://www.reuters.com//article/stjude-results-idUSL2N0KW0IG20140122?type=companyNews,0.9477,0.021,0.772,0.207
2,"  * Q4 op profit 1.01 bln euros vs avg forecast for 1.10 bln* Targets 900 mln euros in cost savings through 2015* Aims to raise dividend payout ratio this year and next* Proposes 0.43 euro dividend per share, just below forecasts* Shares down 0.9 percent   (Adds share price, CEO, analyst comments)By Johan Ahlander and Mia ShanleySTOCKHOLM, Jan 29 Nordea will double its target for cost savings as the Nordic region's biggest bank by market value braces for a prolonged period of weak lending, which had sent its fourth-quarter earnings below analyst forecasts.The bank, one of Europe's most strongly capitalised lenders, said the outlook for the region was uneven, with lukewarm growth in Finland and Denmark and a struggling housing market in Norway contrasting with a more dynamic recovery in Sweden. ""In general, the upswing in Europe is slow - it will not be financed very much by borrowing,"" CEO Christian Clausen said. ""We are adjusting to that, so we are taking out activity-related costs.""Clausen said consumers were starting to spend more, but that they were not borrowing more. Companies, he said, remained cautious on investments and employment.Nordea said it now aims to create 900 million euros in cost savings from 2013 to 2015, up from a previous 450 million euros.Nick Anderson, an analyst at Berenberg bank, said the plan looked aggressive. ""They have a very good track record of delivering, so delivery I wouldn't doubt. The interesting question to pose is: Will this impact revenues?"" he said.Credit Suisse said in a note that the bank's plan to lower its cost base by five percent by 2015 looked credible, saying it implied a 4-6 percent upgrade to earnings forecasts for 2015.Shares in Nordea fell 0.9 percent by 1152 GMT, underperforming a modestly higher blue-chip Stockholm index .Nordea's earnings follow weaker-than-expected results from Swedish rival Swedbank on Tuesday.  Handelsbanken and SEB report next week. Nordic banks have been busy strengthening their balance sheets, pulling out of riskier areas such as Poland and Russia in order to focus on core markets, and have benefited from far lower funding costs relative to peers.Strong public finances in Sweden - with a top-notch AAA investment rating - have made them especially attractive to investors seeking shelter as the debt crisis played out in Europe.Still, many investors who had hoped the well-capitalised banks would start returning more capital through special dividends, share buybacks or higher payout ratios may have to wait a bit longer.Regulatory uncertainty remains a concern, so banks are keen to retain high capital buffers as they wait on authorities to decide on countercyclical capital buffers and possibly higher risk weights for mortgages.Nordea laid the ground for higher dividends this year and next, but said the impact of tougher regulatory requirements was too uncertain for it to decide on its long-term target for returning capital to shareholders.It proposed a dividend of 0.43 euros per share for the year, up 26 percent from a year ago but just missing analyst forecasts.Nordea's operating profit for the fourth quarter was 1.01 billion euros ($1.38 billion) compared with a mean forecast for 1.10 billion seen in a Reuters poll of analysts and a year-ago 1.03 billion. ($1 = 0.7319 euros)   (Reporting by Mia Shanley and Johan Ahlander; editing by Niklas Pollard and Louise Heavens)",2014-01-29,STJ,"Wed Jan 29, 2014 | 6:59am EST",UPDATE 2-Nordea to double cost savings to cope with low growth,http://www.reuters.com//article/nordea-idUSL5N0L30CW20140129?type=companyNews,0.9244,0.073,0.829,0.098
3,"  (Repeats with no changes to text)STOCKHOLM Jan 29 Nordea NDA.ST, the Nordic region's biggest bank by market value, said on Wednesday it plans to accelerate its cost savings programme as its fourth-quarter operating profit landed below expectations.The bank also said it aimed to raise its dividend payout ratio this year and next. Operating profit for the period was 1.01 billion euros ($1.38 billion) compared with a mean forecast for 1.10 billion seen in a Reuters poll of analysts and a year-ago 1.03 billion. ""Since we foresee in the coming years a lower loan demand, lower customer activity and lower interest rates than previously expected, we will increase our focus on cost efficiency,"" CEO Christian Clausen said in a statement. The bank now aims to create 900 million euros in cost savings from 2013 to 2015, up from a previous 450 million euros. ($1 = 0.7319 euros)   (Reporting by Mia Shanley and Johan Ahlander)",2014-01-29,STJ,"Wed Jan 29, 2014 | 1:20am EST",RPT-Nordea speeds up cost savings plan as Q4 profits miss forecast,http://www.reuters.com//article/nordea-idUSWEA00DNQ20140129?type=companyNews,0.6249,0.077,0.827,0.096
4,"  STOCKHOLM Jan 29 Nordea NDA.ST, the Nordic region's biggest bank by market value, said on Wednesday it plans to accelerate its cost savings programme as its fourth-quarter operating profit landed below expectations.The bank also said it aimed to raise its dividend payout ratio this year and next. Operating profit for the period was 1.01 billion euros ($1.38 billion) compared with a mean forecast for 1.10 billion seen in a Reuters poll of analysts and a year-ago 1.03 billion. ""Since we foresee in the coming years a lower loan demand, lower customer activity and lower interest rates than previously expected, we will increase our focus on cost efficiency,"" CEO Christian Clausen said in a statement. The bank now aims to create 900 million euros in cost savings from 2013 to 2015, up from a previous 450 million euros. ($1 = 0.7319 euros)   (Reporting by Mia Shanley and Johan Ahlander)",2014-01-29,STJ,"Wed Jan 29, 2014 | 1:16am EST",Nordea speeds up cost savings plan as Q4 profits miss forecast,http://www.reuters.com//article/nordea-idUSS3N0FN01D20140129?type=companyNews,0.743,0.066,0.834,0.1
5,"  By Susan KellyFeb 4 Boston Scientific Corp on Tuesday reported higher-than-expected quarterly results, citing improving demand for its devices that manage irregular heart rhythms.But U.S. sales of implantable cardioverter defibrillators (ICDs), which shock dangerously fast heartbeats back to normal, were flat. Some analysts were looking for stronger sales of the important product after competitor St. Jude Medical Inc  reported positive sales growth last month.""There were some fits and starts in the quarter,"" said Jefferies analyst Raj Denhoy. ""The U.S. ICD business was particularly light.""Investors have anticipated a recovery in the market for heart rhythm products after several years of declining sales. The U.S. economic downturn had reduced demand for healthcare, and medical studies suggested the devices have been overused. Boston Scientific is also expected to benefit from the introduction of its S-ICD system. The ""lead wires"" in this new type of implantable defibrillator are threaded up the sternum rather than attached to the heart.Boston Scientific last year began to see growth in revenue, which had been falling for years, after the company embarked on a turnaround strategy involving cost cuts and restructuring efforts.In the fourth quarter, Boston Scientific's profit rose to $108 million, or 8 cents a share, from $60 million, or 4 cents a share, a year earlier. Excluding acquisition, divestiture, litigation and restructuring charges, earnings were 21 cents a share. Analysts on average had expected 13 cents, according to Thomson Reuters I/B/E/S.Sales rose 1 percent to $1.84 billion, while analysts had forecast $1.83 billion.Worldwide sales of cardiac rhythm management products, including pacemakers and ICDs, climbed 2 percent to $468 million in the fourth quarter. Sales of interventional cardiology products, primarily stents that are inserted into clogged heart arteries to help prop them open, fell 6 percent to $500 million.Boston Scientific forecast 2014 earnings of 75 cents to 80 cents a share, excluding special items, on revenue of $7.3 billion to $7.5 billion.Analysts on average were expecting a profit of 52 cents a share on revenue of $7.41 billion.Shares of Boston Scientific more than doubled last year on anticipation of a recovery in the heart rhythm device market and enthusiasm about the company's product pipeline.The stock was down 0.3 percent at $12.97 in midday trading on the New York Stock Exchange.",2014-02-04,STJ,"Tue Feb 4, 2014 | 12:02pm EST",UPDATE 2-Boston Scientific profit up as heart device demand improves,http://www.reuters.com//article/bostonscientific-results-idUSL2N0L90J020140204?type=companyNews,0.9803,0.042,0.842,0.116
6,"  SAN FRANCISCO STMicroelectronics (STM.PA) posted lower first-quarter revenue and a loss that narrowed after the European chipmaker exited its mobile joint venture with ST-Ericsson.Franco-Italian STMicro, whose chips are used in cars, computers and mobile phones, posted first-quarter revenue of $1.825 billion, down from $2.009 billion in the year-ago quarter.Six analysts polled by Reuters on average had expected first-quarter revenue of $1.836 billion.Its net loss in the first quarter shrank to $24 million from $171 million in the same quarter the year before. Its non-GAAP loss per share was 1 cent. Last year, STMicro and telecom network gear maker Ericsson ended their money-losing joint venture to make chips for mobile phones. Since then, STMicro has refocused on product lines for automobiles, video game consoles, and high-end smartphones, but that move has yet to pay off in terms of higher profits. Excluding legacy ST-Ericsson products, the chipmaker's revenue grew 1 percent in the quarter.The company said its total revenue in the second quarter would rise 2 percent compared to the first quarter. STMicro is the eighth-largest semiconductor maker by global sales but it has lost ground to rivals like Qualcomm (QCOM.O), Intel (INTC.O) and Samsung in recent years because of its higher cost base and difficulties suffered by Nokia, once its largest customer.(Reporting by Noel Randewich; Editing by Cynthia Osterman)",2014-04-28,STJ,"Mon Apr 28, 2014 | 5:24pm EDT","STMicro posts lower first-quarter revenue, smaller loss",http://www.reuters.com//article/us-stmicroelectron-results-idUSBREA3R1D420140428?type=companyNews,-0.7579,0.079,0.883,0.038
7,"  SAN FRANCISCO, April 28 STMicroelectronics  posted lower first-quarter revenue and a loss that narrowed after the European chipmaker exited its mobile joint venture with ST-Ericsson.Franco-Italian STMicro, whose chips are used in cars, computers and mobile phones, posted first-quarter revenue of $1.825 billion, down from $2.009 billion in the year-ago quarter.Six analysts polled by Reuters on average had expected first-quarter revenue of $1.836 billion. Its net loss in the first quarter shrank to $24 million from $171 million in the same quarter the year before. Its non-GAAP loss per share was 1 cent.Last year, STMicro and telecom network gear maker Ericsson ended their money-losing joint venture to make chips for mobile phones. Since then, STMicro has refocused on product lines for automobiles, video game consoles, and high-end smartphones, but that move has yet to pay off in terms of higher profits. Excluding legacy ST-Ericsson products, the chipmaker's revenue grew 1 percent in the quarter. The company said its total revenue in the second quarter would rise 2 percent compared to the first quarter.STMicro is the eighth-largest semiconductor maker by global sales but it has lost ground to rivals like Qualcomm, Intel and Samsung in recent years because of its higher cost base and difficulties suffered by Nokia, once its largest customer.   (Reporting by Noel Randewich; Editing by Cynthia Osterman)",2014-04-28,STJ,"Mon Apr 28, 2014 | 5:23pm EDT","STMicro posts lower first-quarter revenue, smaller loss",http://www.reuters.com//article/stmicroelectron-results-idUSL2N0NK1WS20140428?type=companyNews,-0.7579,0.079,0.883,0.038
8,"  (Adds Stryker, Vivus, Transcontinental, Orange, St. Jude Medical; Updates Weir, Valeant, General Electric)May 28 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** America Movil aims to hold only a slim majority of shares in Telekom Austria following a $2 billion takeover offer, its finance chief said on Wednesday.America Movil, which owns 27 percent of Telekom Austria, has offered to buy the shares not already owned by it or the Austrian state.** Transcontinental Inc will have to sell 34 community newspapers to complete a deal to buy 74 Quebecor Inc  Sun Media weeklies, Canada's Competition Bureau said in approving the transaction on Wednesday.**  U.S. medical devices manufacturer Stryker Corp  has denied any intention of making a bid for UK rival Smith & Nephew Plc, whose shares had spiked higher after a report that Stryker was planning a bid.**   Vivus Inc's biggest shareholder Aspen Investment Fund said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug.** France's largest telecom group Orange said on Thursday it would support a bid from technology services group Atos to buy rival Bull, in which it owns 8 percent.** Retail foreign exchange operator Travelex (IPO-TUL.L) said UAE Exchange owner B.R. Shetty and Abu Dhabi private equity house Centurion Investments would buy the company from shareholders including Chairman Lloyd Dorfman and Apax Partners. Terms of the deal were not disclosed.** St. Jude Medical Inc said on Wednesday it plans to exercise its option to buy the shares of CardioMEMS it does not already own for $375 million following news the Food and Drug Administration has approved CardioMEMS's wireless heart device.** The co-founder of investment bank Guggenheim Partners and its president are helping billionaire media executive David Geffen put together a group to bid on the Los Angeles Clippers professional basketball team.** Canadian drugmaker Valeant Pharmaceuticals International Inc  raised the cash component of its unsolicited offer for Botox-maker Allergan Inc, valuing the U.S. firm at $49.44 billion and ratcheting up pressure on the target company.Valeant may take its takeover bid for Allergan directly to the target company's shareholders, Valeant Chief Executive Michael Pearson said on Wednesday. ** Swiss food group Nestle stepped up its drive into the fast-growing skincare market, buying the rights to several treatments for facial lines and wrinkles from Valeant Pharmaceuticals International for $1.4 billion in cash.** A Koch Industries Inc unit will take PetroLogistics LP private in a deal worth $2.1 billion, including debt, gaining control of a plant that can convert cheap U.S. shale gas into propylene, a key petrochemical used to make plastics.** Stockland Corp Ltd, Australia's No. 2 property group, upped its offer for Australand Property Group to A$2.02 billion ($1.87 billion), a month after threatening to walk away if the target rejected its original bid.** Investment firm Strategic Value Partners (SVP) is making another attempt to sell German plastic packaging maker Kloeckner Pentaplast in a potential 1.5 billion euro ($2 billion) deal, two sources familiar with the matter said.** General Electric strengthened its position in the battle for the power arm of French group Alstom on Wednesday with a pledge to create new jobs in France and recognition from Paris that it had made a more acceptable offer.** German engineering group Siemens is in final stage talks to sell its 50 percent stake in a household goods joint venture to partner Robert Bosch, two sources familiar with the matter said. ** Petrochemicals company Westlake Chemical Corp  said it would buy Germany polyvinyl chloride (PVC) maker Vinnolit Holdings GmbH and its subsidiary companies for 490 million euros from private-equity firm Advent International.** Hikma Pharmaceuticals said it agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.** Li Ka-shing's Hutchison Whampoa Ltd  conglomerate said two companies controlled by the tycoon had teamed up to buy a Canadian off-airport car park operator for C$397.5 million ($366 million) as Asia's richest man continues to invest abroad.** China's Shanghai Prime Machinery Co Ltd (PMC)  will buy Dutch toolmaker Koninklijke Nedschroef Holding B.V. in a 325 million euro deal, the two firms said, as Chinese companies continue to expand their global footprints.** Swiss media group Tamedia has bowed out of a 468 million-franc ($521 million) takeover battle for Swiss advertising firm PubliGroupe, agreeing with rival bidder Swisscom to jointly take over PubliGroupe's directory business instead.**  Scottish engineering firm Weir Group abandoned efforts to acquire rival Metso after the Finnish company rejected a second, improved takeover bid. ** A unit of Chinese e-commerce giant Alibaba Group Holdings Ltd IPO-ALIB.N will buy a minority stake in Singapore Post Ltd  for S$312.5 million ($249 million), to help set up an international e-commerce logistics business.** Hong Kong-based Hutchison Whampoa gained European Union regulatory approval for its $1 billion bid for Telefonica's Irish business, in a case that could set the tone for Telefonica's bigger German deal.** Unfazed by the threat of further Western sanctions on Russia, commodity trader and mining company Glencore  has agreed to sign a new pre-payment deal with Ruspetro, a Russian oil and gas company operating in western Siberia. Energo Resurs, a subsidiary of London-listed Glencore, has agreed to pre-pay about 750 million roubles ($21.80 million) to Ruspetro, which in return is expected to supply about 1,680 barrels a day of crude for a year, Ruspetro said in a statement.** Lithuanian state-owned firms offered to buy the minority stakes in the country's gas utilities held by Russia's Gazprom  and others, reversing their privatization a decade ago.** A consortium led by Philippine conglomerate Ayala Corp  has submitted the lone bid to undertake a 64.9 billion peso ($1.5 billion) project to renovate and extend Manila's oldest elevated railway.** The owners of German online retailer Mytheresa, specializing in luxury fashion and accessories, have mandated Goldman Sachs to find a buyer, three people familiar with the matter told Reuters.** Germany's Trimet Aluminium said it purchased insolvent German aluminum producer Voerde Aluminium.** Permira is selling a 5.6 percent stake in Hugo Boss, the latest step by the private equity house to exit its investment in the German fashion retailer.($1 = 1.08 Australian dollars)($1 = 1.09 Canadian dollars)($1 = 0.74 euros)($1=0.9 Swiss francs)($1 = 34.41 Russian roubles)($1 = 1.26 Singapore dollars)   (Compiled by Natalie Grover and Shailaja Sharma in Bangalore)",2014-05-28,STJ,"Wed May 28, 2014 | 4:11pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0OE2A620140528?type=companyNews,0.9802,0.036,0.892,0.072
9,"  May 28 St. Jude Medical Inc said on Wednesday it plans to exercise its option to buy the shares of CardioMEMS it does not already own for $375 million following news the Food and Drug Administration has approved CardioMEMS's wireless heart device.The implantable device is designed for use in managing patients with heart failure. It records pulmonary artery pressure and transmits it to physicians, who can monitor it remotely and manage the condition.""FDA approval is in line with our expectation and a positive for St. Jude,"" Larry Biegelsen, an analyst at Wells Fargo Securities, said in a research note. He estimates CardioMEMS sales will reach $259 million annually by 2018.In September 2010, St. Jude paid $60 million for a 19 percent stake in CardioMEMS, with an exclusive option to buy the remaining 81 percent for $375 million. The company said it plans to exercise its option and expects to complete the acquisition in the second quarter of this year. St. Jude's shares rose 3.5 percent to $66.40 in afternoon trading on the New York Stock Exchange.Michael Weinstein, an analyst at J.P. Morgan, said CardioMEMs ""represents a key piece to the growth reacceleration story at St. Jude."" He added the CardioMEMS system ""has the chance to be one of the more meaningful technological advances in heart failure management in recent memory."" Heart failure occurs when the heart is unable to pump enough blood through the body to meet its demands, pushing up blood pressure in the heart. Increased pulmonary artery pressure can precede worsening heart failure. By being able to monitor a patient's pulmonary artery pressure remotely, physicians can manage a patients medications and reduce the likelihood of hospitalization.""The CardioMEMS HF System will not only improve the lives of patients but will also reduce the economic burden of this epidemic disease,"" Dr. Eric Fain, group president of St. Jude, said in a statement. ""We are delighted to have CardioMEMS become a part of St. Jude Medical.""Atlanta-based CardioMEMS was founded by Dr. Jay Yadav, a cardiologist and entrepreneur. Investors in the company include Arcapita Ventures, Boston Millennia Partners and Foundation Medical Partners.   (Reporting by Toni Clarke in Washington; Editing by Paul Simao)",2014-05-28,STJ,"Wed May 28, 2014 | 2:04pm EDT",St. Jude to acquire CardioMEMS following FDA approval of device,http://www.reuters.com//article/cardiome-pharma-st-jude-medical-idUSL1N0OE1I320140528?type=companyNews,0.1011,0.06,0.87,0.069
10,"  (Rewrites with analyst, fund manager comment on potential future deals)By Susan Kelly and Bill BerkrotJune 16 Medtronic Inc's $43 billion deal for Dublin-based Covidien Plc should accelerate already intense efforts by medical device rivals to seek merger partners, industry analysts and bankers said on Monday.Medtronic announced the transaction on Sunday, saying it would re-base the combined company in Ireland, where it can take advantage of lower corporate tax rates and easier access to cash generated overseas.The purchase also gives Medtronic more products, as well as  greater leverage in negotiating with hospital clients that are taking a much harder line on device spending.The intensified competition will bring new pressure on large device makers such as Abbott Laboratories, Stryker Corp  and St Jude Medical Inc to seek acquisitions, industry watchers say. Medtronic plus Covidien will rival industry leader Johnson & Johnson's $28.5 billion in annual device revenue.UK-based Smith & Nephew Plc, which has already attracted takeover interest from companies seeking better tax rates overseas, remains high on the list of targets, they said. Device makers such as  Boston Scientific Corp should feel more pressure to get bigger or face being left out in the cold.The merger mania is a product of pressures on the healthcare systems in the United States and in Europe, where hospitals are getting paid less to deliver care. U.S. hospital systems are consolidating and buying doctor practices to cope with the changes.""It becomes more necessary for the medical device companies to have a broader product line in order to be able compete and have economies of scale,"" said Len Yaffe, portfolio manager of the San Francisco-based healthcare fund StockDoc Partners. Medtronic said its own appetite for deals does not end with absorbing Covidien. It expects to use some of the additional cash flow from the deal on acquisitions and minority investments, and internal research and development.""There still are plenty of opportunities for us to focus on other acquisitions, other innovation. That momentum doesn't need to stop, even in this integration period,"" Medtronic Chief Financial Officer Gary Ellis said in a conference call with analysts.Medtronic has been especially eager to expand beyond selling devices to providing advisory services to hospitals.""To the degree we can bring in other acquisitions to support that further, we will look closely at that,"" Chief Executive Omar Ishrak said. EMULATING MEDTRONIC The latest consolidation wave in the medical device arena began in April when Zimmer Holdings Inc reached a deal to buy rival Biomet Inc for more than $13 billion, expanding its orthopedic product offerings.Rival orthopedics maker St Jude Medical ""could be an acquirer of a smaller company to emulate what Medtronic is doing,"" Yaffe said. Morningstar analyst Debbie Wang has Stryker atop her list of potential acquirers.""That company is a serial acquirer and CEO Kevin Lobo has indicated that it is trying to move the company in the direction of becoming a larger partner with its hospital customers, the same strategy that Johnson & Johnson and Medtronic are taking to heart,"" Wang said.Wang sees Edwards Lifesciences Corp as a target whose specialty in heart valves would fit in with a number of companies interested in cardiac products.Yaffe listed Hospira Inc, Becton Dickson and Co     , Baxter International Inc and Massimo Corp  as attractive takeover candidates that could help a larger company become more of a one-stop shop for hospitals.While several industry experts pointed to Boston Scientific as an acquirer, it could still be wary in the wake of its $27 billion purchase of Guidant in 2006. The deal left it heavily in debt and struggling with a depressed stock price for years.Medtronic is acquiring Covidien in a so-called inversion transaction that allows it to reincorporate in Ireland.Analysts said the strategy will give Medtronic access to cash generated through sales outside the United States and now held overseas without paying a penalty for repatriating the money. This benefit overshadows the modest reduction in the overall corporate tax rate that the company is forecasting.Medtronic also said Monday it would maintain its prior forecast for fiscal 2015 earnings in the range of $4 to $4.10 a share. Its shares were off 1.4 percent at $59.87, while those of Covidien were up 20.7 percent at $86.93.    (Reporting by Susan Kelly in Chicago and Bill Berkrot in New York; Additional reporting by Soyoung Kim in New York; Editing by Michele Gershberg, Nick Zieminski and Steve Orlofsky)",2014-06-16,STJ,"Mon Jun 16, 2014 | 5:04pm EDT",UPDATE 1-Medtronic's Covidien deal raises bar for rivals to merge,http://www.reuters.com//article/medtronic-inc-mergers-idUSL2N0OX18F20140616?type=companyNews,0.9913,0.023,0.889,0.088
11,"  St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California-based manufacturing plant have been resolved.The FDA last year had warned St. Jude of serious violations at the plant where the Durata and Riata leads for implantable defibrillators are made. Violations included a failure to validate testing methods. [ID:nL2N0D40KS]Implantable heart defibrillators are small devices that are placed in the chest to correct irregular heart beat. Durata and Riata leads are wires that connect this device to the heart.St. Jude first recalled Riata wires in 2011 after finding the insulation on them wore away prematurely. Last year, regulators questioned the design process for Durata leads. The company has also been losing market share to competitors Medtronic Inc and Boston Scientific Inc in selling implantable defibrillators due to lingering concerns about problems with its lead wires. [ID:nL2N0KN1CT] St. Jude sells pacemakers, implantable defibrillators, artificial heart valves, stents and neurological products. [ID:nBw22HsSja]The company's shares were little changed at $69.70 on the New York Stock Exchange on Wednesday morning.  (Reporting by Natalie Grover and Amrutha Penumudi in Bangalore; Editing by Joyjeet Das)",2014-07-02,STJ,"Wed Jul 2, 2014 | 10:20am EDT",FDA says manufacturing issues at St. Jude plant resolved,http://www.reuters.com//article/us-st-jude-medical-fda-idUSKBN0F71J120140702?type=companyNews,-0.9062,0.1,0.866,0.034
12,"  (Adds background)July 2 St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California-based manufacturing plant have been resolved.The FDA last year had warned St. Jude of serious violations at the plant where the Durata and Riata leads for implantable defibrillators are made. Violations included a failure to validate testing methods. Implantable heart defibrillators are small devices that are placed in the chest to correct irregular heart beat. Durata and Riata leads are wires that connect this device to the heart.St. Jude first recalled Riata wires in 2011 after finding the insulation on them wore away prematurely. Last year, regulators questioned the design process for Durata leads. The company has also been losing market share to competitors Medtronic Inc and Boston Scientific Inc in selling implantable defibrillators due to lingering concerns about problems with its lead wires. St. Jude sells pacemakers, implantable defibrillators, artificial heart valves, stents and neurological products.The company's shares were little changed at $69.70 on the New York Stock Exchange on Wednesday morning.   (Reporting by Natalie Grover and Amrutha Penumudi in Bangalore; Editing by Joyjeet Das)",2014-07-02,STJ,"Wed Jul 2, 2014 | 10:18am EDT",UPDATE 1-FDA says manufacturing issues at St. Jude plant resolved,http://www.reuters.com//article/st-jude-medical-fda-idUSL4N0PD3AG20140702?type=companyNews,-0.9062,0.1,0.866,0.034
13,"  July 2 St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California-based manufacturing plant have been resolved. The FDA last year had warned St. Jude of serious violations at the plant where the Durata and Riata leads for implantable defibrillators are made. Violations included a failure to validate testing methods.    (Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)  ",2014-07-02,STJ,"Wed Jul 2, 2014 | 8:49am EDT",FDA says manufacturing issues at St. Jude plant resolved,http://www.reuters.com//article/st-jude-medical-fda-idUSL4N0PD36M20140702?type=companyNews,-0.8519,0.172,0.775,0.053
14,"  (Corrects second paragraph to remove reference to ""Riata"" leads)July 2 St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California-based manufacturing plant have been resolved.The FDA last year had warned St. Jude of serious violations at the plant where the Durata leads for implantable defibrillators are made. Violations included a failure to validate testing methods. Implantable heart defibrillators are small devices that are placed in the chest to correct irregular heart beat. Durata and Riata leads are wires that connect this device to the heart.St. Jude first recalled Riata wires in 2011 after finding the insulation on them wore away prematurely. Last year, regulators questioned the design process for Durata leads. The company has also been losing market share to competitors Medtronic Inc and Boston Scientific Inc in selling implantable defibrillators due to lingering concerns about problems with its lead wires. St. Jude sells pacemakers, implantable defibrillators, artificial heart valves, stents and neurological products.The company's shares were little changed at $69.70 on the New York Stock Exchange on Wednesday morning.   (Reporting by Natalie Grover and Amrutha Penumudi in Bangalore; Editing by Joyjeet Das)",2014-07-03,STJ,"Thu Jul 3, 2014 | 5:52am EDT",CORRECTED-UPDATE 1-FDA says manufacturing issues at St. Jude plant resolved,http://www.reuters.com//article/st-jude-medical-fda-idUSL4N0PD3AG20140703?type=companyNews,-0.9062,0.098,0.869,0.033
15,"  (Corrects second paragraph to remove reference to ""Riata"" leads)July 2 St. Jude Medical Inc said the U.S. Food and Drug Administration notified the company that issues regarding its Sylmar, California-based manufacturing plant have been resolved.  The FDA last year had warned St. Jude of serious violations at the plant where the Durata leads implantable defibrillators are made. Violations included a failure to validate testing methods.    (Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das) ",2014-07-03,STJ,"Thu Jul 3, 2014 | 5:51am EDT",CORRECTED-FDA says manufacturing issues at St. Jude plant resolved,http://www.reuters.com//article/st-jude-medical-fda-idUSL4N0PD36M20140703?type=companyNews,-0.8519,0.161,0.789,0.05
16,"   By Bill Berkrot  Heart device maker St. Jude Medical Inc STJ.N said it has no plans to jump on the consolidation bandwagon that has swept the healthcare sector in recent months and is not seeking the type of ""inversion"" deal increasingly popular among U.S. companies seeking to lower taxes by re-basing abroad.In the most recent such deal in the medical device sector, Medtronic Inc MDT.N last month agreed to buy Covidien COV.N for $43 billion. The move will allow Medtronic to re-domicile to Ireland to take advantage of low corporate tax rates and to access cash overseas without having to pay high repatriation costs.St. Jude's chief financial officer, Don Zurbay, said on Wednesday the company was open to deals if they fit with the therapeutic areas that are its focus, such as cardiac care. But a tax inversion strategy is not a priority.""It really would have to be a deal that's highly strategic first, and if those benefits happen to be a part of it, that's great. But for us, we don't really feel the need,"" Zurbay said in a telephone interview, following the company's release of slightly better-than-expected quarterly results.""We have a very low tax rate to begin with, so in our situation I don't think the benefits would be there on the tax side,"" he said.""We've had good success in getting access to most of our cash over time, so for us it really hasn't been a big topic,"" he added. Medtronic and other companies that have recently announced mergers have also cited a desire to get bigger in order to offer a wider array of products to hospital customers looking to cut costs and the number of vendors with which they do business.Zurbay said St. Jude has no great desire to do a major acquisition simply to get bigger.St. Jude has been mentioned by some investors as a potential takeover target by others looking to grow. The company reported higher quarterly earnings and revenue, largely due to increased sales of its devices to treat abnormal heart rhythms.Sales of implantable cardioverter defibrillators and pacemakers, St. Jude's biggest product category, rose 2 percent to $733 million in the second quarter ended June 28. (Full Story)""The market itself has been flat,"" Zurbay said. ""Our growth has come mostly from market share gains."" St. Jude, which competes against Medtronic and Boston Scientific Inc BSX.N in the space, raised its full-year adjusted earnings per share forecast range by a cent to $3.96 to $4.01.The company is targeting mid-to-high single-digit sales growth in 2015, fueled by the introduction of new products.Excluding special items and including a tax benefit, adjusted earnings for the quarter were $1.02 per share, topping analysts' average expectations by 2 cents, according to Thomson Reuters I/B/E/S. Revenue rose 3 percent to $1.45 billion, edging past Wall Street estimates of $1.44 billion.St. Jude Medical shares were down 0.4 percent at $67.98 on the New York Stock Exchange. (Additional reporting by Shailesh Kuber in Bangalore; Editing by Sriraj Kalluvila and Leslie Adler)",2014-07-16,STJ,"Wed Jul 16, 2014 | 3:47pm EDT",St. Jude not keen to join inversion deal craze,http://www.reuters.com//article/us-stjude-medical-results-idUSKBN0FL2IA20140716?type=companyNews,0.9936,0.024,0.85,0.126
17,"  (Recasts with CFO interview)By Bill BerkrotJuly 16 Heart device maker St. Jude Medical Inc  said it has no plans to jump on the consolidation bandwagon that has swept the  healthcare sector in recent months and is not seeking the type of ""inversion"" deal increasingly popular among U.S. companies seeking to lower taxes by re-basing abroad.In the most recent such deal in the medical device sector,   Medtronic Inc last month agreed to buy Covidien  for $43 billion. The move will allow Medtronic to re-domicile to Ireland to take advantage of low corporate tax rates and to access cash overseas without having to pay high repatriation costs.St. Jude's chief financial officer, Don Zurbay, said on Wednesday the company was open to deals if they fit with the therapeutic areas that are its focus, such as cardiac care. But a tax inversion strategy is not a priority.""It really would have to be a deal that's highly strategic first, and if those benefits happen to be a part of it, that's great. But for us, we don't really feel the need,"" Zurbay said in a telephone interview, following the company's release of slightly better-than-expected quarterly results.""We have a very low tax rate to begin with, so in our situation I don't think the benefits would be there on the tax side,"" he said. ""We've had good success in getting access to most of our cash over time, so for us it really hasn't been a big topic,"" he added.Medtronic and other companies that have recently announced mergers have also cited a desire to get bigger in order to offer a wider array of products to hospital customers looking to cut costs and the number of vendors with which they do business.Zurbay said St. Jude has no great desire to do a major acquisition simply to get bigger. St. Jude has been mentioned by some investors as a potential takeover target by others looking to grow.The company reported higher quarterly earnings and revenue, largely due to increased sales of its devices to treat abnormal heart rhythms.Sales of implantable cardioverter defibrillators and pacemakers, St. Jude's biggest product category, rose 2 percent to $733 million in the second quarter ended June 28. ""The market itself has been flat,"" Zurbay said. ""Our growth has come mostly from market share gains.""St. Jude, which competes against Medtronic and Boston Scientific Inc in the space, raised its full-year adjusted earnings per share forecast range by a cent to $3.96 to $4.01.The company is targeting mid-to-high single-digit sales growth in 2015, fueled by the introduction of new products.Excluding special items and including a tax benefit, adjusted earnings for the quarter were $1.02 per share, topping analysts' average expectations by 2 cents, according to Thomson Reuters I/B/E/S. Revenue rose 3 percent to $1.45 billion, edging past Wall Street estimates of $1.44 billion.St. Jude Medical shares were down 0.4 percent at $67.98 on the New York Stock Exchange.   (Additional reporting by Shailesh Kuber in Bangalore; Editing by Sriraj Kalluvila and Leslie Adler)",2014-07-16,STJ,"Wed Jul 16, 2014 | 3:39pm EDT",UPDATE 2-St. Jude not keen to join inversion deal craze,http://www.reuters.com//article/st-jude-medical-results-idUSL4N0PR4HS20140716?type=companyNews,0.9936,0.024,0.849,0.127
18,"  July 16 Heart device maker St. Jude Medical Inc  reported a quarterly net profit that more than doubled as expenses fell.Net earnings attributable to St. Jude rose to $270 million, or 93 cents per share, in the second quarter ended June 28, from $115 million, or 40 cents per share, a year earlier. Net sales rose 3 percent to $1.45 billion. The company said ""other expenses"" fell to $21 million in the latest quarter from $183 million. Excluding special items and including the benefit of an R&D tax credit adjustment, adjusted earnings were $1.02 per share. On that basis, analysts on average had expected $1.00 per share, according to Thomson Reuters I/B/E/S.   (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)",2014-07-16,STJ,"Wed Jul 16, 2014 | 8:42am EDT",St Jude Medical's quarterly profit doubles as expenses fall,http://www.reuters.com//article/st-jude-medical-results-idUSL4N0PR3U120140716?type=companyNews,0.9517,0.0,0.845,0.155
19,"  (The following statement was released by the rating agency) CHICAGO, August 20 (Fitch) Fitch Ratings has affirmed St. Jude Medical, Inc.'s  (STJ) Issuer Default Rating (IDR) at 'A' with a Stable Rating Outlook. Fitch has  also affirmed the company's short-term IDR at 'F1'. A full list of Fitch's  rating actions is available at the end of this release. The ratings apply to approximately $4.21 billion of debt outstanding as of June  28, 2014. KEY RATING DRIVERS Fitch's rating actions reflect the following: --Fitch expects leverage (total debt/EBITDA) of 2.4 times (x) at June 28, 2014  to decline to 1.4x-1.5x during the next 12 - 18 months. --The stabilizing domestic cardiac rhythm management (CRM) market, new product  introductions and emerging market strength support an expectation of low- to  mid-single-digit revenue growth during 2014 and 2015. --Fitch believes STJ's focus on cost control and improving its sales mix will  partially offset the negative effect that pricing and excise taxes will have on  margins.  --Moderate sales growth and modestly pressured margins should drive 2014 free  cash flow (FCF) of $750 million to $850 million. --Fitch expects STJ will balance acquisitions, share repurchases and dividends  with a credit profile supportive of an 'A' rating. --STJ is anticipated to maintain adequate liquidity through cash balances,  reliably positive FCF and ready access to the credit markets. HIGH LEVERAGE TO DECLINE Fitch expects STJ will decrease leverage to 1.4x-1.5x during the next 12 - 18  months through increased EBITDA and meaningful debt reduction. Continued  improving operational performance should provide for EBITDA growth as well as  increased cash generation. Current leverage of approximately 2.4x is largely the  result of acquisitions and to a lesser extent share repurchases. REVENUE GROWTH EXPECTED IN ALL BUSINESS SEGMENTS Fitch expects STJ to generate low- to mid-single-digit revenue growth during the  next 12-24 months. New product introductions, expansion into faster growing  product- and geographic markets, stabilization of the cardiac rhythm market and  two favorable facilities re-inspections by the FDA should more than offset the  negative effect of a weak domestic economic environment and the relatively  austere European markets. STJ has recently launched, or expects to launch in the near term, devices in all  four of its business segments [Cardiac Rhythm Management (CRM), Atrial  Fibrillation (AF), Cardiovascular (CV) and Neuromodulation (NM)]. A number of  these are differentiated by their clinical effectiveness and safety profiles, as  well as by the ability to reduce medical costs compared to competing devices.  Fitch believes the company's new product development and commercialization  efforts will continue to support favorable pricing and potentially incremental  market share gains. While markets outside of the three developed markets of U.S., Europe and Japan  account for only 16% of total firm sales in 2013, their contribution has  increased from roughly 13% in 2011. STJ's annual growth rate in the three  developed markets from 2011 to 2013 was a negative 2%, compared to a growth rate  of 6% for its other markets. Fitch expects positive growth rates to return to  the developed markets; however, growth in the other markets will likely continue  to outperform the developed markets.  CRM demand has somewhat stabilized despite a continued a weak employment  environment, and STJ's recently introduced quadripolar leads have enabled the  company to capture share. The negative effect on volumes from a January 2011  Journal of the American Medical Association (JAMA) article suggesting the  implantable cardioverter defibrillators (ICDs) are overused has likely run its  course. MARGIN HEADWINDS PARTIALLY OFFSET BY COST CONTROL AND MIX Fitch forecasts incrementally stressed margins for STJ, given a number of  persistent headwinds. While STJ margins have remained relatively strong, owing  to mix shift to newer, higher margin devices and its ongoing focus on cost  control, a more challenging hospital reimbursement environment and the ACA  excise tax should modestly offset the supporting trends. Longer term, Fitch  expects that the company will incrementally improve its margins through  continued gains in efficiency and favorable mix shifts (product and geographic).  RELIABLE FCF Fitch believes that increasing revenue with modestly pressured margins will  result in STJ generating $750 million - $850 million of annual FCF (cash flow  from operations minus capital expenditures of roughly $230 million and dividends  of roughly $300 million) during the next two years. Cash generation should be  sufficient to fund targeted acquisitions and moderate share repurchases.  TARGETED ACQUISITIONS AND SHARE REPURCHASES LIKELY Fitch believes that STJ will remain acquisitive, focusing on companies or device  platforms that offer innovation and growth, as technological advancement in the  device sector is still relatively fragmented. Share repurchases will likely  continue, especially in the absence of viable acquisition targets. The company's  recently instituted cash dividend may moderate the level of share repurchases.  Fitch expects STJ will balance its transactions within the context of  maintaining a credit profile supportive of its 'A' ratings. PLANO AND SYLMAR FACILITIES APPROVED TO PRODUCE NEW DEVICES STJ has allayed concerns regarding device production  for its CRM and NM business. During the past few months, the company has  resolved the manufacturing issues that have slowed new product approvals at two  of its facilities in Sylmar, CA and Plano, TX. The FDA has greenlighted both  facilities to produce new devices following recent re-inspections. The Sylmar  facility manufactures CRM devices, such as Durata and Optim, while the Plano  facility makes NM devices. ADEQUATE LIQUIDITY ANTICIPATED At June 28, 2014, STJ had adequate liquidity, comprised of approximately $1.58  billion in cash plus short-term marketable securities and roughly $114 million  (net of $1,336 million commercial paper borrowings) in availability on its $1.5  billion bank revolving credit facility, which expires in May 2018. STJ generated  approximately $641 million in FCF (net of $196 million of capital expenditures  and $292 million of dividends) during latest 12 months (LTM), ended June 30,  2014.  The company had approximately $4.2 billion in debt with (excluding $1,336  million in commercial paper outstanding) approximately $64 million maturing in  2014, $500 million in 2015, $500 million in 2016 and $1,805 million thereafter.  Fitch expects the vast majority of STJ's maturities will be refinanced with its  ample access to credit markets. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: --Fitch does not anticipate an upgrade in the near to intermediate term.  --However, STJ would need to commit to and operate with leverage stronger than  1.3x-1.4x while maintaining relatively stable operations and solid FCF, in order  for Fitch to consider a positive rating action. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Debt sustained above 1.6x-1.7x EBITDA without the prospect for timely  deleveraging.  --This could result from a scenario in which revenue and margins are  significantly stressed (more than Fitch anticipates); resulting FCF weakens; and  capital deployment not being adjusted to reduce the company's need for debt  financing.  --As such, significant debt-financed share repurchases or acquisitions in the  near term would likely prompt a negative rating action, given the limited  flexibility associated with the company's current leverage. RATING ACTIONS Fitch has affirmed STJ's ratings as follows: --IDR at 'A'; --Senior unsecured bank debt at 'A'; --Senior unsecured debt at 'A';  --Short-term IDR at 'F1'; --Commercial paper at 'F1'. The Rating Outlook is Stable. Contact: Primary Analyst Bob Kirby Director  +1-312-368-3147  Fitch Ratings, Inc. 70 W. Madison St. Chicago, IL 60602 Secondary Analyst Megan Neuburger Senior Director  +1-212-908-0501 Committee Chairperson Michael Weaver Managing Director +1-312-368-3156 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research:  --'Corporate Rating Methodology' (May 28, 2014). Applicable Criteria and Related Research:  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-08-20,STJ,"Wed Aug 20, 2014 | 11:54am EDT",Fitch Affirms St. Jude Medical's at 'A'; Outlook Stable,http://www.reuters.com//article/fitch-affirms-st-jude-medicals-at-a-outl-idUSFit72789920140820?type=companyNews,0.9989,0.048,0.816,0.135
20,"   By Bill Berkrot  Heart device maker St. Jude Medical Inc (STJ.N) on Wednesday forecast fourth-quarter revenue below Wall Street estimates, citing soft international sales and unfavorable foreign exchange rates, and its shares fell nearly 4 percent.The maker of pacemakers, implantable defibrillators, replacement heart valves and neurological products said it expects fourth-quarter adjusted profit of $1.02 to $1.04 per share and revenue of $1.39 billion to $1.47 billion.Analysts on average were expecting $1.04 per share on revenue of $1.49 billion, according to Thomson Reuters I/B/E/S.For the full year, the company now expects adjusted earnings of $3.97 to $3.99 per share and revenue of $5.57 billion to $5.65 billion versus its prior forecast of $3.96 to $4.01 per share and $5.60 billion to $5.76 billion.Chief Financial Officer Don Zurbay said strengthening of the dollar in September against the euro EUR= and the yen JPY=, and anticipation that that would continue, was half the reason for taking down its forecast.""The other half was market weakness outside the U.S.,"" Zurbay said in a telephone interview. ""Because of that, we decided to take a cautious approach and bring down Q4 to reflect the same dynamic recurring in the fourth quarter.""  St. Jude said 51 percent of sales came from international markets. A stronger dollar .DXY hurts overseas sales.International sales grew 2 percent to $706 million in the third quarter ended Sept. 27, said the company, which competes with Medtronic Inc (MDT.N) and Boston Scientific Inc (BSX.N).International sales of devices to treat abnormal heart rhythms dipped 2 percent, offsetting 3 percent growth in U.S. sales of pacemakers and implantable defibrillators. ""Sales growth in our international markets was slower than expected,"" Chief Executive Officer Daniel Starks said.One bright spot was sales of products to treat atrial fibrillation, which rose 8 percent from the year-ago quarter to $253 million, fueled by 12 percent growth outside the United States.Total sales increased 3 percent to $1.37 billion, just below the $1.38 billion analysts expected. Third-quarter results were hurt in part by a suspension of sales of the Portico heart valve replacement system while the company investigated a potential problem with part of the valve. The company determined a redesign was not necessary and Portico sales will resume in the current quarter.""The resumption of Portico implants is encouraging,"" Sanford Bernstein analyst Derrick Sung said in a research note. However, he added, ""the ability for St. Jude to accelerate top-line growth to the mid-to-high single digits has now come into question.""Excluding items, the company earned $281 million, or 97 cents per share, edging past analysts' estimates by 1 cent, according to Thomson Reuters I/B/E/S.St. Jude shares were down $2.39, or just under 4 percent, at $57.52 on the New York Stock Exchange. (Additional reporting by Ankur Banerjee and Natalie Grover in Bangalore; Editing by Joyjeet Das and James Dalgleish)",2014-10-15,STJ,"Wed Oct 15, 2014 | 1:14pm EDT",St. Jude Medical lowers forecast; shares fall,http://www.reuters.com//article/us-st-jude-medical-results-idUSKCN0I41AW20141015?type=companyNews,0.9882,0.027,0.859,0.114
21,"  (Adds CFO, analyst comment, full-year forecast; updates shares)By Bill BerkrotOct 15 Heart device maker St. Jude Medical Inc  on Wednesday forecast fourth-quarter revenue below Wall Street estimates, citing soft international sales and unfavorable foreign exchange rates, and its shares fell nearly 4 percent.The maker of pacemakers, implantable defibrillators, replacement heart valves and neurological products said it expects fourth-quarter adjusted profit of $1.02 to $1.04 per share and revenue of $1.39 billion to $1.47 billion.Analysts on average were expecting $1.04 per share on revenue of $1.49 billion, according to Thomson Reuters I/B/E/S.For the full year, the company now expects adjusted earnings of $3.97 to $3.99 per share and revenue of $5.57 billion to $5.65 billion versus its prior forecast of $3.96 to $4.01 per share and $5.60 billion to $5.76 billion.Chief Financial Officer Don Zurbay said strengthening of the dollar in September against the euro and the yen, and anticipation that that would continue, was half the reason for taking down its forecast. ""The other half was market weakness outside the U.S.,"" Zurbay said in a telephone interview. ""Because of that, we decided to take a cautious approach and bring down Q4 to reflect the same dynamic recurring in the fourth quarter.""St. Jude said 51 percent of sales came from international markets. A stronger dollar hurts overseas sales.International sales grew 2 percent to $706 million in the third quarter ended Sept. 27, said the company, which competes with Medtronic Inc and Boston Scientific Inc. International sales of devices to treat abnormal heart rhythms dipped 2 percent, offsetting 3 percent growth in U.S. sales of pacemakers and implantable defibrillators.""Sales growth in our international markets was slower than expected,"" Chief Executive Officer Daniel Starks said.One bright spot was sales of products to treat atrial fibrillation, which rose 8 percent from the year-ago quarter to $253 million, fueled by 12 percent growth outside the United States. Total sales increased 3 percent to $1.37 billion, just below the $1.38 billion analysts expected.Third-quarter results were hurt in part by a suspension of sales of the Portico heart valve replacement system while the company investigated a potential problem with part of the valve. The company determined a redesign was not necessary and Portico sales will resume in the current quarter.""The resumption of Portico implants is encouraging,"" Sanford Bernstein analyst Derrick Sung said in a research note. However, he added, ""the ability for St. Jude to accelerate top-line growth to the mid-to-high single digits has now come into question.""Excluding items, the company earned $281 million, or 97 cents per share, edging past analysts' estimates by 1 cent, according to Thomson Reuters I/B/E/S.St. Jude shares were down $2.39, or just under 4 percent, at $57.52 on the New York Stock Exchange.   (Additional reporting by Ankur Banerjee and Natalie Grover in Bangalore; Editing by Joyjeet Das and James Dalgleish)",2014-10-15,STJ,"Wed Oct 15, 2014 | 1:07pm EDT",UPDATE 2-St. Jude Medical lowers forecast; shares fall,http://www.reuters.com//article/st-jude-medical-results-idUSL3N0SA4O820141015?type=companyNews,0.9882,0.027,0.859,0.114
22,"  Oct 15 Heart device maker St. Jude Medical Inc  reported a lower quarterly profit, as it took a $39 million charge related to impairment and restructuring, despite a rise in sales of its devices to treat abnormal heart rhythms.Net profit fell to $238 million, or 82 cents per share, for the third quarter ended Sept. 27 from $262 million, or 91 cents per share, a year earlier. On an adjusted basis, it earned $281 million, or 97 cents per share. Revenue rose 3 percent to $1.37 billion. Sales of implantable cardioverter defibrillators and pacemakers, St. Jude's biggest product category, rose 1 percent to $688 million.   (Reporting by Ankur Banerjee in Bangalore)",2014-10-15,STJ,"Wed Oct 15, 2014 | 7:49am EDT",St.Jude Medical adjusted profit rises,http://www.reuters.com//article/st-jude-medical-results-idUSL3N0SA4MB20141015?type=companyNews,0.8979,0.019,0.85,0.131
23,"  (Corrects low end of pvs revenue forecast and U.S. pacemaker and defibrillator growth in 4th and 9th paragraphs)By Bill BerkrotOct 15 Heart device maker St. Jude Medical Inc  on Wednesday forecast fourth-quarter revenue below Wall Street estimates, citing soft international sales and unfavorable foreign exchange rates, and its shares fell nearly 4 percent.The maker of pacemakers, implantable defibrillators, replacement heart valves and neurological products said it expects fourth-quarter adjusted profit of $1.02 to $1.04 per share and revenue of $1.39 billion to $1.47 billion.Analysts on average were expecting $1.04 per share on revenue of $1.49 billion, according to Thomson Reuters I/B/E/S.For the full year, the company now expects adjusted earnings of $3.97 to $3.99 per share and revenue of $5.57 billion to $5.65 billion versus its prior forecast of $3.96 to $4.01 per share and $5.64 billion to $5.76 billion.Chief Financial Officer Don Zurbay said strengthening of the dollar in September against the euro and the yen, and anticipation that that would continue, was half the reason for taking down its forecast. ""The other half was market weakness outside the U.S.,"" Zurbay said in a telephone interview. ""Because of that, we decided to take a cautious approach and bring down Q4 to reflect the same dynamic recurring in the fourth quarter.""St. Jude said 51 percent of sales came from international markets. A stronger dollar hurts overseas sales.International sales grew 2 percent to $706 million in the third quarter ended Sept. 27, said the company, which competes with Medtronic Inc and Boston Scientific Inc. International sales of devices to treat abnormal heart rhythms dipped 2 percent, offsetting 4 percent growth in U.S. sales of pacemakers and implantable defibrillators.""Sales growth in our international markets was slower than expected,"" Chief Executive Officer Daniel Starks said.One bright spot was sales of products to treat atrial fibrillation, which rose 8 percent from the year-ago quarter to $253 million, fueled by 12 percent growth outside the United States. Total sales increased 3 percent to $1.37 billion, just below the $1.38 billion analysts expected.Third-quarter results were hurt in part by a suspension of sales of the Portico heart valve replacement system while the company investigated a potential problem with part of the valve. The company determined a redesign was not necessary and Portico sales will resume in the current quarter.""The resumption of Portico implants is encouraging,"" Sanford Bernstein analyst Derrick Sung said in a research note. However, he added, ""the ability for St. Jude to accelerate top-line growth to the mid-to-high single digits has now come into question.""Excluding items, the company earned $281 million, or 97 cents per share, edging past analysts' estimates by 1 cent, according to Thomson Reuters I/B/E/S.St. Jude shares were down $2.39, or just under 4 percent, at $57.52 on the New York Stock Exchange.   (Additional reporting by Ankur Banerjee and Natalie Grover in Bangalore; Editing by Joyjeet Das and James Dalgleish)",2014-10-16,STJ,"Thu Oct 16, 2014 | 4:00pm EDT",CORRECTED-UPDATE 2-St. Jude Medical lowers forecast; shares fall,http://www.reuters.com//article/st-jude-medical-results-idUSL3N0SA4O820141016?type=companyNews,0.9887,0.03,0.853,0.116
24,"  The U.S. Food and Drug Administration said it approved a brain implant from St. Jude Medical Inc that helps reduce symptoms of Parkinson's disease and essential tremor, a neurological disorder that causes rhythmic shaking.The device, Brio Neurostimulation System, is an implantable small generator that delivers low intensity electrical pulses to target areas in the brain. (1.usa.gov/1Bc5ptq)The device can be used when medication alone may not provide adequate relief from symptoms such as walking difficulties, balance problems, and tremors associated with the two movement disorders, the FDA said on Friday.There are no cures for Parkinson's disease or essential tremor, and thus finding better ways to manage symptoms is essential for patients. The implant is the second device approved for the indication after Medtronic Plc's Activa Deep Brain Stimulation Therapy System. About 50,000 Americans are affected by Parkinson's each year, according to the National Institutes of Health. St. Jude's shares closed at $74.34 on the New York Stock Exchange on Friday.  (Reporting by Anjali Rao Koppala in Bengaluru)",2015-06-12,STJ,"Fri Jun 12, 2015 | 6:25pm EDT",FDA approves St. Jude's brain implant for Parkinson's disease,http://www.reuters.com//article/us-st-jude-medical-inc-fda-idUSKBN0OS2G220150612?type=companyNews,-0.5299,0.108,0.82,0.073
25,"  June 12 The U.S. Food and Drug Administration said it approved a brain implant from St. Jude Medical Inc  that helps reduce symptoms of Parkinson's disease and essential tremor, a neurological disorder that causes rhythmic shaking.The device, Brio Neurostimulation System, is an implantable small generator that delivers low intensity electrical pulses to target areas in the brain. (1.usa.gov/1Bc5ptq)The device can be used when medication alone may not provide adequate relief from symptoms such as walking difficulties, balance problems, and tremors associated with the two movement disorders, the FDA said on Friday. There are no cures for Parkinson's disease or essential tremor, and thus finding better ways to manage symptoms is essential for patients. The implant is the second device approved for the indication after Medtronic Plc's Activa Deep Brain Stimulation Therapy System. About 50,000 Americans are affected by Parkinson's each year, according to the National Institutes of Health.St. Jude's shares closed at $74.34 on the New York Stock Exchange on Friday.   (Reporting by Anjali Rao Koppala in Bengaluru)",2015-06-12,STJ,"Fri Jun 12, 2015 | 6:24pm EDT",FDA approves St. Jude's brain implant for Parkinson's disease,http://www.reuters.com//article/stjude-medical-inc-fda-idUSL3N0YY58J20150612?type=companyNews,-0.5299,0.107,0.822,0.072
26,"  (Adds Nokia, Advtech, Conwert, St. Jude Medical, K+S; Updates Horizon)July 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:** Gaming and Leisure Properties Inc, which leases real estate to casino operators, said it would buy Pinnacle Entertainment Inc 's real estate assets in a deal that gives the assets an enterprise value of $4.75 billion.** French food group Bonduelle SCA is in discussions to team up with Centerview Partners in a bid to acquire General Mills Inc's Green Giant frozen and canned vegetable business, according to people familiar with the matter.** Germany's premium car makers are close to a deal to buy Nokia's HERE map business for between 2.5 billion and 3 billion euros ($2.74 billion to $3.29 billion), but a final agreement hinges on the question of who owns the patents that help self-driving cars talk to mobile networks, two sources familiar with the deal told Reuters.** The European Bank for Reconstruction and Development (EBRD) said it had bought into Polish media group Cyfrowy Polsat's 1 billion zloty ($265 million) bond issue.** South African private education group Advtech  rejected a takeover offer from bigger rival Curro Holdings , saying the proposal contained ""unacceptable pre-conditions"".** Austrian property company Conwert is in exclusive talks to buy German residential property group BGP, it said.** Heart device maker St. Jude Medical Inc is in talks to buy smaller rival Thoratec Corp, Bloomberg reported, citing sources familiar with the matter.** Salt and fertilizer group K+S has rejected a new attempt by Canada's Potash Corp to entice the German company into takeover talks, a K+S spokesman said. ** Qualcomm Inc is expected to conduct a strategic review that may result in the breakup of the company, among other options, the Wall Street Journal reported on Monday, citing sources.** Banco Bradesco SA, Brazil's No. 2 private-sector bank, late on Monday began exclusive talks to acquire HSBC Holdings Plc's Brazilian unit, according to a person with direct knowledge of the transaction.The bid values HSBC Bank Brasil Banco Mltiplo at about 12 billion reais ($3.75 billion), the source added.** Ireland-based Horizon Pharma Plc raised its offer to buy Depomed Inc for the second time in two months, pushing ahead with its hostile bid, now worth $1.97 billion, for the smaller drugmaker.** Online gambling firm GVC Holdings Plc could make another attempt to buy peer Bwin.party Digital Entertainment Plc , just days after Bwin accepted a 900 million pound ($1.4 billion) offer from 888 Holdings Plc. ** PetroVietnam Gas, Vietnam's second-largest listed firm by market value, said it is seeking permission from its parent to reduce the state's shareholdings to 65 percent from 96.7 percent by year-end.** Australia's Treasury Wine Estates Ltd, the world's biggest listed standalone wine firm, said it will sell its Asti Winery, Souverain brand and vineyard assets in California to E.& J. Gallo Winery.** South Korea, which has failed in four attempts to sell its controlling stake in Woori Bank, the country's second-largest lender, said it plans to sell around 30-40 percent in several blocks ranging from 4 percent to 10 percent each.** Bermuda-based reinsurer PartnerRe Ltd said it would seek talks with Exor SpA to discuss the Italian holding company's latest takeover offer, the sixth since it began a bidding war with Axis Capital Holdings Ltd in April. ** NMC Health Plc, the London-listed and United Arab Emirates-based healthcare provider, plans to invest in Saudi Arabia and Qatar part of the $325 million which it has available for acquisitions, a senior company official said.** A unit of private equity firm Warburg Pincus LLC  will invest $284 million for a minority stake in India's Piramal Realty, the Mumbai-based real estate developer said in a statement on Tuesday.** Cairn India Ltd Chief Executive Mayank Ashar said on Tuesday the firm's proposed buyout by parent Vedanta Ltd  was ""on track"", brushing off demands from some minority shareholders for a higher price tag.** Shanghai Feilo Acoustics Co Ltd has made a non-binding offer to acquire the lamps business of Germany's Osram Licht AG, the Chinese company said, lifting Osram shares on Tuesday.** Lockheed Martin Corp said on Monday that Pentagon officials planned a detailed review of the company's bid to acquire Sikorsky Aircraft, the helicopter unit of United Technologies Corp, but it did not expect major obstacles.** Sweden's Vattenfall expects to find a buyer for its lignite or brown coal assets in Germany by the end of this year and complete the deal by early 2016, the state-owned company said on Tuesday.** Dutch mapmaker TomTom NV has deepened its partnership in high-definition mapping with German auto supplier Robert Bosch to refine the technology crucial for autonomous driving.** British holiday company Thomas Cook Group Plc and France-based Club Mediterrane said they would look at sharing flights to destinations as part of a new plan underpinned by their common Chinese shareholder Fosun International Ltd .($1 = 3.78 zlotys)($1 = 0.91 euros)   (Compiled by Anet Josline Pinto and Kshitiz Goliya in Bengaluru)",2015-07-21,STJ,"Tue Jul 21, 2015 | 4:00pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N1013IS20150721?type=companyNews,0.9423,0.036,0.899,0.064
27,"  Heart device maker St. Jude Medical Inc (STJ.N) is in talks to buy smaller rival Thoratec Corp THOR.O, Bloomberg reported, citing sources familiar with the matter.No final deal has been agreed and Thoratec could also opt to seek a different buyer, the report said. (bloom.bg/1JeCCqi)Pleasanton, California-based Thoratec's stock rose 27 percent to a record high of $62.05 on the Nasdaq on Tuesday. As of Monday's close, the company, which makes devices used for mechanical circulatory support to treat heart failure patients, was valued at about $2.65 billion. St. Jude's shares were little changed at $76.57.Neither company was immediately available for comment. Shares of medical device maker HeartWare International Inc HTWR.O rose as much as about 9 percent on the news.  (Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel)",2015-07-21,STJ,"Tue Jul 21, 2015 | 1:31pm EDT",Heart device maker St. Jude in talks to buy Thoratec: Bloomberg,http://www.reuters.com//article/us-thoratec-m-a-st-jude-medical-idUSKCN0PV1YC20150721?type=companyNews,0.8591,0.024,0.869,0.107
28,"  (Adds details, updates shares)July 21 Heart device maker St. Jude Medical Inc  is in talks to buy smaller rival Thoratec Corp, Bloomberg reported, citing sources familiar with the matter.No final deal has been agreed and Thoratec could also opt to seek a different buyer, the report said. (bloom.bg/1JeCCqi) Pleasanton, California-based Thoratec's stock rose 27 percent to a record high of $62.05 on the Nasdaq on Tuesday. As of Monday's close, the company, which makes devices used for mechanical circulatory support to treat heart failure patients, was valued at about $2.65 billion. St. Jude's shares were little changed at $76.57. Neither company was immediately available for comment.Shares of medical device maker HeartWare International Inc  rose as much as about 9 percent on the news.   (Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel)",2015-07-21,STJ,"Tue Jul 21, 2015 | 1:22pm EDT",UPDATE 1-Heart device maker St. Jude in talks to buy Thoratec -Bloomberg,http://www.reuters.com//article/thoratec-ma-st-jude-medical-idUSL3N1014ZZ20150721?type=companyNews,0.8074,0.024,0.886,0.09
29,"  * IBM down after revenue falls for 13th straight quarter* United Technologies cuts full-year profit outlook* Tesla falls after UBS downgrade* Apple, Microsoft, Yahoo to report results after market* Indexes down: Dow 1.14 pct, S&P 0.46 pct, Nasdaq 0.23 pct   (Updates to early afternoon)By Tanya AgrawalJuly 21 U.S. stocks fell in early afternoon trading on Tuesday as weak revenue at IBM and United Technologies weighed on the Dow and investors awaited results from tech giants including Apple and Microsoft.The Dow fell over 1 percent, or about 209 points, with IBM and United contributing around 127 points to the fall.IBM's shares fell as much as 6.3 percent to $162.43, a day after the company's revenue fell for the 13th consecutive quarter.United Technologies fell as much as 7.9 percent to $101.78 and was the biggest loser on the Dow, after the company cut its full-year profit outlook. Apple, Microsoft and Yahoo are scheduled to report results after market close. Strong earnings from technology companies have been driving gains on the Nasdaq.""We remain cautious regarding earnings because there is a lack of revenue growth,"" said John Toohey, head of equities at USAA Investments in San Antonio, Texas.""For the bull market to be sustainable, we need to transition from financial engineering to organic revenue growth.""On Monday, the Nasdaq Composite touched a new intra-day high for the third straight day while the S&P 500 was just shy of its all-time high.While markets are at record highs, June-quarter earnings of S&P 500 companies are expected to dip 1.9 percent, according to Thomson Reuters data. Of the companies that have reported earnings so far, 70 percent have reported earnings above analyst expectations, above the 63 percent average beat rate since 1994.However, 53 percent have topped revenue forecasts, below the 61 percent average beat rate since 2002. U.S. companies were expected to post their worst sales decline in nearly six years in the second quarter, in part due to the strong dollar that reduces the value of U.S. companies' overseas income.The dollar index was down 0.8 percent at $97.22, and had earlier traded at its highest level since April on firming expectation of a U.S. interest rate hike later in the year.""The U.S. market is slightly overvalued at the moment, and will be more than slightly overvalued if revenue growth does not pick up,"" Toohey said The S&P 500 trades at 16.9 times forward 12 months earnings, above the 10-year median of 14.7 times.At 13:01 p.m. ET (1701 GMT), the Dow Jones Industrial Average was down 206.51 points, or 1.14 percent, at 17,893.9, the S&P 500 was down 9.78 points, or 0.46 percent, at 2,118.5.The Nasdaq composite was down 12.11 points, or 0.23 percent, at 5,206.75 with Apple's 0.8 percent fall being the biggest drag on the index. The company said it is experiencing some issues with its App Store, Apple Music, iTunes Store and some other services.Nine of the 10 major S&P indexes were lower with the telecommunications index leading the decliners with a 1.78 percent drop. Verizon Communications' 2.6 percent fall weighed the most on the index. The energy index was the lone index in the black.Lexmark International slumped as much as 23.2 percent to $36.36, its lowest in 18 months, after the printer maker said it would cut 500 jobs, or about 4 percent of its global workforce.Tesla fell 4.7 percent to $269.35 after UBS downgraded the stock to ""sell"" from ""neutral"". The downgrade is the third this month.Thoratec jumped as much as 27 percent to a record high of $62.05 after Bloomberg reported that heart device maker St. Jude Medical is in talks to buy it. St. Jude was down 0.4 percent at $76.23.Declining issues outnumbered advancers on the NYSE by 1,752 to 1,218. On the Nasdaq, 1,510 issues fell and 1,171 advanced.The S&P 500 index showed 28 new 52-week highs and 21 new lows, while the Nasdaq recorded 83 new highs and 87 new lows.   (Editing by Don Sebastian)",2015-07-21,STJ,"Tue Jul 21, 2015 | 1:21pm EDT","US STOCKS-IBM, United Tech pull down Dow; tech earnings in focus",http://www.reuters.com//article/markets-stocks-usa-idUSL3N10150720150721?type=companyNews,0.6369,0.055,0.888,0.057
30,"  July 21 Heart device maker St. Jude Medical Inc  is in talks to buy smaller rival Thoratec Corp, Bloomberg reported, citing sources familiar with the matter.While the two companies are in discussions, no final deal has been agreed, and Thoratec could also opt to seek a different buyer, the report said. (bloom.bg/1JeCCqi)  Pleasanton, California-based Thoratec's stock rose 27 percent to a record high on the Nasdaq on Tuesday. As of Monday's close, the implant maker was valued at about $2.65 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel) ",2015-07-21,STJ,"Tue Jul 21, 2015 | 12:53pm EDT",Heart device maker St. Jude in talks to buy Thoratec -Bloomberg,http://www.reuters.com//article/thoratec-ma-st-jude-medical-idUSL3N1014ZI20150721?type=companyNews,0.4215,0.024,0.923,0.054
31,"  * Apple slumps after revenue forecast misses expectations* Microsoft, Yahoo lower after results disappoint* Baker Hughes, Halliburton fall after report on merger* Thoratec jumps after $3.4 bln St. Jude deal* Indexes down: Dow 0.48 pct, S&P 0.34 pct, Nasdaq 0.87 pct   (Updates to early afternoon)By Tanya AgrawalJuly 22 Wall Street declined in early afternoon trading on Wednesday, with the tech-heavy Nasdaq composite falling more than 1 percent after disappointing results from technology giants including Apple, the world's largest publicly traded company.Apple shares slumped as much as 6.7 percent to $121.99, a day after the iPhone maker's revenue forecast for the fourth quarter fell below expectations.The stock was the biggest drag on all three major indexes and contributed 40 points to the Dow's overall decline. Microsoft fell as much as 4 percent to $45.35 after reporting its biggest quarterly loss, as the company wrote down its Nokia phone business and demand fell for its Windows operating system.Yahoo was down 0.8 percent at $39.38 after it forecast lower-than-expected revenue for the current quarter as it struggles to revive its core online advertising business.While markets are near record highs, June-quarter earnings of S&P 500 companies are expected to dip 1.5 percent, according to Thomson Reuters data, well below the 5.9 percent gain forecast on Jan. 1.So far, 70 percent have reported earnings above analyst expectations, above the 63 percent average beat rate since 1994. However, only 55 percent have topped revenue forecasts, below the 61 percent average beat rate since 2002. U.S. companies are expected to post their worst sales decline in nearly six years in the second quarter, in part due to the strong dollar that reduces the value of U.S. companies' overseas income.""The question now is if the markets are fully valued and can they move higher without earnings growth,"" said Jerry Braakman, chief investment officer of First American Trust in Santa Ana, California, which oversees $1.1 billion.Braakman said today's moves could have been worse but positive results from big names such as Boeing and Coca Cola were helping offset some of the losses.""Ultimately, it's earnings that drive the market not revenue and a lot of the growth in earnings is expected to come in the second half of the year."" Adding to the day's weakness, commodities resumed their downward spiral with gold and oil prices under pressure.At 12:47 p.m. ET (1647 GMT) the Dow Jones industrial average  was down 85.82 points, or 0.48 percent, at 17,833.47, the S&P 500 was down 7.21 points, or 0.34 percent, at 2,112 and the Nasdaq Composite was down 45.10 points, or 0.87 percent, at 5,163.02.Five of the 10 major S&P 500 sectors were higher with the utilities index leading the advancers with a 0.8 percent rise. The technology index was the biggest laggard with a 1.71 percent fall, its biggest drop in a week.Coca Cola was down marginally at $40.91 while fellow Dow component Boeing was up 0.4 percent at $145.68 after the companies reported results above expectations.Baker Hughes fell 8.5 percent to $55.70 following a Bloomberg report that the company's deal with Halliburton  was facing resistance from U.S. officials. Halliburton fell 2.7 percent to $40.72.Thoratec jumped as much 10.3 percent to record high of $63.51 after St. Jude Medical agreed to buy the smaller rival for $3.4 billion. St. Jude was little changed at $76.77.Declining issues outnumbered advancers on the NYSE by 1,767 to 1,216. On the Nasdaq, 1,428 issues fell and 1,246 advanced.The S&P 500 index showed 29 new 52-week highs and 38 new lows, while the Nasdaq recorded 75 new highs and 117 new lows.   (Editing by Don Sebastian)",2015-07-22,STJ,"Wed Jul 22, 2015 | 12:59pm EDT","US STOCKS-Apple, other tech stocks weigh on Wall St",http://www.reuters.com//article/markets-stocks-usa-idUSL3N1024US20150722?type=companyNews,0.5989,0.043,0.912,0.045
32,"   By Samantha Kareen Nair and Natalie Grover  St. Jude Medical Inc (STJ.N) agreed to buy smaller rival Thoratec Corp THOR.O for about $3.4 billion, giving it more devices for patients with the highest risk of heart failure.St. Jude said on Wednesday it would offer $63.50 per Thoratec share, which represents a premium of about 10 percent to the stock's Tuesday close.Thoratec's shares closed up 18 percent on Tuesday after Bloomberg reported that St. Jude was in talks to buy the company.Thoratec's shares rose 10 percent to a record high of $63.15. St. Jude's stock was up about 1 percent at $77.34.Rival HeartWare International Inc's HTWR.O shares rise 3.5 percent at $87.37.         Medical device makers are consolidating to offset pricing pressure in the United States as hospitals cut costs with patients reducing doctor visits due to rising out-of-pocket costs for care. ""This acquisition helps accelerate development of our heart failure franchise, led by the upside on CardioMEMS,"" St. Jude Chief Executive Daniel Starks said on a conference call.St. Jude's CardioMEMS heart failure (HF) monitor, the only FDA-approved heart failure monitor, is used to treat slightly less sick, or class III, patients.Thoratec's devices, including HeartMate Left Ventricular Assist Systems and Thoratec VAD, are used for mechanical circulatory support to treat heart failure. HeartMate II is approved for use in patients with the highest risk of heart failure. St. Jude also said the deal helps enter markets totaling more than $1 billion that are expected to grow about 10 percent annually.The company, which also makes neurological products, said it expects the deal to add to adjusted earnings in 2016.The deal, expected to close in the fourth quarter, is net of cash, the companies said. Pleasanton, California-based Thoratec can solicit rival offers for the next 30 days.Bank of America Merrill Lynch is acting as financial adviser to St. Jude and has also provided financing. Gibson, Dunn & Crutcher LLP is serving as legal counsel.     Guggenheim Securities is acting as financial adviser to Thoratec and Latham & Watkins LLP is serving as legal counsel. (Additional reporting by Vidya L Nathan and Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-07-22,STJ,"Wed Jul 22, 2015 | 12:12pm EDT",St. Jude pumps up heart device business with $3.4 billion buy,http://www.reuters.com//article/us-thoratec-m-a-st-jude-medical-idUSKCN0PW14E20150722?type=companyNews,0.8347,0.071,0.824,0.105
33,"  * Offers $63.50/share for Thoratec* Says deal to help enter markets worth more than $1 bln* Thoratec's shares rise 10 pct; St. Jude up about 1 pct* Rival HeartWare's shares rise 3.5 pct   (Adds Breakingviews link)By Samantha Kareen Nair and Natalie GroverJuly 22 St. Jude Medical Inc agreed to buy smaller rival Thoratec Corp for about $3.4 billion, giving it more devices for patients with the highest risk of heart failure.St. Jude said on Wednesday it would offer $63.50 per Thoratec share, which represents a premium of about 10 percent to the stock's Tuesday close.Thoratec's shares closed up 18 percent on Tuesday after Bloomberg reported that St. Jude was in talks to buy the company. Thoratec's shares rose 10 percent to a record high of $63.15. St. Jude's stock was up about 1 percent at $77.34.Rival HeartWare International Inc's shares rise 3.5 percent at $87.37.Medical device makers are consolidating to offset pricing pressure in the United States as hospitals cut costs with patients reducing doctor visits due to rising out-of-pocket costs for care. ""This acquisition helps accelerate development of our heart failure franchise, led by the upside on CardioMEMS,"" St. Jude Chief Executive Daniel Starks said on a conference call.St. Jude's CardioMEMS heart failure (HF) monitor, the only FDA-approved heart failure monitor, is used to treat slightly less sick, or class III, patients.Thoratec's devices, including HeartMate Left Ventricular Assist Systems and Thoratec VAD, are used for mechanical circulatory support to treat heart failure. HeartMate II is approved for use in patients with the highest risk of heart failure.St. Jude also said the deal helps enter markets totaling more than $1 billion that are expected to grow about 10 percent annually. The company, which also makes neurological products, said it expects the deal to add to adjusted earnings in 2016.The deal, expected to close in the fourth quarter, is net of cash, the companies said.Pleasanton, California-based Thoratec can solicit rival offers for the next 30 days.Bank of America Merrill Lynch is acting as financial adviser to St. Jude and has also provided financing. Gibson, Dunn & Crutcher LLP is serving as legal counsel.Guggenheim Securities is acting as financial adviser to Thoratec and Latham & Watkins LLP is serving as legal counsel.(Additional reporting by Vidya L Nathan and Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2015-07-22,STJ,"Wed Jul 22, 2015 | 12:11pm EDT",UPDATE 3-St. Jude pumps up heart device business with $3.4 bln buy,http://www.reuters.com//article/thoratec-ma-st-jude-medical-idUSL3N1023SA20150722?type=companyNews,0.9594,0.058,0.823,0.118
34,"  * Apple slumps after revenue forecast misses expectations* Microsoft, Yahoo lower after results disappoint* Thoratec jumps after $3.4 bln St. Jude deal* Indexes down: Dow 0.42 pct, S&P 0.22 pct, Nasdaq 0.70 pct   (Adds details, changes comment, updates prices)By Tanya AgrawalJuly 22 Wall Street declined in late morning trading on Wednesday, with the tech-heavy Nasdaq composite falling more than 1 percent after disappointing results from technology giants including Apple, the world's largest publicly traded company.Apple shares slumped as much as 6.7 percent to $121.99, a day after the iPhone maker's revenue forecast for the fourth quarter fell below expectations.The stock was the biggest drag on all three major indexes and contributed 40 points to the Dow's overall decline. Microsoft fell as much as 4 percent to $45.35 after reporting its biggest quarterly loss, as the company wrote down its Nokia phone business and demand fell for its Windows operating system.Yahoo was down 1.4 percent at $39.18 after it forecast lower-than-expected revenue for the current quarter as it struggles to revive its core online advertising business.While markets are near record highs, June-quarter earnings of S&P 500 companies are expected to dip 1.5 percent, according to Thomson Reuters data, well below the 5.9 percent gain forecast on Jan. 1.So far, 70 percent have reported earnings above analyst expectations, above the 63 percent average beat rate since 1994. However, only 55 percent have topped revenue forecasts, below the 61 percent average beat rate since 2002. U.S. companies are expected to post their worst sales decline in nearly six years in the second quarter, in part due to the strong dollar that reduces the value of U.S. companies' overseas income.""The question now is if the markets are fully valued and can they move higher without earnings growth,"" said Jerry Braakman, chief investment officer of First American Trust in Santa Ana, California, which oversees $1.1 billion.Braakman said today's moves could have been worse but positive results from big names such as Boeing and Coca Cola were helping offset some of the losses.""Ultimately, it's earnings that drive the market not revenue and a lot of the growth in earnings is expected to come in the second half of the year."" Adding to the day's weakness, commodities resumed their downward spiral with gold and oil prices under pressure.At 11:13 a.m. ET (1513 GMT), the Dow Jones industrial average was down 74.43 points, or 0.42 percent, at 17,844.86, the S&P 500 was down 4.59 points, or 0.22 percent, at 2,114.62 and the Nasdaq Composite was down 36.62 points, or 0.7 percent, at 5,171.50.Six of the 10 major S&P 500 sectors were higher with the utilities index leading the advancers with a 0.72 percent rise. The technology index was the biggest laggard with a 1.45 percent fall, its biggest drop in a week.Dow components Coca Cola was up marginally at $41.21 while Boeing was up 0.4 percent at $145.57 after the companies reported results above expectations.Thoratec jumped as much 10.3 percent to record high of $63.51 after St. Jude Medical agreed to buy the smaller rival for $3.4 billion. St. Jude was little changed at $76.77.Declining issues outnumbered advancers on the NYSE by 1,577 to 1,301. On the Nasdaq, 1,334 issues fell and 1,254 advanced.The S&P 500 index showed 28 new 52-week highs and 34 new lows, while the Nasdaq recorded 58 new highs and 100 new lows.   (Editing by Don Sebastian)",2015-07-22,STJ,"Wed Jul 22, 2015 | 11:27am EDT","US STOCKS-Apple, other tech stocks weigh on Wall St",http://www.reuters.com//article/markets-stocks-usa-idUSL3N1024QK20150722?type=companyNews,0.5989,0.046,0.907,0.047
35,"  * Apple slumps after revenue forecast misses expectations* Microsoft, Yahoo lower after results disappoint* Thoratec jumps after $3.4 bln St. Jude deal* Indexes down: Dow 0.12 pct, S&P 0.26 pct, Nasdaq 0.84 pct   (Updates to open)By Tanya AgrawalJuly 22 U.S. stocks fell in early trading on Wednesday, with the tech-heavy Nasdaq composite falling more than 1 percent after disappointing results from technology giants including Apple, the world's largest publicly traded company.Apple shares slumped as much as 6.7 percent to $121.99, a day after the iPhone maker's revenue forecast for the fourth quarter fell below expectations.The stock was the biggest drag on all three major indexes.Microsoft fell as much as 4 percent to $45.35 after reporting its biggest quarterly loss, as the company wrote down its Nokia phone business and demand fell for its Windows operating system. Yahoo was down 2.7 percent at $38.66 after it forecast lower-than-expected revenue for the current quarter as it struggles to revive its core online advertising business.While markets are near record highs, June-quarter earnings of S&P 500 companies are expected to dip 1.5 percent, according to Thomson Reuters data, well below the 5.9 percent gain forecast on Jan. 1.So far, 70 percent have reported earnings above analyst expectations, above the 63 percent average beat rate since 1994.However, only 55 percent have topped revenue forecasts, below the 61 percent average beat rate since 2002. U.S. companies are expected to post their worst sales decline in nearly six years in the second quarter, in part due to the strong dollar that reduces the value of U.S. companies' overseas income. ""Underwhelming reports from headline companies is moving the market today as the focus shifts from the macro to micro,"" said Art Hogan, chief market strategist at Wunderlich Securities in New York.""There is concern regarding the lack of organic revenue growth and the strong dollar which will continue to be a drag as we head into the second half of the year but that effect should moderate over time.""Adding to the weakness, commodities resumed their downward spiral with gold and oil prices under pressure.At 9:46 a.m. ET, the Dow Jones industrial average was down 21.68 points, or 0.12 percent, at 17,897.61, the S&P 500  was down 5.48 points, or 0.26 percent, at 2,113.73 and the Nasdaq Composite was down 43.85 points, or 0.84 percent, at 5,164.28. Five of the 10 major S&P 500 sectors were lower with the technology index leading the decliners with a 1.36 percent fall.Dow component Coca Cola was up 0.4 percent at $41.36 after the company reported better-than-expected results but said it may spend lesser to buy back shares this year.Boeing was up 2.1 percent at $148.1 after the company reported a better-than-expected quarterly profit, helped by booming demand for commercial aircraft.Thoratec jumped as much 9.4 percent to record high of $63 after St. Jude Medical agreed to buy the smaller rival for $3.4 billion. St. Jude rose 1.2 percent to $77.56.Data expected on Wednesday includes existing home sales data. Home sales, which reached a 5-1/2-year high in May, are expected to have risen 1.2 percent at an annual rate of 5.40 million units in June. The data is expected at 10 a.m. ET (1400 GMT).Declining issues outnumbered advancers on the NYSE by 1,584 to 1,103. On the Nasdaq, 1,352 issues fell and 932 advanced.The S&P 500 index showed 16 new 52-week highs and 30 new lows, while the Nasdaq recorded 30 new highs and 73 new lows.     (Editing by Don Sebastian)",2015-07-22,STJ,"Wed Jul 22, 2015 | 9:53am EDT",US STOCKS-Wall St falls after Apple results disappoint,http://www.reuters.com//article/markets-stocks-usa-idUSL3N1024HS20150722?type=companyNews,-0.4019,0.052,0.905,0.044
36,"  * Apple slumps after revenue forecast misses expectations* Microsoft, Yahoo lower after results disappoint* Thoratec jumps after $3.4 bln St. Jude deal* Futures down: Dow 75 pts, S&P 11 pts, Nasdaq 67 pts   (Adds details, comment, updates prices)By Tanya AgrawalJuly 22 Wall Street was set to open lower on Wednesday as the initial optimism over earnings faded after disappointing results from technology giants including Apple and Microsoft.Apple shares slumped 7 percent to $121.58 in premarket trading, a day after the iPhone maker's revenue forecast for the fourth quarter fell below expectations.Microsoft fell 3.5 percent to $45.64 after reporting its biggest quarterly loss, as the company wrote down its Nokia phone business and demand fell for its Windows operating system. Yahoo was down 2.3 percent at $38.85 after it forecast lower-than-expected revenue for the current quarter as it struggles to revive its core online advertising business.While markets are near record highs, June-quarter earnings of S&P 500 companies are expected to dip 1.9 percent, according to Thomson Reuters data, well below the 5.9 percent gain forecast on Jan. 1.So far, 70 percent have reported earnings above analyst expectations, above the 63 percent average beat rate since 1994. However, only 53 percent have topped revenue forecasts, below the 61 percent average beat rate since 2002. U.S. companies are expected to post their worst sales decline in nearly six years in the second quarter, in part due to the strong dollar that reduces the value of U.S. companies' overseas income.""Underwhelming reports from headline companies is moving the market today as the focus shifts from the macro to micro,"" said Art Hogan, chief market strategist at Wunderlich Securities in New York.""There is concern regarding the lack of organic revenue growth and the strong dollar which will continue to be a drag as we head into the second half of the year but that effect should moderate over time.""Adding to the weakness, commodities resumed their downward spiral with gold and oil prices under pressure. S&P 500 e-minis were down 10.75 points, or 0.51 percent, with 132,827 contracts traded at 8:49 a.m. ET.Nasdaq 100 e-minis were down 67 points, or 1.44 percent, on volume of 26,524 contracts while Dow e-minis  were down 75 points, or 0.42 percent, with 15,149 contracts changing hands.Dow component Coca Cola fell marginally to $41.10 after the company reported better-than-expected results but said it may spend lesser to buy back shares this year.Boeing was up 1.5 percent at $147.49 after the company reported a better-than-expected quarterly profit, helped by booming demand for commercial aircraft.Thoratec jumped 9.5 percent to $63.07 after St. Jude Medical agreed to buy the smaller rival for $3.4 billion. St. Jude fell 2.3 percent to $75.Data expected on Wednesday includes existing home sales data. Home sales, which reached a 5-1/2-year high in May, are expected to have risen 1.2 percent at an annual rate of 5.40 million units in June. The data is expected at 10 a.m. ET (1400 GMT).   (Editing by Don Sebastian)",2015-07-22,STJ,"Wed Jul 22, 2015 | 9:01am EDT",US STOCKS-Wall St set to open lower as tech earnings weigh,http://www.reuters.com//article/markets-stocks-usa-idUSL3N1024AJ20150722?type=companyNews,0.4767,0.049,0.896,0.055
37,"  ** Heart device maker's shares up 9.3 pct at $62.94 premarket; set for new record high** Bigger rival St. Jude Medical Inc agrees to buy Thoratec for $3.4 bln ($63.50/share) to expand heart failure device portfolio ** Thoratec shares closed up 18 pct Tuesday after Bloomberg report on St. Jude deal talk ** 7 of 14 brokerages rate stock ""buy"" or higher, 7 ""hold""; median PT is $47 ** Up to Tuesday's close, stock had risen 76 pct in past year",2015-07-22,STJ,"Wed Jul 22, 2015 | 8:00am EDT",BUZZ-Thoratec Corp: St. Jude Medical to buy for $3.4 bln,http://www.reuters.com//article/idUSL3N1023WI20150722?type=companyNews,0.4939,0.038,0.862,0.099
38,"  July 22 Heart device maker St. Jude Medical Inc  said it would buy smaller rival Thoratec Corp  for $3.4 billion.St. Jude said it would offer $63.50 per Thoratec share, which represents a premium of about 10 percent to the stock's Tuesday close.  Thoratec shares closed up 18 percent on Tuesday after Bloomberg reported that St. Jude was in talks to buy the company.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila) ",2015-07-22,STJ,"Wed Jul 22, 2015 | 7:10am EDT",Heart device maker St. Jude to buy Thoratec for $3.4 bln,http://www.reuters.com//article/thoratec-ma-st-jude-medical-idUSL3N1023RG20150722?type=companyNews,0.5267,0.0,0.941,0.059
39,"   By Vidya L Nathan  Drugmaker Abbott Laboratories (ABT.N), knocking down a report in the Financial Times, denied on Thursday that it was preparing a bid for medical device maker St Jude Medical Inc (STJ.N).The FT, citing people familiar with the matter, reported that Abbott has been working with advisers for several weeks to line up financing for a $25 billion cash and stock bid for St. Paul, Minnesota-based St Jude. St Jude's shares, which jumped 15 percent premarket trading following the report, were up 3.4 percent at $71.72 in early trading.The company had a market value of about $19.5 billion as of Wednesday's close. ""I can tell you that we are not pursuing an offer for St Jude,"" Abbott spokesman Scott Stoffel told Reuters.St Jude did not immediately respond to a request for comment. A source familiar with Abbott's thinking said he did not believe a deal was seriously contemplated, while Evercore ISI analyst Vijay Kumar said Abbott was more likely to do medium-sized deals than a big transaction.Abbott Chief Executive Miles White said last month that he was interested in acquisitions, including in the device sector,  but would be cautious because a flurry of deals in the healthcare industry had pushed up valuations. Abbott had cash on hand of almost $4 billion as of June 30.RBC Capital Markets analyst Glenn Novarro said last month that a deal in the region of $5 billion for a device maker was more likely than something larger.Kumar and Wells Fargo Securities' Larry Biegelsen said on Thursday they expected Abbott to strike a deal in either the medical device or generic drug industries. Abbott shares, which had fallen about 2 percent this year up to Wednesday's close, were up 1.8 percent at $44.75.    (This version of the story was refiled to correct syntax in paragraph 5) (Additional reporting by Mike Stone in New York; Editing by Saumyadeb Chakrabarty and Ted Kerr)",2015-08-27,STJ,"Thu Aug 27, 2015 | 10:21am EDT",Drugmaker Abbott says not pursuing an offer for St Jude Medical,http://www.reuters.com//article/us-st-jude-medical-m-a-abbott-idUSKCN0QW1B720150827?type=companyNews,0.8271,0.031,0.911,0.058
40,"  (Refiles to correct syntax in paragraph 5)By Vidya L NathanAug 27 Drugmaker Abbott Laboratories, knocking down a report in the Financial Times, denied on Thursday that it was preparing a bid for medical device maker St Jude Medical Inc.The FT, citing people familiar with the matter, reported that Abbott has been working with advisers for several weeks to line up financing for a $25 billion cash and stock bid for St. Paul, Minnesota-based St Jude. (on.ft.com/1JxHqTe)St Jude's shares, which jumped 15 percent premarket trading following the report, were up 3.4 percent at $71.72 in early trading. The company had a market value of about $19.5 billion as of Wednesday's close.""I can tell you that we are not pursuing an offer for St Jude,"" Abbott spokesman Scott Stoffel told Reuters.St Jude did not immediately respond to a request for comment. A source familiar with Abbott's thinking said he did not believe a deal was seriously contemplated, while Evercore ISI analyst Vijay Kumar said Abbott was more likely to do medium-sized deals than a big transaction.Abbott Chief Executive Miles White said last month that he was interested in acquisitions, including in the device sector,  but would be cautious because a flurry of deals in the healthcare industry had pushed up valuations. Abbott had cash on hand of almost $4 billion as of June 30.RBC Capital Markets analyst Glenn Novarro said last month that a deal in the region of $5 billion for a device maker was more likely than something larger.Kumar and Wells Fargo Securities' Larry Biegelsen said on Thursday they expected Abbott to strike a deal in either the medical device or generic drug industries.Abbott shares, which had fallen about 2 percent this year up to Wednesday's close, were up 1.8 percent at $44.75.       (Additional reporting by Mike Stone in New York; Editing by Saumyadeb Chakrabarty and Ted Kerr)",2015-08-27,STJ,"Thu Aug 27, 2015 | 10:19am EDT",REFILE-UPDATE 3-Drugmaker Abbott says not pursuing an offer for St Jude Medical,http://www.reuters.com//article/st-jude-medical-ma-abbott-idUSL4N11241Q20150827?type=companyNews,0.8271,0.032,0.908,0.06
41,"  Aug 27 Drugmaker Abbott Laboratories is preparing a bid for St Jude Medical Inc that would value the medical device maker at about $25 billion, the Financial Times reported, citing people familiar with the matter.Abbott has been working with advisers for several weeks to line up financing for a cash and stock offer, the report said. (on.ft.com/1JxHqTe)  (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr) ",2015-08-27,STJ,"Thu Aug 27, 2015 | 7:10am EDT",Drugmaker Abbott preparing bid for device maker St Jude - FT,http://www.reuters.com//article/st-jude-medical-ma-abbott-idUSL4N1123Z720150827?type=companyNews,0.34,0.0,0.964,0.036
42,"  (Adds details, analyst comments, shares)Sept 9 Medical device maker St. Jude Medical Inc  said Chief Executive Daniel J. Starks would retire in January and Chief Operating Officer Michael T. Rousseau would replace him.Starks, who joined the company in 1998 and was appointed CEO in May 2004, will become executive chairman, St. Jude Medical said on Wednesday.Rousseau joined St. Jude Medical in 1999 and he has led the company's four product divisions that sell devices for heart and nervous system. Rousseau, who turns 60 in December, was named chief operating officer last year.Evercore ISI analyst Vijay Kumar said Rousseau was the ""natural successor"" to the top position. St. Jude Medical agreed in July to buy heart device maker Thoratec Corp for about $3.4 billion. Investors will be keen to know if Rousseau will focus on core growth or go for acquisitions, Kumar said.U.S. medical device makers are consolidating to offset pricing pressure, with hospitals cutting costs as patients reduce doctor visits due to rising out-of-pocket costs for care.St. Jude Medical's shares fell about 2 percent to $69.97 on the New York Stock Exchange. Up to Tuesday's close, the stock had gained 87 percent since Starks took over as CEO.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Ted Kerr and Kirti Pandey)",2015-09-09,STJ,"Wed Sep 9, 2015 | 11:11am EDT",UPDATE 1-St. Jude Medical CEO Daniel Starks to retire in January,http://www.reuters.com//article/stjude-medical-inc-moves-idUSL4N11F4LK20150909?type=companyNews,0.886,0.026,0.892,0.082
43,"  Sept 9 Medical device maker St. Jude Medical Inc  said Chief Executive Daniel J. Starks will retire in January and be replaced by Chief Operating Officer Michael T. Rousseau. Starks, who has been CEO since May 2004, will become executive chairman.    (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Ted Kerr)  ",2015-09-09,STJ,"Wed Sep 9, 2015 | 9:34am EDT",St. Jude Medical CEO Daniel Starks to retire in January,http://www.reuters.com//article/stjude-medical-inc-moves-idUSL4N11F4DR20150909?type=companyNews,0.0,0.0,1.0,0.0
44,"  (The following statement was released by the rating agency) CHICAGO, September 14 (Fitch) Fitch Ratings has downgraded St. Jude Medical,  Inc.'s (STJ/St. Jude) long-term ratings to 'A-' from 'A', and its short-term  rating to 'F2' from 'F1'. The ratings are removed from Negative Rating Watch,  and assigned a Stable Outlook. See the full list of rating actions at the end of  this release. Fitch has also assigned an 'A-' rating to the company's $1.5 billion notes  offering, which will be used to partly fund its recently announced $3.4 billion  cash acquisition of Thoratec Corporation (Thoratec).  KEY RATING DRIVERS The rating actions reflect the following: --Fitch believes the acquisition of Thoratec is strategically constructive and  provides an adjacent product platform to STJ's cardiovascular business, as well  as an expansion of its treatment offerings for heart failure patients.  --The acquisition will increase leverage (total debt/EBITDA) in the intermediate  term, which was already stressed for the company's 'A' rating. --The stabilizing domestic cardiac rhythm management (CRM) market, new product  introductions, and emerging market opportunities should support mid-single-digit  organic revenue growth for STJ during 2015 and beyond. --STJ's focus on cost control and improving its sales mix should more than  offset pricing headwinds and incrementally improve margins during 2015-2017. --Decent sales growth and modestly improving margins will drive strong and  consistently positive free cash flow (FCF). --Fitch anticipates that STJ will maintain adequate liquidity through cash  balances, reliably positive FCF and ready access to the credit markets. THORATEC ACQUISITION STRATEGICALLY SOUND STJ's decision to enter into the mechanical circulatory support market through  the acquisition of Thoratec will help to expand the company's presence in  treating heart failure patients. The demand for heart pumps should increase over  time, given the increasing number of new heart failure patients. In addition,  these devices can provide health and economic benefits to patients and payors,  to the extent that they can more effectively and more safely treat patients than  with alternative treatments.  Thoratec's device platforms are adjacent to STJ's current cardiovascular  platforms. Potential sales and technological synergies exist between the two's  product platforms. STJ forecasts only modest operating cost synergies, however,  although it should also be able to augment the growth in Thoratec's products  through its scale. Thoratec operates in the ventricular-assist heart pump  market, which is a duopoly, and has a roughly 58% market share. In addition,  Fitch expects Thoratec to enter what will most likely become a duopolistic  percutaneous heart pump market in the near future.  TRANSACTION WILL INCREASE LEVERAGE STJ expects to close the transaction in fourth quarter 2015 (4Q15), and leverage  will likely increase above what is already a stressed balance sheet for similar  'A' rated issuers, precipitating Fitch's downgrade to 'A-'. Despite STJ's  expected operating stability and acquisition-related opportunities to enhance  growth, Fitch believes that leverage will remain above 1.7x during the  intermediate term. GROWTH EXPECTED Fitch looks for STJ to generate mid-single-digit organic revenue growth during  the next 12-24 months. Growth will be supported by new product introductions,  growth in recently introduced products, and expansion into faster growing  product and geographic markets. These factors should more than offset a soft CRM  market and foreign exchange rate headwinds. STJ has recently launched, or will soon launch devices in all four of its  business segments (CRM, Atrial Fibrillation, Cardiovascular  and  Neuromodulation ). A number of these devices are differentiated by their  clinical effectiveness and safety profiles, as well as by their ability to  reduce medical costs compared to competing devices. Fitch believes the company's  new product development and commercialization efforts will continue to support  favorable pricing and potentially incremental market share gains. IMPROVING MARGINS Fitch forecasts improving margins for STJ, despite some persistent headwinds.  STJ margins have remained relatively strong, owing to mix shift to newer and  higher margin devices and its ongoing focus on cost control which offset a more  challenging hospital reimbursement environment and the ACA excise tax. Longer  term, Fitch expects margins will benefit from continued gains in operational  efficiency and favorable shifts in product sales mix. RELIABLE FCF Increasing revenue with improving margins should result in STJ generating $800  million - $1.1 billion of annual FCF (cash flow from operations minus capital  expenditures of roughly $250 million minus dividends of roughly $320 million)  during the next two years. Cash generation should be sufficient to fund roughly  $2.3 billion of debt reduction that will likely be needed to maintain the 'A-'  rating if the acquisition is executed as announced. KEY ASSUMPTIONS Fitch's key assumptions within the rating case for St. Jude Medical, Inc.  include: --Mid-single-digit organic revenue growth; --Stressed leverage in the intermediate term mainly due to the proposed Thoratec  acquisition; --Improving margins of 50-75 basis points by 2017 with consistently positive and  solid FCF of $800 million - $.1 billion annually; --Adequate liquidity from balance sheet cash and adequate access to the bank and  credit markets; --Roughly $2.3 billion in debt reduction within approximately two years of the  acquisition. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: An upgrade is not anticipated in the near- to intermediate-term. However, STJ  would need to commit to and operate with leverage stronger than 1.6x-1.7x while  maintaining relatively stable operations and solid FCF, in order for Fitch to  consider a positive rating action. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Debt sustained above 2x-2.1x EBITDA without the prospect of timely  deleveraging.  --Stressed leverage could result from a scenario in which revenue and margins  are significantly stressed (more than Fitch anticipates), resulting in weakening  FCF, and capital deployment not being adjusted to reduce the company's need for  debt financing.  --As such, significant debt-financed share repurchases or acquisitions in the  near term would likely prompt a negative rating action, given the limited  flexibility associated with the company's forecasted leverage during the next  two years. LIQUIDITY At July 4, 2015, STJ had adequate liquidity, comprising approximately $910  million in cash plus short-term marketable securities and roughly $251 million  (net of $1.25 billion commercial paper borrowings) in availability on its  $1.5 billion bank revolving credit facility, which expires in August 2020. STJ  generated approximately $690 million in FCF (net of $179 million of capital  expenditures and $312 million of dividends) during latest 12 months (LTM), ended  July 4, 2015.  The company had approximately $3.75 billion in debt with (including $1.25  million in CP outstanding) approximately $52 million maturing in 2015, $675  million in 2016, $1.25 billion in 2018 and $1.77 billion thereafter. Fitch  expects STJ to refinance the majority of its non-bank-loan maturities, utilizing  its anticipated access to credit markets. FULL LIST OF RATING ACTIONS Fitch has downgraded the following ratings: --Issuer Default Rating (IDR) to 'A-' from 'A'; --Senior unsecured bank debt to 'A-' from 'A'; --Senior unsecured debt to 'A-' from 'A';  --Short-term IDR to 'F2' from 'F1'; --Commercial paper to F2' from 'F1'. The Rating Outlook is Stable. Contact:  Primary Analyst Bob Kirby Director  +1-312-368-3147  Fitch Ratings, Inc. 70 W. Madison St. Chicago, IL 60602 Secondary Analyst Megan Neuburger Managing Director  +1-212-908-0501 Committee Chairperson Peter Molica Senior Director +1-212-908-1288  Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Additional information is available on www.fitchratings.com Applicable Criteria  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage (pub. 17 Aug 2015) here Additional Disclosures  Dodd-Frank Rating Information Disclosure Form  here   _id=990775 Solicitation Status  here Endorsement Policy  here   ail=31 ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-09-14,STJ,"Mon Sep 14, 2015 | 11:01am EDT",Fitch Downgrades St. Jude Medical; Rates Notes Offering 'A-',http://www.reuters.com//article/idUSFit93376620150914?type=companyNews,0.9991,0.041,0.818,0.14
45,"   By Rosmi Shaji  Heart device maker St Jude Medical Inc  received a warning letter from the U.S. Food and Drug Administration, which said that various devices of the company manufactured at its Atlanta plant are adulterated.The health regulator in a letter dated Sept. 30 also warned that the company's manufacturing, packing, storage and installation practices ""are not in conformity"" to the current goods and manufacturing practise (CGMP) requirements. St Jude said in a regulatory filing that the FDA had from June 8 to 26 inspected the company's Atlanta facility, where it makes heart failure monitor CardioMEMS HF system. (1.usa.gov/1KWuXtN)St Jude said it would continue to manufacture and ship the product from the Atlanta facility and does not expect customer orders to be impacted. The St Paul, Minnesota-based company earlier resolved manufacturing issues regarding its Sylmar, California plant in July 2014. The FDA had then warned the company of serious violations at Sylmar, the plant where the Durata leads for implantable defibrillators are made. Violations included a failure to validate testing methods.The company's shares were marginally down at $63.80 in extended trading on Friday.",2015-10-02,STJ,"Fri Oct 2, 2015 | 6:59pm EDT",St Jude gets FDA warning letter for Atlanta facility,http://www.reuters.com//article/st-jude-medical-fda-idUSL1N1222SH20151002?type=companyNews,-0.9313,0.109,0.858,0.033
46,"  Heart device maker St. Jude Medical Inc received a warning letter from the U.S. Food and Drug Administration, which said that various devices of the company manufactured at its Atlanta plant are adulterated.The health regulator in a letter dated Sept. 30 also warned that the company's manufacturing, packing, storage and installation practices ""are not in conformity"" to the current goods and manufacturing practise (CGMP) requirements.St Jude said in a regulatory filing that the FDA had from June 8 to 26 inspected the company's Atlanta facility, where it makes heart failure monitor CardioMEMS HF system. (1.usa.gov/1KWuXtN)St Jude said it would continue to manufacture and ship the product from the Atlanta facility and does not expect customer orders to be impacted. The St Paul, Minnesota-based company earlier resolved manufacturing issues regarding its Sylmar, California plant in July 2014. The FDA had then warned the company of serious violations at Sylmar, the plant where the Durata leads for implantable defibrillators are made. Violations included a failure to validate testing methods.The company's shares were marginally down at $63.80 in extended trading on Friday.  (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)",2015-10-02,STJ,"Fri Oct 2, 2015 | 6:43pm EDT",St. Jude gets FDA warning letter for Atlanta facility,http://www.reuters.com//article/us-st-jude-medical-fda-idUSKCN0RW2FO20151002?type=companyNews,-0.9313,0.106,0.862,0.032
47,"  (Adds details and shares)Oct 2 Heart device maker St Jude Medical Inc  received a warning letter from the U.S. Food and Drug Administration, which said that various devices of the company manufactured at its Atlanta plant are adulterated.The health regulator in a letter dated Sept. 30 also warned that the company's manufacturing, packing, storage and installation practices ""are not in conformity"" to the current goods and manufacturing practise (CGMP) requirements. St Jude said in a regulatory filing that the FDA had from June 8 to 26 inspected the company's Atlanta facility, where it makes heart failure monitor CardioMEMS HF system. (1.usa.gov/1KWuXtN)St Jude said it would continue to manufacture and ship the product from the Atlanta facility and does not expect customer orders to be impacted. The St Paul, Minnesota-based company earlier resolved manufacturing issues regarding its Sylmar, California plant in July 2014. The FDA had then warned the company of serious violations at Sylmar, the plant where the Durata leads for implantable defibrillators are made. Violations included a failure to validate testing methods.The company's shares were marginally down at $63.80 in extended trading on Friday.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)",2015-10-02,STJ,"Fri Oct 2, 2015 | 6:41pm EDT",UPDATE 1-St Jude gets FDA warning letter for Atlanta facility,http://www.reuters.com//article/st-jude-medical-fda-idUSL3N1223HQ20151002?type=companyNews,-0.9313,0.104,0.865,0.031
48,"  Oct 2 Medical device maker St Jude Medical Inc  said it had received a warning letter from the U.S. Food and Drug Administration related to ""some non-conformities"" observed from its manufacturing facility in Atlanta, Georgia. The company manufactures its CardioMEMS HF system, which is used to monitor heart failure, at the Atlanta facility. (1.usa.gov/1KWuXtN)   (Reporting by Rosmi Shaji in Bengaluru; Editing by Maju Samuel)  ",2015-10-02,STJ,"Fri Oct 2, 2015 | 5:48pm EDT",St Jude Medical gets warning letter from FDA,http://www.reuters.com//article/st-jude-medical-fda-idUSL3N1223HA20151002?type=companyNews,-0.6908,0.087,0.913,0.0
49,"   By Rosmi Shaji  St. Jude Medical Inc said the U.S. Food and Drug Administration has issued a Class I recall on faulty parts of its devices implanted into patients to control irregular heartbeats.The devices, Optisure dual coil defibrillation leads, are connected to Implantable Cardioverter Defibrillators or ICDs, which monitor patients with abnormal heartbeats and then delivers an electric current to restore it to normal levels.In patients with serious heartbeat variations, a failure in the device could result in cardiac arrest. A Class 1 recall is the strictest form of recall issued by the health regulator, in situations where the use of faulty devices may cause serious injury or death.St. Jude said it had advised physicians to monitor the patients who were implanted with the 447 Optisure leads that are the subject of the recall. The device maker said it has not received any reports of compromised performance of the impacted Optisure leads.The company said a technique used to remove excess medical adhesive around the shock coil may have damaged the insulation surrounding the Optisure leads. As a result, the lead may not be able to deliver the required current needed to restore heartbeat, the company said.Of the 447 damaged Optisure leads, 278 were distributed in the United States, the company said in a statement.The company's shares closed at $54.77 on the New York Stock Exchange.",2016-01-22,STJ,"Fri Jan 22, 2016 | 6:41pm EST",FDA issues Class I recall on St. Jude's defibrillator leads,http://www.reuters.com//article/st-jude-medical-recall-idUSL2N1562IE?type=companyNews,-0.9136,0.102,0.858,0.04
50,"  Jan 22 St. Jude Medical Inc said the U.S. Food and Drug Administration has issued a Class I recall on faulty parts of its devices implanted into patients to control irregular heartbeats.The devices, Optisure dual coil defibrillation leads, are connected to Implantable Cardioverter Defibrillators or ICDs, which monitor patients with abnormal heartbeats and then delivers an electric current to restore it to normal levels.In patients with serious heartbeat variations, a failure in the device could result in cardiac arrest.A Class 1 recall is the strictest form of recall issued by the health regulator, in situations where the use of faulty devices may cause serious injury or death. St. Jude said it had advised physicians to monitor the patients who were implanted with the 447 Optisure leads that are the subject of the recall.The device maker said it has not received any reports of compromised performance of the impacted Optisure leads. The company said a technique used to remove excess medical adhesive around the shock coil may have damaged the insulation surrounding the Optisure leads. As a result, the lead may not be able to deliver the required current needed to restore heartbeat, the company said.Of the 447 damaged Optisure leads, 278 were distributed in the United States, the company said in a statement.The company's shares closed at $54.77 on the New York Stock Exchange.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian)",2016-01-22,STJ,"Fri Jan 22, 2016 | 6:33pm EST",FDA issues Class I recall on St. Jude's defibrillator leads,http://www.reuters.com//article/st-jude-medical-recall-idUSL3N1565GE?type=companyNews,-0.9349,0.103,0.859,0.038
51,"   By Amrutha Penumudi  St. Jude Medical Inc (STJ.N) issued a 2016 profit forecast that fell short of Wall Street expectations as the heart device maker continues to suffer from loss of U.S. market share in its cardiac rhythm management (CRM) unit which sells pacemakers and defibrillators.The company also said it expects 2016 adjusted profit of $3.95 to $4.05 per share, below the average analyst estimate of $4.14 per share.The guidance represents revenue growth deceleration primarily due to expected CRM softness while stunted earnings growth will be driven by lighter CRM margins, Cowen and Co analysts wrote in a note.St. Jude, which got almost half of its revenue from outside the United States in 2015, said fourth-quarter sales were negatively affected by about $91 million due to a stronger dollar. On a constant currency basis, worldwide sales in the company's atrial fibrillation unit, which sells catheters used in invasive heart surgery, rose 4 percent to $276 million.Sales in its neuromodulation unit which sells devices for spinal cord stimulation rose 9 percent to $128 million, with Thoratec sales for the quarter coming in at $136 million. ""The bright spot in the quarter was the contribution from Thoratec,"" RBC Capital Markets analyst Glenn Navarro said in a note.For the fourth quarter ended Jan. 2, earnings attributable to the company fell to $113 million, or 39 cents per share, from $245 million, or 84 cents per share a year earlier. The company's total sales rose 7 percent to $1.45 billion, below average analyst estimate of $1.47 billion according to Thomson Reuters I/B/E/S/.On an adjusted basis St. Jude earned $1.02 per share, slightly above the average analyst estimate of $1.01. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta)",2016-01-27,STJ,"Wed Jan 27, 2016 | 9:19am EST",Medical device maker St. Jude 2016 forecast disappoints,http://www.reuters.com//article/us-st-jude-medical-results-idUSKCN0V51HQ?type=companyNews,0.9633,0.025,0.874,0.101
52,"   By Amrutha Penumudi  St. Jude Medical Inc (STJ.N) issued a 2016 profit forecast that fell short of Wall Street expectations as the heart device maker continues to suffer from loss of U.S. market share in its cardiac rhythm management (CRM) unit which sells pacemakers and defibrillators.The company also said it expects 2016 adjusted profit of $3.95 to $4.05 per share, below the average analyst estimate of $4.14 per share.The guidance represents revenue growth deceleration primarily due to expected CRM softness while stunted earnings growth will be driven by lighter CRM margins, Cowen and Co analysts wrote in a note.St. Jude, which got almost half of its revenue from outside the United States in 2015, said fourth-quarter sales were negatively affected by about $91 million due to a stronger dollar. On a constant currency basis, worldwide sales in the company's atrial fibrillation unit, which sells catheters used in invasive heart surgery, rose 4 percent to $276 million.Sales in its neuromodulation unit which sells devices for spinal cord stimulation rose 9 percent to $128 million, with Thoratec sales for the quarter coming in at $136 million. ""The bright spot in the quarter was the contribution from Thoratec,"" RBC Capital Markets analyst Glenn Navarro said in a note.For the fourth quarter ended Jan. 2, earnings attributable to the company fell to $113 million, or 39 cents per share, from $245 million, or 84 cents per share a year earlier. The company's total sales rose 7 percent to $1.45 billion, below average analyst estimate of $1.47 billion according to Thomson Reuters I/B/E/S/.On an adjusted basis St. Jude earned $1.02 per share, slightly above the average analyst estimate of $1.01. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta)",2016-01-27,STJ,"Wed Jan 27, 2016 | 9:19am EST",UPDATE 2-Medical device maker St. Jude 2016 forecast disappoints,http://www.reuters.com//article/st-jude-medical-results-idUSL3N15B4H8?type=companyNews,0.9633,0.025,0.874,0.101
53,"  Jan 27 Medical device maker St. Jude Medical Inc's quarterly profit more than halved as sales in its cardiac rhythm management business continued to fall.For the fourth quarter ended Jan.2, earnings attributable to the company fell to $113 million, or 39 cents per share, from $245 million, or 84 cents per share a year earlier. Revenue in the cardiac rhythm management business, which which sells pacemakers and defibrillators, fell 15 percent.  (Reporting by Amrutha Penumudi in Bengaluru)",2016-01-27,STJ,"Wed Jan 27, 2016 | 7:27am EST",Medical device maker St. Jude reports lower quarterly profit,http://www.reuters.com//article/st-jude-medical-results-idUSL3N15B4FQ?type=companyNews,0.743,0.0,0.909,0.091
54,"   By Amrutha Penumudi  St. Jude Medical Inc (STJ.N) reported better-than-expected quarterly results helped by strong heart failure device sales and said it was making progress in getting its pacemaker and defibrillator business back on track.The company's shares jumped as much as 5.1 pct on the New York Stock Exchange on Wednesday, putting them on track for their best day in nearly eight months.Sales in the heart failure unit rose 49 percent to $374 million on better adoption of its heart pump, HeartMate II in the United States.However, the company's traditional cardiac rhythm management (CRM) unit which sells pacemakers and defibrillators reported a 10 percent fall in revenue as it continues to lose U.S. market share to rivals.CRM revenues have been falling as St. Jude does not yet have MRI-compatible devices in the United States, making patients choose rival products. In the first quarter of this year, CRM sales contributed 25 percent to the total revenue of the company. Only three years ago, the unit contributed about half of it.The company said it has been working with the United States Food and Drug Administration to secure approval for a range of MRI-compatible products.The launch of its MRI-compatible pacemaker has now been shifted to the second half of 2016 from the first half. Chief Financial Officer Donald Zurbay said he expected the delay to cost St. Jude about $5 million a quarter. With new product launches likely to boost performance in the second half of the year and 2017, Leerink Partners analysts said the first quarter was a positive step for St. Jude in stabilizing growth going forward.For the first quarter ended April 2, earnings attributable to the company fell to $95 million, or 33 cents per share, from $262 million, or 91 cents per share, a year earlier.Excluding after-tax charges of 57 cents per share, the company earned 90 cents per share during the quarter, beating average analysts' estimate of 88 cents per share according to Thomson Reuters I/B/E/S. St. Jude's total sales rose to $1.45 billion from $1.35 billion. Analysts were expecting sales of $1.43 billion.The company also raised its 2016 adjusted profit forecast to $4.01 to $4.11 per share from its previous estimate of $3.95 to $4.05 per share.(This story has been refiled to remove duplicate word 'profit' from headline) (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel and Shounak Dasgupta)",2016-04-20,STJ,"Wed Apr 20, 2016 | 12:40pm EDT","Heart failure devices pump up St. Jude's profit, revenue",http://www.reuters.com//article/us-st-jude-medical-results-idUSKCN0XH19N?type=companyNews,0.9874,0.042,0.828,0.13
55,"   By Amrutha Penumudi  St. Jude Medical Inc (STJ.N) reported better-than-expected quarterly results helped by strong heart failure device sales and said it was making progress in getting its pacemaker and defibrillator business back on track.The company's shares jumped as much as 5.1 pct on the New York Stock Exchange on Wednesday, putting them on track for their best day in nearly eight months.Sales in the heart failure unit rose 49 percent to $374 million on better adoption of its heart pump, HeartMate II in the United States.However, the company's traditional cardiac rhythm management (CRM) unit which sells pacemakers and defibrillators reported a 10 percent fall in revenue as it continues to lose U.S. market share to rivals.CRM revenues have been falling as St. Jude does not yet have MRI-compatible devices in the United States, making patients choose rival products. In the first quarter of this year, CRM sales contributed 25 percent to the total revenue of the company. Only three years ago, the unit contributed about half of it.The company said it has been working with the United States Food and Drug Administration to secure approval for a range of MRI-compatible products.The launch of its MRI-compatible pacemaker has now been shifted to the second half of 2016 from the first half. Chief Financial Officer Donald Zurbay said he expected the delay to cost St. Jude about $5 million a quarter. With new product launches likely to boost performance in the second half of the year and 2017, Leerink Partners analysts said the first quarter was a positive step for St. Jude in stabilizing growth going forward.For the first quarter ended April 2, earnings attributable to the company fell to $95 million, or 33 cents per share, from $262 million, or 91 cents per share, a year earlier.Excluding after-tax charges of 57 cents per share, the company earned 90 cents per share during the quarter, beating average analysts' estimate of 88 cents per share according to Thomson Reuters I/B/E/S. St. Jude's total sales rose to $1.45 billion from $1.35 billion. Analysts were expecting sales of $1.43 billion.The company also raised its 2016 adjusted profit forecast to $4.01 to $4.11 per share from its previous estimate of $3.95 to $4.05 per share.(This story has been refiled to remove duplicate word 'profit' from headline) (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel and Shounak Dasgupta)",2016-04-20,STJ,"Wed Apr 20, 2016 | 12:40pm EDT","REFILE-UPDATE 2-Heart failure devices pump up St. Jude's profit, revenue",http://www.reuters.com//article/st-jude-medical-results-idUSL3N17N3SI?type=companyNews,0.9874,0.042,0.828,0.13
56,"  (Corrects fourth paragraph to say sales rose from $1.35 billion, not $1.25 billion)April 20 St. Jude Medical Inc reported a 7.6 percent rise in quarterly revenue, helped by higher sales in its heart failure and neuromodulation businesses. For the first quarter ended April 2, earnings attributable to the company fell to $95 million, or 33 cents per share, from $262 million, or 91 cents per share a year earlier. In the quarter, the company recognized net after-tax charges of $164 million, or $0.57 per share, primarily related to acquisition-related costs and restructuring activities. The company's total sales rose to $1.45 billion from $1.35 billion.    (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-04-20,STJ,"Wed Apr 20, 2016 | 7:59am EDT",CORRECTED-Medical device maker St. Jude reports 7.6 pct rise in revenue,http://www.reuters.com//article/st-jude-medical-results-idUSL3N17M4F8?type=companyNews,0.0516,0.045,0.899,0.055
57,"  April 20 St. Jude Medical Inc* Q1 adjusted earnings per share $0.90* Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S* Raises fy 2016 adjusted earnings per share view to $4.01 to $4.11* Sees fy 2016 revenue up 2 to 4 percent* st. Jude medical reports first quarter 2016 results* Q1 sales $1.448 billion versus i/b/e/s view $1.43 billion * Raises q2 2016 adjusted earnings per share view to $1.05 to $1.07* Q1 earnings per share $0.33 including items* Sees q2 revenue up 1 to 3 percent * st. Jude medical inc says total cardiovascular sales were $301 million for q1 of 2016, flat compared to prior year quarter* Total crm sales were $366 million for q1 of 2016, a 10 percent decline compared with q1 of 2015* In q1 company recognized net after-tax charges of $164 million, or $0.57 per diluted share * For q2 st. Jude medical expects revenue to grow in range of 1 percent to 3 percent on a comparable constant currency basis* Sees currency negatively impacting q2 revenue by approximately $10 million to $15 million* Q2 earnings per share view $1.02 -- Thomson Reuters I/B/E/S* Sees currency negatively impacting full-year 2016 revenue by approximately $35 million to $55 million* Fy2016 earnings per share view $3.99, revenue view $5.99 billion -- Thomson Reuters I/B/E/S* Q2 revenue view $1.53 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-04-20,STJ,"Wed Apr 20, 2016 | 7:27am EDT",BRIEF-St. Jude Medical reports Q1 adj share of $0.90,http://www.reuters.com//article/idUSASD08E98?type=companyNews,0.91,0.009,0.916,0.075
58,"  (The following statement was released by the rating agency) CHICAGO, April 28 (Fitch) Fitch Ratings has placed St. Jude Medical, Inc. (STJ,  St. Jude) on Rating Watch Negative. The rating action follows Abbott  Laboratories' (ABT, Abbott) announcement of its intention to acquire St. Jude. Fitch will resolve the Rating Watch as more details regarding the transactions  become available. However, given the currently available information and  assuming Abbott acquires both Alere and St. Jude, Fitch will likely downgrade  St. Jude to 'BBB'. St. Jude had approximately $6.43 billion in outstanding debt at Jan. 2, 2016. A  full list of rating actions follows at the end of this release. KEY RATING DRIVERS Sound Acquisitions/High Leverage: Abbott's planned acquisition of St. Jude for  an equity value of roughly $25 billion ($46.75 in cash and 0.8708 shares of  Abbott common stock per share of St. Jude) plus approximately $5.7 billion net  debt (which will be assumed or refinanced) is a good strategic fit. St. Jude  will expand Abbott's market presence in segments that Abbott currently operates,  by providing it with broader product offerings. The acquired portfolio, in  aggregate, will also offer organic growth potential.  The acquisition will significantly increase Abbott's debt, with leverage  forecasted (assuming Abbott also acquires Alere) to remain above 3.0x through  2019. Fitch expects Abbott will reduce leverage to durably below 3.0x  thereafter, through a combination of debt reduction and increased EBITDA.  Operating margins will likely improve because of favorable shifts in sales mix,  good cost control and synergies. FCF should stay significantly positive  (excluding one-time restructuring costs). The potential 'BBB' post-transaction  rating for St. Jude assumes that Abbott will pursue a more conservative approach  to capital deployment, with share repurchases, dividend increases and  acquisitions remaining modest. The transaction is likely to close near year-end 2016, pending regulatory  approvals and St. Jude shareholder approval. The addition of St. Jude's products  will significantly expand Abbott's medical device portfolio, particularly in the  area of cardiovascular disease. The deal will position Abbott as the number-one  or number-two player in many of the sub-segments of the cardiovascular device  market. The combination provides minimal overlap in product categories and  offers Abbott a larger presence in the faster growing device areas of atrial  fibrillation, structural heart and neuromodulation. Abbott estimates it will realize roughly $500 million in annual synergies by  2020 from the St. Jude acquisition. Broader portfolios within the sub-segments  of cardiovascular should provide Abbott with increased bundling/shelf space  opportunities when contracting with hospital management and purchasing groups.  Cost-related synergies in the areas of sourcing plus some overlap in sales force  and administrative functions should be attainable. In addition, Abbott has a  demonstrable record of accomplishment of acquiring and successfully integrating  acquisitions. Thoratec Acquisition Strategically Sound: St. Jude's entered the mechanical  circulatory support market through the acquisition of Thoratec on Oct. 8, 2015.  The transaction will help to expand St. Jude's presence in treating heart  failure patients. Thoratec's device platforms are adjacent to St. Jude's current  cardiovascular platforms. Potential sales and technological synergies exist  between the two's product platforms.  St. Jude forecasts only modest operating cost synergies, but it should also be  able to augment the growth in Thoratec's products through its scale. The  acquisition was a cash transaction valued at approximately $3.4 billion, net of  cash acquired. The transaction further stressed leverage, and Fitch believes  that leverage will remain above 1.7x during the intermediate term. Growth Expected: St. Jude will likely generate mid-single-digit organic revenue  growth during the next 12-24 months. Growth will be supported by new product  introductions, growth in recently introduced products, and expansion into faster  growing product and geographic markets. These factors should more than offset a  soft CRM market and foreign exchange rate headwinds. St. Jude has recently launched, or will soon launch devices in all four of its  business segments (CRM, Atrial Fibrillation, Cardiovascular  and  Neuromodulation ). A number of these devices are differentiated by their  clinical effectiveness and safety profiles, as well as by their ability to  reduce medical costs compared to competing devices. Fitch believes the company's  new product development and commercialization efforts will continue to support  favorable pricing and potentially incremental market share gains. Improving Margins: Fitch forecasts improving margins for St. Jude, despite some  persistent headwinds. They have remained relatively strong, owing to mix shift  to newer and higher margin devices and its ongoing focus on cost control which  offset a more challenging hospital reimbursement environment. Longer-term, Fitch  expects margins will benefit from continued gains in operational efficiency and  favorable shifts in product sales mix. Reliable FCF: Increasing revenue with improving margins should result in St.  Jude generating $800 million - $1.1 billion of annual FCF (cash flow from  operations minus capital expenditures of roughly $250 million minus dividends of  roughly $320 million) during the next two years. Cash generation should be  sufficient to fund roughly $2.3 billion of debt reduction. KEY ASSUMPTIONS Fitch's key assumptions within the rating case for standalone St. Jude Medical,  Inc. include: --Mid-single-digit organic revenue growth; --Stressed leverage in the intermediate term mainly due to the proposed Thoratec  acquisition; --Improving margins of 50-75 basis points by 2017 with consistently positive and  solid FCF of $800 million - $.1 billion annually; --Adequate liquidity from balance sheet cash and adequate access to the bank and  credit markets; --Roughly $2.3 billion in debt reduction within approximately two years of the  acquisition. RATING SENSITIVITIES Fitch will resolve the Rating Watch once more details regarding the transaction  are available. However, given the currently available information and assuming  Abbott acquires both Alere and St. Jude, Fitch believes St. Jude's ratings would  likely move to 'BBB'. The following rating sensitivities are for standalone St. Jude. Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: An upgrade is not anticipated in the near to intermediate term. However, St.  Jude would need to commit to and operate with leverage stronger than 1.6x-1.7x  while maintaining relatively stable operations and solid FCF, in order for Fitch  to consider a positive rating action. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Debt sustained above 2.0x-2.1x EBITDA without the prospect of timely  deleveraging.  --Stressed leverage could result from a scenario in which revenue and margins  are significantly stressed (more than Fitch anticipates), resulting in weakening  FCF, and capital deployment not being adjusted to reduce the company's need for  debt financing.  --As such, significant debt-financed share repurchases or acquisitions in the  near term would likely prompt a negative rating action, given the limited  flexibility associated with the company's forecasted leverage during the next  two years. LIQUIDITY At Jan. 2, 2016, St. Jude had adequate liquidity, comprising approximately $667  million in cash plus short-term marketable securities and roughly $996 million  (net of $504 million commercial paper borrowings) in availability on its  $1.5 billion bank revolving credit facility, which expires in August 2020. St.  Jude generated approximately $531 million in FCF (net of $186 million of capital  expenditures and $322 million of dividends) during latest 12 months (LTM), ended  Jan. 2, 2016.  The company had approximately $6.43 billion in debt with (including $504 million  in CP outstanding) approximately $1,163 million maturing in 2017, $173 million  in 2018, $658 million in 2019 and $4.32 billion thereafter. Fitch expects St.  Jude to refinance the majority of its non-bank-loan maturities, utilizing its  anticipated access to credit markets. FULL LIST OF RATING ACTIONS Fitch has placed the following ratings on Rating Watch Negative: St. Jude Medical, Inc. --Long-term Issuer Default Rating (IDR) 'A-'; --Senior unsecured bank debt 'A-'; --Senior unsecured debt 'A-';  --Short-term IDR 'F2'; --CP 'F2'. Fitch expects that Abbott would pay down St. Jude's outstanding CP upon the  close of the transaction. Contact:  Primary Analyst Bob Kirby Director  +1-312-368-3147  Fitch Ratings, Inc. 70 W. Madison St. Chicago, IL 60602 Secondary Analyst Megan Neuburger Managing Director  +1-212-908-0501 Committee Chairperson Peter Molica Senior Director +1-212-908-0288 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Fitch has made no material financial adjustments that are not disclosed within  the company's public filings. Additional information is available on www.fitchratings.com. Applicable Criteria  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage (pub. 17 Aug 2015) here Additional Disclosures  Solicitation Status  here Endorsement Policy  here   ail=31 ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2016-04-28,STJ,"Thu Apr 28, 2016 | 4:15pm EDT",Fitch Places St. Jude Medical on Rating Watch Negative,http://www.reuters.com//article/idUSFit957121?type=companyNews,0.999,0.048,0.822,0.13
59,  April 28 S&P: * Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude Medical  Source text: (bit.ly/21hkyCp)   (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)  ,2016-04-28,STJ,"Thu Apr 28, 2016 | 11:34am EDT",BRIEF-S&P- Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude,http://www.reuters.com//article/idUSFWN17V1A1?type=companyNews,-0.5719,0.11,0.89,0.0
60,"  April 28 Abbott Laboratories* Abbott to acquire st. Jude medical* Transaction expected to be accretive to abbott's adjusted earnings per share(1) in first full year after closing and increasing thereafter* Abbott laboratories says st. Jude medical shareholders will receive $46.75 in cash and 0.8708 shares of abbott common stock* Total transaction equity value of $25 billion* Says Abbott Intends To Fund Cash Portion Of This Transaction With Medium-And long-term debt* Transaction has been approved by boards of directors of st. Jude medical and abbott * Says st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott* Expects to issue $3 billion of common stock in secondary market to rebalance its capital structure* Combination is anticipated to result in annual pre-tax synergies of $500 million by 2020 * Combination is anticipated to result in annual pre-tax synergies of $500 million by 2020* st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott* Abbott has obtained a commitment letter from BofA Merrill lynch for full cash portion of consideration for both transactions * Says st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott* Evercore is serving as lead financial advisor for abbott with wachtell, lipton, rosen & katz serving as legal counsel* Evercore is serving as lead financial advisor for abbott* BofA Merrill lynch will be providing financing and also is serving as a financial advisor to abbott* Guggenheim securities is acting as financial advisor and gibson, dunn & crutcher llp is serving as legal counsel to st. Jude medical  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-04-28,STJ,"Thu Apr 28, 2016 | 7:03am EDT",BRIEF-Abbott to acquire St. Jude medical,http://www.reuters.com//article/idUSASD08FPV?type=companyNews,0.6908,0.027,0.92,0.054
61,"  April 28 Abbott Laboratories said it agreed to buy medical device maker St. Jude Medical Inc  for $25 billion.St. Jude shareholders will receive $46.75 in cash and 0.8708 Abbott shares, representing total consideration of about $85 per share.  The offer represents a 37 percent premium to St. Jude's Wednesday closing.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty) ",2016-04-28,STJ,"Thu Apr 28, 2016 | 6:56am EDT",Abbott to acquire St. Jude Medical for $25 bln,http://www.reuters.com//article/st-jude-medical-ma-abbott-idUSL3N17V4AE?type=companyNews,0.6705,0.0,0.896,0.104
62,  May 4 St. Jude Medical Inc * Sets quarterly dividend of $0.31per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-04,STJ,"Wed May 4, 2016 | 9:26am EDT",BRIEF-st. Jude medical sets quarterly dividend of $0.31per share,http://www.reuters.com//article/idUSFWN1810XZ?type=companyNews,0.296,0.0,0.901,0.099
63,"  May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrust Robinson cuts to neutral rating        * Gap Inc        : JP Morgan, Nomura, others cut target price on the stock                   Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order. See bottom of the table for sector changes.            * Affiliated Managers Group Inc        : Deutsche Bank raises target to $203 from $202        * Aflac Inc        : FBR cuts price target to $68 from $71        * Aflac Inc        : FBR cuts to market perform rating        * Agree Realty        : Raymond James raises target price to $46 from $41; outperform        * Alexandria Real Estate Equities Inc        : JMP Securities ups target to $105 from $101        * Altria Group Inc       : Independent Research raises target to $68.0 from $65.0; hold        * A-Mark Precious Metals Inc         : B. Riley raises target price to $18.50 from $16.75        * Amazon.Com         : Bernstein raises target price to $1,000 from $770; outperform        * Amdocs Ltd        : Jefferies raises target price to $56; rating hold        * American Capital         : JP Morgan raises target price to $18 from $17.50        * American International Group Inc        : FBR cuts price target to $53 from $56        * American Public Education Inc         : BMO raises target to $23; market perform        * American Science and Engineering Inc         : Benchmark raises to buy rating        * Amphastar Pharmaceuticals         : Jefferies cuts target price to $16 from $17; buy        * AngloGold       : JP Morgan raises target price to $17.42 from $15.76       * Apache Corp        : JP Morgan raises target price to $55 from $48        * Appfolio Inc         : Credit Suisse raises target price to $14 from $13        * Applied Optoelectronics Inc         : Cowen cuts target to $15 from $25; outperform        * Applied Optoelectronics Inc         : Craig-Hallum cuts price target to $15; rating buy        * Applied Optoelectronics Inc         : Northland Capital cuts target to $9 from $11        * Applied Optoelectronics Inc         : Raymond James cuts target price to $15 from $21        * Applied Optoelectronics Inc        :Piper Jaffray cuts target to $14 from $21;overweight        * Apricus Biosciences         : Ascendiant Capital cuts price target to $1 from $2; buy        * Ardelyx Inc         : Leerink cuts target price to $17 from $20; rating outperform        * Ariad Pharmaceuticals Inc         : RBC raises target to $10 from $8; sector perform        * Armstrong World        : Barclays cuts target price to $39 from $45; underweight        * Baidu Inc         : Oppenheimer cuts target to $225 from $240        * Baker Hughes Inc        : Barclays cuts target price to $55 from $58; rating overweight        * Baxter        : Cowen and Company raises price target to $46 from $42        * Baxter International        : Leerink raises target to $47 from $46; market perform        * Baxter International        : RBC Capital raises price target to $47; sector perform        * Baxter International        : UBS raises target price to $48 from $47      * Bellicum Pharmaceuticals         : Jefferies raises target price to $20 from $19; buy        * Bill Barrett Corp        : Barclays raises price target to $7 from $6; equal weight        * BlackRock Inc        : Deutsche Bank raises target price to $386 from $383        * Blackstone Group LP       : Deutsche Bank cuts target price to $28 from $29        * Bonanza Creek Energy         : Imperial Capital raises target to $3.50 from $1; in-line        * Cabot        : Deutsche Bank raises price target to $48 from $44; rating hold        * CenterPoint Energy Inc        : Ladenburg Thalmann raises target to $23 from $20;neutral        * CEVA Inc         : Oppenheimer raises target price to $32 from $25        * Check Point Software Technologies Ltd         : Citigroup cuts target to $88 from $94        * Check Point Software Technologies Ltd         : Citigroup cuts to neutral rating        * Chimerix Inc         : JP Morgan cuts target price to $7 from $8        * Choice Hotels International Inc        : Goldman Sachs raises target to $44 from $42        * Clovis Oncology Inc         : Goldman Sachs cuts target price to $11 from $18; neutral        * Coherus Biosciences         : JP Morgan cuts target price to $30 from $35; overweight        * Coherus BioSciences Inc         : JP Morgan cuts target price to $30 from $35        * Colony Starwood Homes        : KBW raises target price to $30 from $29        * Colony Starwood Homes        : Wells Fargo cuts to market perform rating        * Comerica Inc        : Deutsche Bank raises target price to $43 from $42        * Concho Resources Inc        : JP Morgan raises target to $126 from $113; overweight        * Concho Resources Inc        : KLR raises target to $120; rating accumulate        * Cone Midstream Partners         : Barclays raises target to $18 from $12; equal weight        * Connecture Inc         : Raymond James cuts target price to $4; rating strong buy        * Continental Building Products         : Barclays ups target to $22 from $19; overweight        * Continental Building Products         : Credit Suisse ups target to $23; outperform        * Continental Resources Inc        : KLR raises target to $48; rating buy        * ContraFect Corp         : Maxim cuts price target to $5 from $7; rating buy        * ContraFect Corp         : Roth Capital cuts price target to $3.30        * ContraFect Corp         : Roth Capital cuts to neutral from buy        * Crawford & Co         : SunTrust Robinson raises target price to $7 from $6; neutral        * Credicorp        : Goldman Sachs raises price target by 3.7 pct to $169; rating buy       * CSI Compressco LP         : RBC raises target price to $8 from $7; sector perform        * Cullen/Frost Bankers Inc        : Deutsche Bank raises target price to $60 from $57        * Danaher Corp        : UBS raises target price to $108 from $103      * DCT Industrial Trust Inc        : Raymond James raises target price to $45.5; outperform        * Demand Media Inc        : B. Riley cuts target price to $9 from $10; rating buy        * Dermira Inc         : Leerink raises target price to $46 from $39; rating outperform        * Diamondrock Hospitality Co        : Goldman Sachs cuts price target to $7 from $7.25        * Dicerna Pharmaceuticals         : Leerink cuts target to $18.00 from $20.00; outperform        * Dicerna Pharmaceuticals Inc         : Stifel cuts target price to $16 from $20        * Dillard's Inc        : Deutsche Bank cuts target price to $65 from $70        * Diplomat Pharmacy Inc         : Leerink raises target price to $36 from $35        * DRDGOLD        : JP Morgan raises target price to $4.90 from $3.15        * E. W. Scripps Co        : Jefferies cuts target price to $18 from $20; rating hold        * Eagle Pharmaceuticals Inc         : RBC cuts target price to $78 from $94; outperform        * Easterly Government Properties Inc        : RBC raises target to $19 from $18        * Eclipse Resources Corp        : BMO raises target price to $4 from $3; market perform        * Eldorado Gold        : CIBC raises target price to $4.75 from $4; sector performer      * Eldorado Gold        : RBC raises target price to $4.75 from $3.50      * Eldorado Gold Corp        : TD Securities raises target price to $5.5 from $5; buy       * EMC Insurance Group Inc         : KBW raises target price to $28 from $27        * Emergent Capital Inc        : FBR cuts price target to $6 from $7; rating outperform        * Enanta Pharmaceuticals Inc         : JP Morgan cuts target price to $31 from $38        * Endologix Inc         : Canaccord Genuity raises price target to $11.25 from $8.25; hold        * Endologix Inc         : BMO raises target price to $11.50 from $9.50; market perform        * Endologix Inc         : Credit Suisse raises target price to $14 from $10; outperform        * Endologix Inc         : RBC raises target price to $15 from $11; rating outperform        * Energen Corp        : Seaport Global Securities raises target to $50 from $36        * Energen Corp        : Seaport Global Securities raises to buy from neutral        * Engility Holdings Inc        : Jefferies raises target price to $27; rating buy        * Epizyme Inc         : Mizuho cuts target price to $18 from $20; rating buy        * EQT Corp        : JP Morgan raises target price to $80 from $73        * Estee Lauder Companies       : RBC raises target price to $107 from $105; outperform        * Exelon Corp        : UBS raises target price to $35 from $30        * Extended Stay America Inc         : Goldman Sachs raises price target to $14.75 from $13        * Fibrogen Inc         : Credit Suisse cuts target price to $38 from $40        * Fiesta Restaurant Group         : Jefferies cuts target price to $45 from $50; buy        * Fiesta Restaurant Group         : Piper Jaffray cuts target price to $36 from $45; overweight        * Fiesta Restaurant Group         : Raymond James cuts price target to $37.50 from $45        * Fiesta Restaurant Group         : Raymond James cuts to outperform rating        * Fiesta Restaurant Group         : Stephens cuts target to $40 from $55; overweight        * Fiesta Restaurant Group Inc         : Sterne Agee CRT cuts to neutral from buy        * First Republic Bank        : Deutsche Bank raises target price to $73 from $69        * Fiserv Inc         : Jefferies raises target price to $119; rating buy        * Fleetcor Technologies Inc        : Jefferies raises target price to $175; rating buy        * Four Corners Property Trust         : Ladenburg Thalmann raises target price to $21; buy        * Franklin Resources Inc        : Deutsche Bank raises target price to $37 from $36        * Franklin Resources Inc        : Sandler O'Neill cuts target to $38; rating hold        * Freeport-McMoran        : Berenberg raises target price to $9.75 from $7.35; rating hold        * Gap Inc        : Baird cuts target price to $22 from $26; rating neutral        * Gap Inc        : Bernstein cuts target price to $17 from $23        * Gap Inc        : Credit Suisse cuts target price to $21 from $27; rating underperform        * Gap Inc        : Deutsche Bank cuts target price to $17 from $21        * Gap Inc        : Goldman Sachs cuts price target to $22 from $24        * Gap Inc        : Jefferies cuts target price to $28 from $34; rating buy        * Gap Inc        : JP Morgan cuts target price to $18 from $20; rating underweight        * Gap Inc        : Keybanc cuts target price to $33 from $36; rating overweight        * Gap Inc        : Nomura cuts target price to $19 from $26; rating neutral        * Gap Inc        : RBC cuts target price to $20 from $26; rating sector perform        * Gap Inc        : Stifel cuts target price to $28 from $35        * Gap Inc        : SunTrust Robinson cuts target price to $20 from $23; rating neutral        * Gap Inc        : Topeka Capital cuts target price to $22 from $40        * Gap Inc        : Topeka Capital cuts to hold from buy        * Gap Inc        : UBS cuts target price to $18 from $23        * Gap Inc        : Wedbush cuts target price to $19 from $25; rating neutral        * Globant         : JP Morgan raises price target to $40 from $36; rating overweight        * Gold Fields        : JP Morgan raises target price to $4 from $3.70        * Golub Capital BDC         : Raymond James raises target to $19 from $18; outperform        * Grand Canyon Education Inc         : BMO raises target price to $49 from $44; outperform        * Gray Television Inc        : RBC cuts target price to $17 from $18; rating outperform        * GrubHub Inc         : Cowen and Company raises target to $22 from $20; market perform        * GSV Capital Corp         : Ascendiant Capital cuts price target to $11 from $12; buy        * Halozyme Therapeutics         : Canaccord Genuity raises target to $11 from $10; buy        * Halozyme Therapeutics Inc         : JP Morgan cuts target price to $16 from $18        * Harmony Gold        : JP Morgan raises target price to $3.23 from $2.24       * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight        * HCP Inc        : BMO raises target price to $30; underperform rating        * HCP Inc        : Jefferies raises target price to $32 from $25        * HCP Inc        : Jefferies raises to hold from underperform        * HCP Inc        : RBC Capital raises price target to $32 from $30; rating underperform        * HCP Inc        : UBS raises target price to $35 from $31        * Heritage Insurance Holdings Inc         : KBW cuts target price to $22 from $27        * Hilton Worldwide Holdings Inc        : Goldman Sachs raises target to $21.50 from $20        * Horizon Pharma PLC         : Mizuho Securities cuts target price to $24 from $25        * Hyatt Hotels Corp      : Goldman Sachs raises price target to $38 from $36        * Icahn Enterprises LP        : UBS cuts target price to $52 from $62        * Infoblox Inc         : Deutsche Bank cuts target price to $12 from $13; rating sell        * Infoblox Inc         : JMP Securities cuts target price to $20 from $23        * InnerWorkings Inc         : Craig-Hallum raises price target to $10; rating buy        * Inogen Inc         : Stifel raises target price to $52 from $46        * Intercontinental Exchange        : RBC reinstates with sector perform; price target $255        * International Flavors & Fragrances Inc        : UBS raises target to $118 from $115        * Interxion Holding         : Barclays raises price target to $38 from $35; overweight        * InvenSense Inc         : Craig-Hallum cuts price target to $7; rating hold        * Invensense Inc         : Morgan Stanley cuts target price to $6.50 from $8; equal-weight        * Invensense Inc         : Topeka Capital cuts price target to $8 from $9 ; buy rating        * Ironwood Pharmaceuticals Inc         : Mizuho raises target price to $16 from $15; buy        * J C Penney Company Inc        : Jefferies starts with hold rating; $9 price target        * JD.Com       : Credit Suisse cuts target price to $21 from $38        * JD.com Inc       : Brean cuts target price to $36 from $37; rating buy        * JD.com Inc       : Credit Suisse cuts to neutral       * JD.com Inc       : Goldman Sachs cuts target price to $33 from $35.5; rating buy        * JD.com Inc       : MKM cuts target price to $32 from $34; rating buy        * JG Wentworth Co        : Jefferies cuts price target to $1 from $1.25; rating hold        * Juno Therapeutics Inc         : Guggenheim raises target price to $46 from $41; buy        * Kearny Financial Corp         : KBW raises target price to $13 from $12        * Kite Pharma Inc         : Goldman Sachs cuts price target to $80        * Kite Pharma Inc         : Mizuho cuts price target to $80 from $90; rating buy        * Kohls Corp        : Deutsche Bank cuts target price to $43 from $44        * Kohls Corp        : Jefferies cuts target price to $55 from $57; rating buy        * Krispy Kreme Doughnuts Inc        : Longbow cuts to neutral rating       * Laredo Petroleum Inc        : Credit Suisse raises price target to $8 from $6; neutral        * Laredo Petroleum Inc        : KLR raises target price to $10; rating hold        * LaSalle Hotel Properties        : Goldman Sachs cuts price target to $18.50 from $19        * Lattice Semiconductor         : Jefferies cuts target price to $6.50 from $7.00; buy        * Lattice Semiconductor Corp         : Craig-Hallum cuts price target to $6; rating hold        * LendingClub Corp       : Craig-Hallum cuts price target to $8.; rating buy        * LendingClub Corp       : Credit Suisse cuts target price to $11 from $16; rating neutral        * LendingClub Corp       : Guggenheim cuts to neutral rating      * LendingClub Corp       : Pacific Crest cuts to sector weight from overweight        * Louisiana-Pacific Corp        : TD Securities raises target price to $19 from $17.5        * Malibu Boats Inc         : BMO cuts to market perform; cuts target price to $15 from $20        * MannKind Corp         : Piper Jaffray raises target to $0.10 from $0.05; underweight        * MannKind Corp         : RBC raises target price to $0.20 from $0.15; underperform        * MaxLinear Inc        : Benchmark raises target price to $24 from $22        * MaxLinear Inc        : Needham raises target price to $20 from $19        * Medicines Co         : Jefferies cuts target price to $43 from $44; rating buy        * Mesoblast         : Maxim cuts target price to $14 from $18; rating buy        * Morgans Hotel Group Co         : MKM raises fair value to $2.25 from $1.30        * Morgans Hotel Group Co         : MKM raises to neutral from sell        * MYR Group Inc         : Maxim cuts price target to $28 from $30        * Navigators Group Inc         : KBW raises target price to $82 from $81        * Nevro Corp         : BMO raises target price to $79 from $78; rating outperform        * Nevro Corp         : JMP Securities raises target price to $90 from $85        * Nevro Corp         : JP Morgan raises target price to $84 from $80        * Nevro Corp         : Leerink raises price target to $90 from $80        * New York Community Bancorp Inc         : Deutsche Bank cuts target to $15.5 from $16        * NewLink Genetics Corp         : Baird cuts target price to $23 from $27; outperform        * NewLink Genetics Corp         : Jefferies cuts target price to $10 from $19; rating hold        * NewLink Genetics Corp         : Mizuho cuts price target to $20 from $52; rating buy        * NewLink Genetics Corp         : Stifel cuts target price to $23 from $63        * NewLink Genetics Corp         : SunTrust Robinson cuts target price to $15; buy        * Noble Energy Inc        : JP Morgan raises target price to $40 from $38        * Nordic American Tanker Ltd        : Jefferies cuts target price to $10 from $12        * Nordic American Tanker Ltd        : Jefferies cuts to underperform from hold        * Northrop Grumman Corp        : Deutsche Bank raises target price to $230 from $220        * Novatel Wireless         : Canaccord Genuity cuts target price to $2.50 from $3; hold        * Novocure Ltd         : Barclays cuts target price to $12 from $13; rating underweight        * Oasis Petroleum Inc        : Jefferies raises target price to $12 from $9        * Oasis Petroleum Inc        : Jefferies raises to buy from hold        * Oasis Petroleum Inc        : Topeka Capital raises target price to $14 from $10; buy        * Oasis Petroleum Inc        : UBS raises target price to $9 from $5; rating neutral        * ON Semiconductor       : JP Morgan raises target price to $11 from $10        * ON Semiconductor       : Raymond James raises target price to $10 from $8.50; outperform        * OvaScience Inc         : Ladenburg Thalmann raises price target to $8 from $7; buy        * Parkway Properties        : Baird raises target price to $19 from $16; outperform        * Pattern Energy Group         : NBF raises target price to $23 from $22; outperform        * PDC Energy Inc         : KLR raises target price to $79; rating buy        * Penntex Midstream Partners         : Barclays raises target to $13 from $12; overweight        * Pennymac Mortgage Investment Trust        : Barclays raises price target to $14 from $13        * Penumbra Inc        : Canaccord Genuity raises target price to $62 from $60; rating buy        * Penumbra Inc        : JP Morgan raises target price to $62 from $60; rating overweight        * PharMerica Corp        : Barrington raises price target to $34 from $30        * Phibro Animal Health Corp         : Credit Suisse cuts target price to $35 from $42        * Piedmont Office Realty Trust Inc        : Stifel raises target price to $18 from $16.50       * Platform Specialty Products        : Nomura raises target to $11 from $10; neutral        * Ply Gem Holdings         : Imperial Capital raises target to $17.50 from $17; outperform        * PRA Group Inc         : Raymond James cuts price target to $32 from $47        * PRA Group Inc         : Raymond James cuts to outperform rating        * Premier Inc         : Oppenheimer cuts target price to $40 from $44        * Presbia PLC         : Rodman & Renshaw starts with buy; target price $14        * Prosperity Bancshares Inc       : Deutsche Bank raises target price to $52 from $48        * Proteon Therapeutics         : Raymond James cuts target to $18 from $20; outperform        * Prudential Financial        : Raymond James cuts target to $91 from $94; strong buy        * Q2 Holdings Inc         : Raymond James raises target price to $30 from $25; outperform        * QTS Realty        : Stifel cuts to hold from buy on valuation        * Rackspace        : Raymond James cuts to outperform      * Rackspace Hosting Inc        : Credit Suisse cuts target price to $20 from $22        * Rackspace Hosting Inc        : Raymond James cuts price target to $25 from $28        * Rackspace Hosting Inc        :Cowen and Company raises target to $38 from $36;outperform        * Ralph Lauren Corp       : Goldman Sachs cuts price target to $123 from $128        * Regal Beloit Corp        : Keybanc cuts to sector weight from overweight        * Rice Midstream Partners        : Barclays raises target to $22 from $17; overweight        * Ritchie Bros. Auctioneers        : Jefferies raises target price to $35 from $32; buy      * Ritchie Bros. Auctioneers        :Raymond James ups target to $34.50 from $31;outperform  RBA.TO       * Ritchie Bros. Auctioneers Inc        : BMO ups target to $30.5 from $27; market perform  RBA.TO       * Ritchie Bros. Auctioneers Inc        : TD Securities raises target to $26 from $23        * RLJ Lodging Trust        : Baird cuts target price to $26 from $27; rating outperform        * Rose Rock Midstream LP         : RBC raises price target to $19 from $15; outperform        * Ryerson Holding Corp        : Deutsche Bank raises price target to $11 from $5; hold        * Sanchez Energy Corp       : RBC raises target price to $9 from $8; rating outperform        * Seagate Technology PLC        : UBS cuts target price to $14 from $20; rating sell        * Semgroup Corp         : RBC raises price target to $39 from $30; outperform rating        * SolarCity Corp         : Baird cuts target price to $37 from $47; rating neutral        * SolarCity Corp         : Credit Suisse cuts target price to $38 from $62        * SolarCity Corp         : JP Morgan cuts target price to $25 from $29        * SolarCity Corp         : Oppenheimer cuts target price to $27 from $54        * SolarCity Corp         : Raymond James cuts target price to $50 from $60; strong buy        * SolarCity Corp         : Stifel cuts target price to $46 from $56        * Solaredge         : Goldman Sachs cuts to neutral from buy      * Solaredge         :Goldman Sachs cuts target to $25;removes from Americas conviction buy list       * Solaredge Technologies         : Canaccord Genuity cuts target to $30 from $36; buy        * Spirit Realty Capital Inc        : Wunderlich raises target price to $14 from $12.5        * Sprouts Farmers market Inc        : Goldman Sachs cuts target price to $22 from $24        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * St. Jude Medical Inc        : SunTrust Robinson cuts to neutral rating        * St. Jude Medical Inc        : SunTrust Robinson raises price target to $80 from $70        * STAG Industrial Inc         : Raymond James raises target price to $23.50; outperform        * StemCells Inc         : Rodman & Renshaw adjusts target to $18 from $1.5      * Store Capital Corp         : Wunderlich Securities raises price target to $29.50; buy        * Summit Midstream Partners         : Barclays raises target to $23 from $21; equal weight        * Sunpower Corp         : Barclays cuts target price to $23 from $32; rating overweight        * SunTrust Banks Inc        : Goldman Sachs raises target price to $46 from $45        * Tetra Technologies Inc        : Cowen and Company cuts target to $8 from $10; outperform        * Tetra Technologies Inc        : Johnson Rice raises to buy; cuts target price to $9        * Tetra Technologies Inc        : Raymond James cuts target price to $7 from $8;outperform        * Tetra Technologies Inc        : Wunderlich cuts target price to $6 from $9; rating buy        * Teva         : Mizuho Securities cuts target price to $75 from $78        * Teva Pharmaceutical Industries         : Deutsche Bank cuts target to $71 from $80; buy       * Teva Pharmaceutical Industries         : Leerink cuts target to $63 from $65; outperform      * THL Credit Inc         : Raymond James cuts target price to $13 from $14        * Triangle Capital Corp         : Jefferies raises to buy from hold        * Trinet Group Inc         : Jefferies raises target price to $17; rating hold        * Tyson Foods Inc        : BMO raises target price to $78 from $68; rating outperform        * Tyson Foods Inc        : Credit Suisse raises target price to $70 from $61        * Tyson Foods Inc        : Goldman Sachs raises target to $80 from $75;conviction list buy        * Tyson Foods Inc        : RBC raises target price to $68 from $65; rating sector perform        * Ultragenyx Pharmaceutical Inc         : Credit Suisse cuts target to $101 from $104        * Ultragenyx Pharmaceutical Inc         : JMP Securities cuts target price to $80 from $85        * Ultragenyx Pharmaceutical Inc         : Morgan Stanley cuts target to $98 from $105        * United Natural Foods Inc         : BMO raises target to $36 from $32; market perform        * United States Cellular        : Raymond James cuts target to $49 from $50; strong buy        * US Auto Parts Network Inc         : Craig-Hallum raises price target to $4.50;rating buy        * Vale         : Renaissance Capital raises target price to $3.5 from $3      * Valeant Pharmaceuticals        : JP Morgan cuts target price to $60 from $70; overweight      * Vericel Corp         : Ladenburg Thalmann raises price target to $11.60 from $11.45; buy        * Wayfair Inc      : Citigroup cuts price target to $45 from $51        * Wayfair Inc      : Citigroup cuts to neutral rating        * Wayfair Inc      : Goldman Sachs cuts price target to $46 from $48        * Western Asset Mortgage        : Wunderlich Securities cuts to sell; cuts target to $8        * Western Gas Equity Partners        : Barclays ups target to $42 from $34; equal weight        * Western Gas Partners        : Barclays raises price target to $56 from $48; overweight      * William Lyon Homes        : JP Morgan raises target price to $19 from $17        * Willis Towers Watson Plc         : Jefferies cuts target price to $147 from $151; buy        * Xcel Energy Inc        : Jefferies raises target price to $42 from $38.50; rating hold        * Xenith Bankshares Inc         : KBW raises target price to $8 from $7.25        * Your Community Bankshares Inc        : KBW cuts to market perform from outperform        * Your Community Bankshares Inc        : KBW raises target price to $39.50 from $37       * Zebra Technologies Corp         : JP Morgan cuts price target to $88 from $99;overweight             SECTOR CHANGES      * Global Equity Strategy:Credit Suisse raises luxury sector to overweight from underweight                 (Compiled by Geetha Panchaksharam in Bengaluru)   ",2016-05-10,STJ,"Tue May 10, 2016 | 2:06pm EDT","U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, Gap",http://www.reuters.com//article/research-us-idUSL3N1872JF?type=companyNews,-0.9988,0.099,0.845,0.056
64,  May 18 St. Jude Medical Inc* Announces European launch of latest in PressureWire Guidewire technology to measure pressure differences across narrowed coronary arteries  * Pressurewire X Guidewire European launch will include a measured rollout to targeted countries throughout 2016  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-18,STJ,"Wed May 18, 2016 | 8:23am EDT",BRIEF-St Jude Medical announces European launch of latest in pressurewire guidewire technology,http://www.reuters.com//article/idUSFWN18F0AU?type=companyNews,-0.296,0.047,0.953,0.0
65,"   By Jonathan Stempel  St. Jude Medical Inc has reached a $39.25 million class action settlement with shareholders to resolve claims it downplayed the possible dangers associated with a product used to connect implantable defibrillators to patients' hearts.The preliminary settlement, disclosed Thursday with the U.S. District Court in Minneapolis, requires a judge's approval.It resolves claims that St. Jude inflated its stock price by concealing risks revealed in a November 2012 U.S. Food and Drug Administration report about its Durata lead, a cable linking the heart to a defibrillator.St. Jude used a material called Optim to insulate Durata and help preserve its ability to deliver needed electric shocks.But the FDA report raised questions about whether St. Jude had properly tested Durata, and whether the lead could face problems similar to what prompted a 2011 recall of Riata, a lead that was prone to failure because the insulation wore away. St. Jude's share price fell more than 12 percent on Nov. 21, 2012, the day after the FDA report was released, wiping out roughly $1.3 billion of its market value.The St. Paul, Minnesota-based company denied liability in agreeing to the settlement, which averted a February 2017 trial.St. Jude had no immediate comment on Friday. In a May 4 regulatory filing, it said it had not taken a charge for a possible settlement. The company reported $880 million of profit on net sales of $5.54 billion for 2015. Abbott Laboratories agreed in April to buy St. Jude for about $25 billion.Forsta AP-Fonden of Sweden and Danske Invest Management A/S of Denmark led the class action on behalf of St. Jude shareholders from Feb. 5, 2010 to Nov. 20, 2012. Their law firms, Kessler Topaz Meltzer & Check and Motley Rice, plan to request up to $9.81 million in legal fees plus up to $2.9 million for costs.Gregory Castaldo, from Kessler Topaz, and Gregg Levin, from Motley Rice, on Friday said they were pleased to settle.The case is Forsta AP-Fonden et al v. St. Jude Medical Inc et al, U.S. District Court, District of Minnesota, No. 12-03070.     (Reporting by Jonathan Stempel in New York; Editing by Bernadette Baum)",2016-07-08,STJ,"Fri Jul 8, 2016 | 12:38pm EDT",St Jude in $39.25 million shareholder settlement over heart devices,http://www.reuters.com//article/us-st-jude-medical-settlement-idUSKCN0ZO1ZP?type=companyNews,0.25,0.06,0.873,0.068
66,"   By Jonathan Stempel  St. Jude Medical Inc has reached a $39.25 million class action settlement with shareholders to resolve claims it downplayed the possible dangers associated with a product used to connect implantable defibrillators to patients' hearts.The preliminary settlement, disclosed Thursday with the U.S. District Court in Minneapolis, requires a judge's approval.It resolves claims that St. Jude inflated its stock price by concealing risks revealed in a November 2012 U.S. Food and Drug Administration report about its Durata lead, a cable linking the heart to a defibrillator.St. Jude used a material called Optim to insulate Durata and help preserve its ability to deliver needed electric shocks.But the FDA report raised questions about whether St. Jude had properly tested Durata, and whether the lead could face problems similar to what prompted a 2011 recall of Riata, a lead that was prone to failure because the insulation wore away. St. Jude's share price fell more than 12 percent on Nov. 21, 2012, the day after the FDA report was released, wiping out roughly $1.3 billion of its market value.The St. Paul, Minnesota-based company denied liability in agreeing to the settlement, which averted a February 2017 trial.St. Jude had no immediate comment on Friday. In a May 4 regulatory filing, it said it had not taken a charge for a possible settlement. The company reported $880 million of profit on net sales of $5.54 billion for 2015. Abbott Laboratories agreed in April to buy St. Jude for about $25 billion.Forsta AP-Fonden of Sweden and Danske Invest Management A/S of Denmark led the class action on behalf of St. Jude shareholders from Feb. 5, 2010 to Nov. 20, 2012. Their law firms, Kessler Topaz Meltzer & Check and Motley Rice, plan to request up to $9.81 million in legal fees plus up to $2.9 million for costs.Gregory Castaldo, from Kessler Topaz, and Gregg Levin, from Motley Rice, on Friday said they were pleased to settle.The case is Forsta AP-Fonden et al v. St. Jude Medical Inc et al, U.S. District Court, District of Minnesota, No. 12-03070.     (Reporting by Jonathan Stempel in New York; Editing by Bernadette Baum)",2016-07-08,STJ,"Fri Jul 8, 2016 | 12:38pm EDT",St Jude in $39.25 mln shareholder settlement over heart devices,http://www.reuters.com//article/st-jude-medical-settlement-idUSL1N19U12E?type=companyNews,0.25,0.06,0.873,0.068
67,"  July 11 St. Jude Medical Inc * FDA approval and launch of SyncAV CRT software, designed to build upon company's first-to-market multipoint pacing technology  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ",2016-07-11,STJ,"Mon Jul 11, 2016 | 8:23am EDT",BRIEF-St. Jude Medical receives FDA approval of SyncAV CRT software,http://www.reuters.com//article/idUSFWN19X0IA?type=companyNews,0.4767,0.0,0.919,0.081
68,"  July 12 St Jude Medical:* Abbott labs, st. Jude medical each received request for additional information from u.s. Ftc relating to abbott's potential acquisition of st. Jude medical  * Effect of requests, which were issued under hart-scott rodino antitrust improvements act, is to extend waiting period imposed by Hart-Scott-Rodino act  Source text (bit.ly/29wyp2B) Further company coverage: [STJ.N ]   (Bengaluru Newsroom: +1-646-223-8780) ",2016-07-12,STJ,"Tue Jul 12, 2016 | 6:31pm EDT",BRIEF-St Jude and Abbott Labs receive request for additional information from U.S. FTC,http://www.reuters.com//article/idUSFWN19Y0NL?type=companyNews,0.4019,0.021,0.914,0.065
69,"   By Amrutha Penumudi  Abbott Laboratories reported better-than-expected quarterly sales and profit as strong sales in its medical device business more than made up for the hit from an economic turmoil in Venezuela.Abbott is one of the major U.S. companies to be affected by troubled operations in Venezuela.The Latin American nation's economy contracted by 4.5 percent in the first nine months of last year as plunging oil prices, and what critics of President Nicolas Maduro see as policy missteps, took an increasing toll.Venezuela's official annual inflation rate was the world's highest at 141.5 percent in the nine months.Abbott, which rakes in two-thirds of its revenue from outside the United States, said emerging market sales increased 1.1 percent but would have risen 4.8 percent excluding the impact of Venezuelan operations.The company's results, however, beat Wall Street estimates, largely helped by its booming medical device business, where sales rose 6.4 percent to $1.37 billion in the second quarter. Abbott's device unit develops products for heart, diabetes and eye patients and has been helped by launches including glucose monitor FreeStyle Libre and MitraClip, which repairs heart valves less invasively.Abbott is in the process of acquiring St. Jude Medical Inc for $25 billion. St. Jude on Wednesday reported second-quarter earnings and revenue roughly in line with Wall Street estimates.Miles White, chief executive of Abbott, said he had still expected to close the transaction before year-end, as the company prepares to respond to a second request of information from the U.S. Federal Trade Commision. Abbott's acquisition of diagnostic company Alere Inc however, continues to see challenges, especially after Alere was subpoenaed by the U.S. Department of Justice over its sales practices.Alere rejected a request by Abbott to terminate the deal for a breakup fee in April.""To be honest, no matter what kind of teeth grinding and gnashing we go through with them .. one thing I'm certain of is that they are trying to do everything they can, in their way to address the challenges,"" Miles said on a conference call with analysts. On an adjusted basis, Abbott earned 55 cents per share in the quarter ended June 30, above the average analyst estimate of 53 cents, according to Thomson Reuters I/B/E/S. The company's net sales rose 3.2 percent to $5.33 billion, beating analysts' estimate of $5.24 billion. (prn.to/2atEUVO)Abbott's shares were up 2.3 percent at $42.76 in mid-morning trading. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-07-20,STJ,"Wed Jul 20, 2016 | 10:45am EDT",UPDATE 3-Abbott sales beat on higher demand for medical devices,http://www.reuters.com//article/abbott-results-idUSL4N1A63JZ?type=companyNews,0.8625,0.042,0.889,0.069
70,"  July 20 St. Jude Medical Inc* Total crm sales were $395 million for q2 of 2016, an 8 percent decline compared with Q2 of 2015* Qtrly international sales increased 10 percent as reported, or 7 percent on a comparable constant currency basis* St. Jude medical reports second quarter 2016 results * Q2 adjusted earnings per share $1.06* Q2 earnings per share $0.83 * Q2 sales $1.562 billion versus I/B/E/S view $1.55 billion * Q2 earnings per share view $1.06 -- Thomson Reuters I/B/E/S* Total cardiovascular sales were $319 million for Q2 of 2016, an increase of 1 percent compared to prior year quarter* Due to planned merger with Abbott, St. Jude Medical is withdrawing financial guidance for fiscal year 2016  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-20,STJ,"Wed Jul 20, 2016 | 7:37am EDT",BRIEF-St Jude Medical reports Q2 earnings per share $0.83,http://www.reuters.com//article/idUSASC08XF3?type=companyNews,0.8402,0.0,0.915,0.085
71,"  Aug 25 Shares of medical device maker St Jude Medical Inc fell sharply on Thursday after short-selling firm Muddy Waters said it had placed a bet that the shares would fall because of cyber security vulnerabilities in a cardiac device.Shares of St Jude, which agreed in April to be purchased by Abbott Laboratories, were last down nearly 4 percent on heavy volume after Carson Block, head of the firm Muddy Waters, announced his position against the stock on Twitter. He also discussed the rationale for his position on Bloomberg television. Block also said he has taken a ""long"" position in Abbott, a bet that its stock will rise. Abbott shares were little changed following the report.  Representatives for St. Jude and Abbott had no immediate comment. But St. Jude told Bloomberg it takes the security of its devices seriously.   (Reporting By Dan Burns; editing by Grant McCool)",2016-08-25,STJ,"Thu Aug 25, 2016 | 11:35am EDT",St Jude shares drop after Muddy Waters unveils short stake,http://www.reuters.com//article/stjude-cyber-idUSL1N1B60UH?type=companyNews,0.5719,0.072,0.826,0.102
72,"   By Jim Finkle  Medical device manufacturer St. Jude Medical Inc (STJ.N) said on Friday a report by short-selling firm Muddy Waters and a cyber-security researcher alleging its heart devices were riddled with bugs was ""false and misleading."" The report, which caused St. Jude shares to fall 5 percent  after its release on Thursday, alleged there were significant security bugs in the company's Merlin@home device for monitoring implanted heart devices. St. Jude chief technology officer Phil Ebeling on Thursday said ""the allegations are absolutely untrue"" but provided no specific examples of errors.St. Jude on Friday said most of the observations in the report applied to older versions of its Merlin@home devices, which had not been patched with security upgrades that the company automatically pushes out to customers. ""We want to reassure our patients that our systems meet the highest international security requirements, as required by regulatory authorities and international standards organizations,"" St Jude said. Muddy Waters late on Friday said it plans to publicly refute the response of St. Jude, which in April agreed to sell itself for $25 billion to Abbott Laboratories (ABT.N).""This was a missed opportunity for St. Jude to take responsibility for their flawed devices,"" the short seller said in a statement."" MedSec executives could not be reached for comment.Muddy Waters had no immediate response to St Jude's claim that the testing was done on older versions of its devices with unpatched software. ""We continue to stand by the report and are pleased the company has actually decided to respond to the allegations."" St. Jude shares closed marginally higher on Friday after the company released its statement following a halt in trading. Earlier they had traded as low as $75.34 in heavy trade.Muddy Waters founder Carson Block said on Thursday he decided to short the stock after MedSec approached Muddy Waters about three months ago with results of research it had conducted into its medical device security.The two struck a deal under which Block agreed to hire the cyber security firm as a consultant, pay it a licensing fee for the research and a percentage of any profits from the investment, Block said. In its rebuttal on Friday, St Jude said the researchers used a ""flawed test methodology on outdated software,"" demonstrating ""lack of understanding of medical device technology."" Beau Woods, a medical-device security expert with the non-profit Atlantic Council, said that while he had no knowledge of MedSecs research methodology, St. Judes explanation sounded reasonable.It makes sense that they would not have the current versions of software; that rings true to me, said Woods. He said that medical device makers typically push out regular updates to their software, which include security patches. (Reporting by Jim Finkle in Toronto; Editing by Jeffrey Benkoe and James Dalgleish)",2016-08-26,STJ,"Fri Aug 26, 2016 | 6:44pm EDT",St. Jude says report by short sellers 'false and misleading',http://www.reuters.com//article/us-st-jude-medical-cyber-idUSKCN11129K?type=companyNews,0.9194,0.068,0.836,0.096
73,"   By Carl O'Donnell and Lauren Hirsch  One day after a short seller claimed that St. Jude Medical Inc's (STJ.N) heart implants are vulnerable to deadly cyber attacks, investors appear most concerned about whether the accusation will derail St. Jude's $24 billion planned deal for Abbott Labs (ABT.N) to buy it.St. Jude's stock at one point fell around 3 percent on Friday, though it ended the day slightly up, following a drop of around 5 percent on Thursday after Muddy Waters Capital leveled the accusation against St. Jude. The stock continues to trade well below its price on Wednesday of around $82 per share.    St. Jude called the allegations ""false and misleading.""    St. Jude in April agreed to sell itself to Abbott, and the deal was widely considered a slam dunk before the cyber security concerns were raised.     ""It's hard to imagine that this could scuttle the deal,"" said one investor, who asked to remain anonymous because he wasn't authorized to speak with the press. ""But there are a few paths that could lead to problems.""     Abbott could decide to back out of the St. Jude deal or push for a lower valuation ""if they were to conclude remediation steps must be taken with St. Jude's technology,"" Jason Mills, an analyst at Canaccord Genuity, said in a note.      One concern being voiced is that the U.S. Food and Drug Administration could demand a full-scale product recall, which in turn could trigger a ""material adverse change"" clause in St. Jude's merger agreement.That would give Abbott the ability to walk away from the deal, according to investors and analysts interviewed by Reuters.    If the deal were called off due to an adverse event, St. Jude would probably fall below the approximately $60 per share that it was trading at before the Abbott deal was announced, investors said. A forced recall, though, is unlikely, according to Mills. The FDA issued its first guidance on managing cybersecurity in medical devices only eight months ago, and is still seen primarily as playing an advisory role in the area.       The more likely solution to any concerns about cyber security would be a software update, which is relatively inexpensive, said another investor, who asked not to be named because he wasn't authorized to speak with the press. (Reporting by Carl O'Donnell in New York; Additional reporting by Mike Erman in New York; Editing by Eric Effron and James Dalgleish)",2016-08-26,STJ,"Fri Aug 26, 2016 | 6:43pm EDT",Whiplashed investors stay skittish about St. Jude,http://www.reuters.com//article/us-st-jude-medical-cyber-investors-idUSKCN1112GA?type=companyNews,-0.7549,0.069,0.883,0.048
74,"   By Carl O'Donnell and Lauren Hirsch  Aug 26 One day after a short seller claimed that St. Jude Medical Inc's heart implants are vulnerable to deadly cyber attacks, investors appear most concerned about whether the accusation will derail St. Jude's $24 billion planned deal for Abbott Labs to buy it.St. Jude's stock at one point fell around 3 percent on Friday, though it ended the day slightly up, following a drop of around 5 percent on Thursday after Muddy Waters Capital leveled the accusation against St. Jude. The stock continues to trade well below its price on Wednesday of around $82 per share.St. Jude called the allegations ""false and misleading.""St. Jude in April agreed to sell itself to Abbott, and the deal was widely considered a slam dunk before the cyber security concerns were raised. ""It's hard to imagine that this could scuttle the deal,"" said one investor, who asked to remain anonymous because he wasn't authorized to speak with the press. ""But there are a few paths that could lead to problems.""Abbott could decide to back out of the St. Jude deal or push for a lower valuation ""if they were to conclude remediation steps must be taken with St. Jude's technology,"" Jason Mills, an analyst at Canaccord Genuity, said in a note. One concern being voiced is that the U.S. Food and Drug Administration could demand a full-scale product recall, which in turn could trigger a ""material adverse change"" clause in St. Jude's merger agreement.That would give Abbott the ability to walk away from the deal, according to investors and analysts interviewed by Reuters. If the deal were called off due to an adverse event, St. Jude would probably fall below the approximately $60 per share that it was trading at before the Abbott deal was announced, investors said.A forced recall, though, is unlikely, according to Mills. The FDA issued its first guidance on managing cybersecurity in medical devices only eight months ago, and is still seen primarily as playing an advisory role in the area.The more likely solution to any concerns about cyber security would be a software update, which is relatively inexpensive, said another investor, who asked not to be named because he wasn't authorized to speak with the press.   (Reporting by Carl O'Donnell in New York; Additional reporting by Mike Erman in New York; Editing by Eric Effron and James Dalgleish)",2016-08-26,STJ,"Fri Aug 26, 2016 | 6:38pm EDT",Whiplashed investors stay skittish about St. Jude,http://www.reuters.com//article/st-jude-medical-cyber-investors-idUSL1N1B71TC?type=companyNews,-0.8252,0.07,0.887,0.044
75,"   By Jim Finkle  Medical device manufacturer St. Jude Medical Inc (STJ.N) said on Friday a report by short-selling firm Muddy Waters and a cyber-security researcher alleging its heart devices were riddled with bugs was ""false and misleading."" The report, which caused St. Jude shares to fall 5 percent  after its release on Thursday, alleged there were significant security bugs in the company's Merlin@home device for monitoring implanted heart devices. St. Jude chief technology officer Phil Ebeling on Thursday said ""the allegations are absolutely untrue"" but provided no specific examples of errors.St. Jude on Friday said most of the observations in the report applied to older versions of its Merlin@home devices, which had not been patched with security upgrades that the company automatically pushes out to customers. ""We want to reassure our patients that our systems meet the highest international security requirements, as required by regulatory authorities and international standards organizations,"" St Jude said. Muddy Waters late on Friday said it plans to publicly refute the response of St. Jude, which in April agreed to sell itself for $25 billion to Abbott Laboratories (ABT.N).""This was a missed opportunity for St. Jude to take responsibility for their flawed devices,"" the short seller said in a statement."" MedSec executives could not be reached for comment.Muddy Waters had no immediate response to St Jude's claim that the testing was done on older versions of its devices with unpatched software. ""We continue to stand by the report and are pleased the company has actually decided to respond to the allegations."" St. Jude shares closed marginally higher on Friday after the company released its statement following a halt in trading. Earlier they had traded as low as $75.34 in heavy trade.Muddy Waters founder Carson Block said on Thursday he decided to short the stock after MedSec approached Muddy Waters about three months ago with results of research it had conducted into its medical device security.The two struck a deal under which Block agreed to hire the cyber security firm as a consultant, pay it a licensing fee for the research and a percentage of any profits from the investment, Block said. In its rebuttal on Friday, St Jude said the researchers used a ""flawed test methodology on outdated software,"" demonstrating ""lack of understanding of medical device technology."" Beau Woods, a medical-device security expert with the non-profit Atlantic Council, said that while he had no knowledge of MedSecs research methodology, St. Judes explanation sounded reasonable.It makes sense that they would not have the current versions of software; that rings true to me, said Woods. He said that medical device makers typically push out regular updates to their software, which include security patches. (Reporting by Jim Finkle in Toronto; Editing by Jeffrey Benkoe and James Dalgleish)",2016-08-26,STJ,"Fri Aug 26, 2016 | 6:44pm EDT",UPDATE 3-St. Jude says report by short sellers 'false and misleading',http://www.reuters.com//article/st-jude-medical-cyber-idUSL1N1B71ML?type=companyNews,0.9194,0.068,0.836,0.096
76,"  NEW YORK Carson Block, the head of short-selling firm Muddy Waters, said on Friday that shares of medical device maker St. Jude Medical Inc (STJ.N) could fall to $55 per share or lower if Abbott Laboratories' (ABT.N) deal to buy the company falls apart. ""If the deal were to break, I think that we could be $55 or lower,"" Block told cable television network CNBC. That implied a drop of more than 27 percent from St. Jude's current share price. St. Jude agreed in April to be purchased by Abbott Laboratories. Muddy Waters unveiled a ""short"" bet on Thursday that St. Jude's shares would fall because of cyber security vulnerabilities in a cardiac device.St. Jude said Friday that Muddy Waters' report on its heart devices was ""false and misleading."" Shares of the company, which were halted before the company's statement, resumed trading and were last down 0.18 percent at $77.68 a share. Block said on Thursday the firm's position was motivated by research from a cyber security firm, MedSec Holdings Inc, which has a financial arrangement with Muddy Waters. MedSec asserted that St. Jude's heart devices were vulnerable to cyber attack and were a risk to patients.A MedSec report warned of two primary hacks on St. Jude pacemakers and defibrillators: One that could cause implanted devices to pace at potentially dangerous rates and one that drains their batteries. MedSec approached Muddy Waters about three months ago and the two struck a deal under which Block agreed to hire MedSec as a consultant, pay it a licensing fee for research and a percentage of any profits from the investment, Block told Reuters.  Reuters was not able to confirm the allegations by Block and MedSec, a firm founded 18 months ago focusing on cyber vulnerabilities in the healthcare industry. The allegations were detailed in a report published on the Muddy Waters website. (Reporting by Sam Forgione; Editing by Jeffrey Benkoe and James Dalgleish)",2016-08-26,STJ,"Fri Aug 26, 2016 | 4:11pm EDT",Muddy Waters says St. Jude shares could fall below $55 a share: CNBC,http://www.reuters.com//article/us-funds-investing-stjude-idUSKCN1112AA?type=companyNews,-0.8885,0.117,0.802,0.081
77,"  Aug 26 Medical device manufacturer St. Jude Medical Inc said on Friday that a report by short-selling firm Muddy Waters and a cyber-security researcher alleging its heart devices were riddled with bugs was ""false and misleading.""The report, which caused St Jude shares to decline after its release on Thursday, alleged there were significant security bugs in the company's Merlin@home device for monitoring implanted heart devices.  (Reporting by Jim Finkle in Toronto; Editing by Jeffrey Benkoe) ",2016-08-26,STJ,"Fri Aug 26, 2016 | 3:25pm EDT",St. Jude says report by short sellers 'false and misleading',http://www.reuters.com//article/st-jude-medical-cyber-idUSFWN1B70KW?type=companyNews,0.6597,0.0,0.916,0.084
78,"  (Repeats to fix formatting. No changes to text)By Carl O'Donnell and Lauren HirschAug 26 One day after a short seller claimed that St. Jude Medical Inc's heart implants are vulnerable to deadly cyber attacks, investors appear most concerned about whether the accusation will derail St. Jude's $24 billion planned deal for Abbott Labs to buy it.St. Jude's stock at one point fell around 3 percent on Friday, though it ended the day slightly up, following a drop of around 5 percent on Thursday after Muddy Waters Capital leveled the accusation against St. Jude. The stock continues to trade well below its price on Wednesday of around $82 per share.St. Jude called the allegations ""false and misleading."" St. Jude in April agreed to sell itself to Abbott, and the deal was widely considered a slam dunk before the cyber security concerns were raised.""It's hard to imagine that this could scuttle the deal,"" said one investor, who asked to remain anonymous because he wasn't authorized to speak with the press. ""But there are a few paths that could lead to problems."" Abbott could decide to back out of the St. Jude deal or push for a lower valuation ""if they were to conclude remediation steps must be taken with St. Jude's technology,"" Jason Mills, an analyst at Canaccord Genuity, said in a note.One concern being voiced is that the U.S. Food and Drug Administration could demand a full-scale product recall, which in turn could trigger a ""material adverse change"" clause in St. Jude's merger agreement. That would give Abbott the ability to walk away from the deal, according to investors and analysts interviewed by Reuters.If the deal were called off due to an adverse event, St. Jude would probably fall below the approximately $60 per share that it was trading at before the Abbott deal was announced, investors said.A forced recall, though, is unlikely, according to Mills. The FDA issued its first guidance on managing cybersecurity in medical devices only eight months ago, and is still seen primarily as playing an advisory role in the area.The more likely solution to any concerns about cyber security would be a software update, which is relatively inexpensive, said another investor, who asked not to be named because he wasn't authorized to speak with the press.   (Reporting by Carl O'Donnell in New York; Additional reporting by Mike Erman in New York; Editing by Eric Effron and James Dalgleish)",2016-08-27,STJ,"Sat Aug 27, 2016 | 1:02pm EDT",RPT-Whiplashed investors stay skittish about St. Jude,http://www.reuters.com//article/st-jude-medical-cyber-investors-idUSL1N1B80BY?type=companyNews,-0.7689,0.073,0.877,0.05
79,"  (Repeats to broaden distribution with no change to text)Sept 7 St. Jude Medical Inc said on Wednesday it had filed a lawsuit against short-selling firm Muddy Waters and cyber security company MedSec Holdings Ltd alleging they intentionally disseminated false and misleading information in order to lower the value of St. Jude's stock and profit as a result.St. Jude's shares fell sharply on Aug. 25 after Muddy Waters, run by Carson Block, said it had taken a short position in the company's stock.Block said his firm's position was motivated by research from MedSec, which has a financial arrangement with Muddy Waters. MedSec had asserted that St. Jude's heart devices were vulnerable to cyber attack and were a risk to patients.Short sellers borrow shares and then sell them in the expectation that the price will fall. When it does, the short-sellers buy back the shares, return them to the lender, pay borrowing fees and pocket the difference. St. Jude agreed in April to sell itself to Abbott Laboratories for $25 billion.""We felt this lawsuit was the best course of action to make sure those looking to profit by trying to frighten patients and caregivers, and by circumventing appropriate and established channels for raising cyber security concerns, do not use this avenue to do so again,"" St. Jude Chief Executive Michael T. Rousseau said in a statement on Wednesday. University of Michigan researchers said last week their own experiments had undermined allegations of security flaws in St. Jude's pacemakers and other implantable devices.Muddy Waters and MedSec did not immediately respond to requests for comment. St. Jude's shares were untraded before the opening bell on Wednesday after closing at $78.90 on Tuesday.The stock has fallen about 4 percent since Muddy Waters disclosed its position.The case is St. Jude Medical vs. Muddy Waters, MedSec Holdings et al, in the United States District Court for the District of Minnesota, No. 16-cv-03002.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)",2016-09-07,STJ,"Wed Sep 7, 2016 | 8:49am EDT","RPT-UPDATE 1-St. Jude sues Muddy Waters, MedSec over heart device allegations",http://www.reuters.com//article/st-jude-medical-cyber-idUSL3N1BJ3VV?type=companyNews,0.8271,0.089,0.803,0.108
80,"   By Jessica Dye and Jim Finkle  St. Jude Medical will face an uphill battle in its corporate defamation lawsuit over a short-seller's report that said the medical device company's heart implants were vulnerable to cyber attacks, lawyers familiar with such cases said.The Minnesota-based company on Wednesday sued short-selling firm Muddy Waters and cyber security company MedSec Holdings Ltd in Minneapolis federal court, saying they intentionally distributed false information in an Aug. 25 report to manipulate St Jude's stock price. Muddy Waters placed a bet that the shares would fall.In a statement, Muddy Waters and MedSec Holdings said they would ""vigorously defend our right to criticize a company that puts its profits before its patients.""The right to free speech will be hard for St Jude to overcome. The First Amendment of the U.S. Constitution is the ""first line of defense"" in defamation lawsuits brought against short-sellers, researchers, analysts, bloggers and anyone else whose opinion of a company may have influenced its stock price, said Michael Asaro of Akin Gump, who specializes in white-collar and regulatory investigations and litigation.In defamation cases generally, the plaintiff must prove the defendant's statements were false. For public figures, such as politicians or celebrities, there is an added burden of showing statements were not just false, but also published willfully and maliciously.Under Minnesota law, St Jude, as a company whose products have health implications, will almost certainly be considered a public figure and have to meet that tougher standard, said Minneapolis media lawyer Mark Anfinson, who has his own practice.But that does not necessarily mean Muddy Waters and MedSec are out of the woods, Anfinson said. The actual malice defense, more commonly wielded by the press, may not prove as powerful for a short-seller with a financial motive to cause a stock to fall.""They may not get the benefit of the doubt"" on malice, said Anfinson.Muddy Waters said in its report that St. Jude's pacemakers and defibrillators, which are used to regulate heart rhythm and treat cardiac arrest, had cyber security flaws that enabled them to be hacked and manipulated, with potentially fatal consequences. 'SCARE TACTICS' St Jude was unsparing in its complaint.""Only driving down the stock price by defaming [Cardiac Rhythm Management] Devices with market-bombshell scare tactics could make the short-positioned Defendants richer - with the very unfortunate (and despicable) concomitant result of fueling significant concern and fear in patients and their families,"" the company said.In a pair of high-profile cases in recent years, defamation claims against short-sellers failed on free speech grounds. Last year, a San Francisco federal judge threw out a lawsuit brought by casino magnate Steve Wynn against short-seller James Chanos over comments Chanos made at a conference. The judge awarded Chanos more than $420,000 in attorneys' fees.A New York judge ruled in 2012 against a Canadian silver producer, finding negative reports circulated by hedge funds were constitutionally protected opinions.Muddy Waters said its report was an expression of opinion. The report raised the possibility of product recalls and St. Jude's revenue disappearing for two years while safety problems were fixed.MedSec had a financial arrangement with Muddy Waters in which the firm agreed to hire MedSec as a consultant, pay it a licensing fee for research and a percentage of any profits from the investment.Speaking generally, white-collar lawyer Asaro said the guiding principle was that even wrong opinions could be protected, so long as they were made in good faith and the underlying facts were presented fairly. ""Where people get into trouble is where they misrepresent the facts,"" Asaro said. ""That's why these cases are so fact-specific."" Muddy Waters has courted controversy before with its criticism of companies whose stocks it bet against. Two targets of those comments, rice trader Olam International and bankrupt Chinese timber company Sino-Forest, sued Muddy Waters in Singapore and Canada, respectively. The cases were later dropped.""St. Jude Medical now joins the ranks of Sino-Forest and Olam International as companies that have filed frivolous lawsuits against us for criticizing them,"" said Muddy Waters founder Carson Block in an email.St. Jude's spokeswoman Candace Steele Flippin said the company is ""confident in its legal position and took this action because of the irresponsible manner in which the defendants have acted.""Aside from any question of legal wrongdoing, some industry  experts are troubled by MedSec's arrangement with Muddy Waters.""I think it would be a dark day if we go down this path,""  said Kevin Fu, a University of Michigan scientist who a decade ago pioneered research into heart-device vulnerabilities.Fu said researchers should abide by voluntary industry guidelines for vulnerability disclosures in which researchers typically give companies time to fix flaws before going public.IOActive, NCC Group and Optiv, three prominent firms that provide vulnerability consulting, said they would not enter into an arrangement with short-sellers.Yet some argue that the public interest is served by such an alliance.Andrea Matwyshyn, a Northeastern University computer scientist, said she supported using research to short a stock because the approach pressures companies to be more upfront about the risks associated with security bugs.",2016-09-07,STJ,"Wed Sep 7, 2016 | 7:09pm EDT",St. Jude's lawsuit against short-seller faces steep climb -lawyers,http://www.reuters.com//article/st-jude-medical-cyber-legal-idUSL1N1BJ1U3?type=companyNews,-0.992,0.132,0.777,0.091
81,"   By Jessica Dye and Jim Finkle | Sept 7  Sept 7 St. Jude Medical will face an uphill battle in its corporate defamation lawsuit over a short-seller's report that said the medical device company's heart implants were vulnerable to cyber attacks, lawyers familiar with such cases said.The Minnesota-based company on Wednesday sued short-selling firm Muddy Waters and cyber security company MedSec Holdings Ltd in Minneapolis federal court, saying they intentionally distributed false information in an Aug. 25 report to manipulate St Jude's stock price. Muddy Waters placed a bet that the shares would fall.In a statement, Muddy Waters and MedSec Holdings said they would ""vigorously defend our right to criticize a company that puts its profits before its patients.""The right to free speech will be hard for St Jude to overcome. The First Amendment of the U.S. Constitution is the ""first line of defense"" in defamation lawsuits brought against short-sellers, researchers, analysts, bloggers and anyone else whose opinion of a company may have influenced its stock price, said Michael Asaro of Akin Gump, who specializes in white-collar and regulatory investigations and litigation.In defamation cases generally, the plaintiff must prove the defendant's statements were false. For public figures, such as politicians or celebrities, there is an added burden of showing statements were not just false, but also published willfully and maliciously.Under Minnesota law, St Jude, as a company whose products have health implications, will almost certainly be considered a public figure and have to meet that tougher standard, said Minneapolis media lawyer Mark Anfinson, who has his own practice.But that does not necessarily mean Muddy Waters and MedSec are out of the woods, Anfinson said. The actual malice defense, more commonly wielded by the press, may not prove as powerful for a short-seller with a financial motive to cause a stock to fall.""They may not get the benefit of the doubt"" on malice, said Anfinson.Muddy Waters said in its report that St. Jude's pacemakers and defibrillators, which are used to regulate heart rhythm and treat cardiac arrest, had cyber security flaws that enabled them to be hacked and manipulated, with potentially fatal consequences. 'SCARE TACTICS' St Jude was unsparing in its complaint.""Only driving down the stock price by defaming [Cardiac Rhythm Management] Devices with market-bombshell scare tactics could make the short-positioned Defendants richer - with the very unfortunate (and despicable) concomitant result of fueling significant concern and fear in patients and their families,"" the company said.In a pair of high-profile cases in recent years, defamation claims against short-sellers failed on free speech grounds. Last year, a San Francisco federal judge threw out a lawsuit brought by casino magnate Steve Wynn against short-seller James Chanos over comments Chanos made at a conference. The judge awarded Chanos more than $420,000 in attorneys' fees.A New York judge ruled in 2012 against a Canadian silver producer, finding negative reports circulated by hedge funds were constitutionally protected opinions.Muddy Waters said its report was an expression of opinion. The report raised the possibility of product recalls and St. Jude's revenue disappearing for two years while safety problems were fixed.MedSec had a financial arrangement with Muddy Waters in which the firm agreed to hire MedSec as a consultant, pay it a licensing fee for research and a percentage of any profits from the investment.Speaking generally, white-collar lawyer Asaro said the guiding principle was that even wrong opinions could be protected, so long as they were made in good faith and the underlying facts were presented fairly. ""Where people get into trouble is where they misrepresent the facts,"" Asaro said. ""That's why these cases are so fact-specific."" Muddy Waters has courted controversy before with its criticism of companies whose stocks it bet against. Two targets of those comments, rice trader Olam International and bankrupt Chinese timber company Sino-Forest, sued Muddy Waters in Singapore and Canada, respectively. The cases were later dropped.""St. Jude Medical now joins the ranks of Sino-Forest and Olam International as companies that have filed frivolous lawsuits against us for criticizing them,"" said Muddy Waters founder Carson Block in an email.St. Jude's spokeswoman Candace Steele Flippin said the company is ""confident in its legal position and took this action because of the irresponsible manner in which the defendants have acted.""Aside from any question of legal wrongdoing, some industry  experts are troubled by MedSec's arrangement with Muddy Waters.""I think it would be a dark day if we go down this path,""  said Kevin Fu, a University of Michigan scientist who a decade ago pioneered research into heart-device vulnerabilities.Fu said researchers should abide by voluntary industry guidelines for vulnerability disclosures in which researchers typically give companies time to fix flaws before going public.IOActive, NCC Group and Optiv, three prominent firms that provide vulnerability consulting, said they would not enter into an arrangement with short-sellers.Yet some argue that the public interest is served by such an alliance.Andrea Matwyshyn, a Northeastern University computer scientist, said she supported using research to short a stock because the approach pressures companies to be more upfront about the risks associated with security bugs.   (Reporting by Jessica Dye and Jim Finkle; Editing by Anthony Lin and Grant McCool)",2016-09-07,STJ,"Wed Sep 7, 2016 | 7:06pm EDT",St. Jude's lawsuit against short-seller faces steep climb -lawyers,http://www.reuters.com//article/st-jude-medical-cyber-legal-idUSL1N1BJ1HD?type=companyNews,-0.9907,0.13,0.778,0.093
82,  Sept 7 St. Jude Medical Inc said on Wednesday it had filed a lawsuit against short-seller Muddy Waters and cyber security firm MedSec Holdings Ltd alleging they intentionally disseminated false and misleading information in order to lower the value of St. Jude's stock and profit as a result.St. Jude's shares fell sharply on Aug. 25 after Muddy Waters and MedSec said they had found significant security bugs in the company's Merlin@home implanted heart monitoring device. University of Michigan researchers said last week their own experiments had undermined allegations of security flaws in St. Jude's pacemakers and other implantable medical devices. The lawsuit was filed in the United States District Court for the District of Minnesota. Muddy Waters and MedSec were not immediately available for comment.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr),2016-09-07,STJ,"Wed Sep 7, 2016 | 8:14am EDT","St. Jude sues Muddy Waters, MedSec over heart device allegations",http://www.reuters.com//article/st-jude-medical-cyber-idUSL3N1BJ3S6?type=companyNews,0.7964,0.075,0.796,0.129
83,"  Oct 4 St. Jude Medical Inc : * St. Jude Medical announces FDA approval of Burstdr stimulation, a new superior spinal cord stimulation option for patients suffering from chronic pain  Source text for Eikon:  Further company coverage:  ",2016-10-04,STJ,"Tue Oct 4, 2016 | 8:51am EDT",BRIEF-St.Jude Medical reports FDA approval of Burstdr stimulation,http://www.reuters.com//article/idUSFWN1CA0EM?type=companyNews,0.0516,0.152,0.69,0.157
84,"  BRUSSELS EU antitrust regulators will decide by Nov. 9 whether to clear U.S. pharmaceuticals company Abbott Laboratories' (ABT.N) $25-billion bid for St. Jude Medical Inc (STJ.N) aimed at helping it better compete with bigger rivals.Abbott sought the European Commission's approval for the deal on Oct. 3,  according to a filing on the EU competition enforcer's website on Tuesday.The Commission can either clear the deal with or without concessions or it can open a full-scale investigation if it has serious concerns. The majority of pharmaceutical mergers get the green light with or without conditions in the EU's preliminary review. Abbott's takeover bid comes as medical equipment makers come under pressure to offer a wider portfolio of products to hospital customers, which have gained more negotiating power on pricing after a wave of mergers. Abbott competes against Medtronic Plc (MDT.N) and Boston Scientific Corp (BSX.N).  (Reporting by Foo Yun Chee; Editing by Mark Potter)",2016-10-04,STJ,"Tue Oct 4, 2016 | 6:01am EDT","EU ruling on $25 billion Abbott, St. Jude deal due by November 9",http://www.reuters.com//article/st-jude-medical-m-a-abbott-eu-idUSKCN1240VG?type=companyNews,0.91,0.022,0.877,0.101
85,"  BRUSSELS EU antitrust regulators will decide by Nov. 9 whether to clear U.S. pharmaceuticals company Abbott Laboratories' (ABT.N) $25-billion bid for St. Jude Medical Inc (STJ.N) aimed at helping it better compete with bigger rivals.Abbott sought the European Commission's approval for the deal on Oct. 3,  according to a filing on the EU competition enforcer's website on Tuesday.The Commission can either clear the deal with or without concessions or it can open a full-scale investigation if it has serious concerns. The majority of pharmaceutical mergers get the green light with or without conditions in the EU's preliminary review. Abbott's takeover bid comes as medical equipment makers come under pressure to offer a wider portfolio of products to hospital customers, which have gained more negotiating power on pricing after a wave of mergers. Abbott competes against Medtronic Plc (MDT.N) and Boston Scientific Corp (BSX.N).  (Reporting by Foo Yun Chee; Editing by Mark Potter)",2016-10-04,STJ,"Tue Oct 4, 2016 | 6:01am EDT","EU ruling on $25 bln Abbott, St Jude deal due by Nov. 9",http://www.reuters.com//article/st-jude-medical-ma-abbott-eu-idUSL5N1CA27S?type=companyNews,0.91,0.022,0.877,0.101
86,  Oct 5 St. Jude Medical Inc :* st. Jude medical announces European full market release of ensite precision Cardiac Mapping System  * New ensite precision Cardiac Mapping System is now active in more than 100 sites across Europe  Source text for Eikon:  Further company coverage: ,2016-10-05,STJ,"Wed Oct 5, 2016 | 8:48am EDT",BRIEF-St. Jude Medical announces European market release of ensite precision Cardiac Mapping System,http://www.reuters.com//article/idUSFWN1CB07Q?type=companyNews,0.7351,0.0,0.869,0.131
87,  Oct 6 St. Jude Medical Inc : * St. Jude Medical announces U.S. launch and first implant of new deep brain stimulation system and directional lead for patients suffering from movement disorders  Source text for Eikon:  Further company coverage:  ,2016-10-06,STJ,"Thu Oct 6, 2016 | 8:26am EDT","BRIEF-St. Jude Medical announces U.S. launch, first implant of new deep brain stimulation system, directional lead for patients suffering from movement disorders",http://www.reuters.com//article/idUSFWN1CC0EW?type=companyNews,-0.4767,0.081,0.919,0.0
88,  Oct 10 St. Jude Medical Inc :* St. Jude Medical announces FDA clearance and launch of the new Pressurewire X Guidewire designed to optimize PCI procedures in patients with complex anatomies  * St. Jude Medical -  fame trial body of evidence also demonstrated reductions in risk of death or heart attack in patients undergoing PCI  Source text for Eikon:  Further company coverage: ,2016-10-10,STJ,"Mon Oct 10, 2016 | 8:24am EDT","BRIEF-St. Jude medical announces FDA clearance, launch of PressureWire X Guidewire",http://www.reuters.com//article/idUSFWN1CG0DD?type=companyNews,0.128,0.127,0.739,0.134
89,"   By Jim Finkle  Oct 11 St. Jude Medical Inc warned on Tuesday that some of its implanted heart devices are at risk of premature battery depletion, a condition it said has been linked to two patient deaths and could require the replacement of some devices.News of the issue surfaced on Monday evening when short-selling firm Muddy Waters tweeted a copy of a physician advisory on the matter from St. Jude, which agreed in April to sell itself for $25 billion to Abbott Laboratories.That letter said such problems with the lithium batteries that power the devices were rare and could be identified by patients using tools for monitoring battery levels from their homes.Out of nearly 400,000 devices manufactured through May of last year, the company has identified 841 failed implanted cardioverter defibrillators with lithium clusters, which can form after a device delivers electricity to the heart, according to St. Jude.Lithium clusters sometimes cause battery power to deplete quickly, making devices unable to deliver doses of electricity when needed, St. Jude Vice President of Quality Control Jeff Fecho said in the letter to physicians. ""There have been two deaths that have been associated with the loss of defibrillation therapy as a result of premature battery depletion,"" Fecho said.The company advised physicians to replace devices with damaged batteries immediately, but cautioned against swapping out devices that were operating normally because of the potential for complications from such procedures.""We encourage any patient with questions about their medical device to contact their doctor,"" St. Jude Chief Medical Officer Mark Carlson said in a statement. ""While this risk is very small, we have provided doctors with information so that they can discuss the most appropriate course of action for each individual patient,"" Carlson said.St. Jude said it planned to launch a webpage on Tuesday where patients could see which devices were affected: (www.sjm.com/batteryadvisory). The site tells patients how they can monitor battery activity, look for vibrating alerts when batteries are low and connect to the Merlin.net remote monitoring service.The alert comes as St. Jude defends itself against unrelated allegations that its heart devices are riddled with bugs that make them vulnerable to fatal cyber hacks.The Food and Drug Administration is investigating the claims by Muddy Waters and research firm MedSec Holdings Inc.St. Jude has denied the allegations and sued both firms, saying they disseminated false information to manipulate its stock price.(Reporting by Jim Finkle in BOSTON; Editing by Paul Tait)",2016-10-11,STJ,"Tue Oct 11, 2016 | 7:00am EDT",St. Jude warns of heart-device battery issue linked to 2 deaths,http://www.reuters.com//article/st-jude-medical-batteries-idUSL1N1CH053?type=companyNews,-0.9432,0.069,0.908,0.023
90,"   By Jim Finkle  Medical-device maker St. Jude Medical Inc said on Monday that it planned to set up a medical advisory board focused on cyber-security issues affecting patient care and safety.St. Jude said in a statement that the group, known as the Cyber Security Medical Advisory Board, would provide advice on cyber security standards for medical devices.The St. Paul, Minnesota-based company is establishing the group as the U.S. Food and Drug Administration investigates claims that St. Jude heart devices are riddled with defects that make them vulnerable to fatal cyber hacks. The FDA launched that probe in August after short-seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St. Jude shares would fall after they discovered the alleged vulnerabilities. We take the cyber security of our devices very seriously and creating the Cyber Security Medical Advisory Board is one more demonstration of our ongoing commitment to advancing standards of patient care around the world without comprising safety and security, St. Jude Chief Medical Officer Mark Carlson said in a statement. The board, whose membership has yet to be finalized, will work with technology experts at St. Jude Medical as well as external researchers to help ""maintain and enhance cyber security and patient safety, Carlson said.  Suzanne Schwartz, a senior official in the FDA's Center for Devices and Radiological Health, said the agency supports efforts by medical device manufacturers to prioritize cyber security.""Doing so in collaboration with other stakeholders such as cyber security researchers, health care providers, patients and government agencies, means cyber security vulnerabilities are more likely to be identified, assessed and fixed in a timely manner before they can cause patient harm,"" she said in a statement. St. Jude agreed in April to sell itself for $25 billion to Abbott Laboratories.The company last week said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. (Reporting by Jim Finkle in Boston; editing by Bernard Orr and Nick Zieminski)",2016-10-17,STJ,"Mon Oct 17, 2016 | 4:49pm EDT",St. Jude forms cyber panel after claims of heart-device bugs,http://www.reuters.com//article/us-st-jude-medical-cyber-idUSKBN12H286?type=companyNews,0.9801,0.048,0.821,0.131
91,"   By Jim Finkle  Medical-device maker St. Jude Medical Inc  said on Monday that it planned to set up a medical advisory board focused on cyber-security issues affecting patient care and safety.St. Jude said in a statement that the group, known as the Cyber Security Medical Advisory Board, would provide advice on cyber security standards for medical devices.The St. Paul, Minnesota-based company is establishing the group as the U.S. Food and Drug Administration investigates claims that St. Jude heart devices are riddled with defects that make them vulnerable to fatal cyber hacks. The FDA launched that probe in August after short-seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St. Jude shares would fall after they discovered the alleged vulnerabilities.""We take the cyber security of our devices very seriously and creating the Cyber Security Medical Advisory Board is one more demonstration of our ongoing commitment to advancing standards of patient care around the world without comprising safety and security,"" St. Jude Chief Medical Officer Mark Carlson said in a statement. The board, whose membership has yet to be finalized, will work with technology experts at St. Jude Medical as well as external researchers to help ""maintain and enhance cyber security and patient safety,"" Carlson said.Suzanne Schwartz, a senior official in the FDA's Center for Devices and Radiological Health, said the agency supports efforts by medical device manufacturers to prioritize cyber security. ""Doing so in collaboration with other stakeholders such as cyber security researchers, health care providers, patients and government agencies, means cyber security vulnerabilities are more likely to be identified, assessed and fixed in a timely manner before they can cause patient harm,"" she said in a statement.St. Jude agreed in April to sell itself for $25 billion to Abbott Laboratories.The company last week said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe.",2016-10-17,STJ,"Mon Oct 17, 2016 | 4:46pm EDT",St Jude forms cyber panel after claims of heart-device bugs,http://www.reuters.com//article/st-jude-medical-cyber-idUSL1N1CN1NI?type=companyNews,0.9836,0.045,0.811,0.143
92,"   By Jim Finkle  Medical-device maker St. Jude Medical Inc said on Monday that it planned to set up a medical advisory board focused on cyber-security issues affecting patient care and safety.St. Jude said in a statement that the group, known as the Cyber Security Medical Advisory Board, would provide advice on cyber security standards for medical devices.The St. Paul, Minnesota-based company is establishing the group as the U.S. Food and Drug Administration investigates claims that St. Jude heart devices are riddled with defects that make them vulnerable to fatal cyber hacks. The FDA launched that probe in August after short-seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St. Jude shares would fall after they discovered the alleged vulnerabilities. We take the cyber security of our devices very seriously and creating the Cyber Security Medical Advisory Board is one more demonstration of our ongoing commitment to advancing standards of patient care around the world without comprising safety and security, St. Jude Chief Medical Officer Mark Carlson said in a statement. The board, whose membership has yet to be finalized, will work with technology experts at St. Jude Medical as well as external researchers to help ""maintain and enhance cyber security and patient safety, Carlson said.  Suzanne Schwartz, a senior official in the FDA's Center for Devices and Radiological Health, said the agency supports efforts by medical device manufacturers to prioritize cyber security.""Doing so in collaboration with other stakeholders such as cyber security researchers, health care providers, patients and government agencies, means cyber security vulnerabilities are more likely to be identified, assessed and fixed in a timely manner before they can cause patient harm,"" she said in a statement. St. Jude agreed in April to sell itself for $25 billion to Abbott Laboratories.The company last week said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. (Reporting by Jim Finkle in Boston; editing by Bernard Orr and Nick Zieminski)",2016-10-17,STJ,"Mon Oct 17, 2016 | 4:49pm EDT",UPDATE 1-St Jude forms cyber panel after claims of heart-device bugs,http://www.reuters.com//article/st-jude-medical-cyber-idUSL1N1CN1MC?type=companyNews,0.9801,0.048,0.821,0.131
93,"  Oct 17 St. Jude Medical Inc :* St. Jude Medical announces it is forming a cyber security medical advisory board  * Anticipate board will work with technology experts at co, external researchers to help us maintain and enhance cyber security  Source text for Eikon:  Further company coverage: ",2016-10-17,STJ,"Mon Oct 17, 2016 | 2:41pm EDT",BRIEF-St. Jude Medical says is forming cyber security medical advisory board,http://www.reuters.com//article/idUSFWN1CN0EU?type=companyNews,0.875,0.0,0.788,0.212
94,"   By Jim Finkle  Oct 17 Medical-device maker St. Jude Medical Inc  said on Monday that it planned to set up a medical advisory board focused on cyber-security issues affecting patient care and safety.St. Jude said in a statement that the group, known as the Cyber Security Medical Advisory Board, would provide advice on cyber security standards for medical devices.The St. Paul, Minnesota-based company is establishing the group as the U.S. Food and Drug Administration investigates claims that St. Jude heart devices are riddled with defects that make them vulnerable to fatal cyber hacks. The FDA launched that probe in August after short-seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St. Jude shares would fall after they discovered the alleged vulnerabilities.""We take the cyber security of our devices very seriously and creating the Cyber Security Medical Advisory Board is one more demonstration of our ongoing commitment to advancing standards of patient care around the world without comprising safety and security,"" St. Jude Chief Medical Officer Mark Carlson said in a statement. The board, whose membership has yet to be finalized, will work with technology experts at St. Jude Medical as well as external researchers to help ""maintain and enhance cyber security and patient safety,"" Carlson said. An FDA representative said the agency had no immediate comment.St. Jude agreed in April to sell itself for $25 billion to Abbott Laboratories.The company last week said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe.    (Reporting by Jim Finkle in Boston; Editing by Bernard Orr)",2016-10-17,STJ,"Mon Oct 17, 2016 | 2:35pm EDT",St Jude forms cyber panel after claims of heart-device bugs,http://www.reuters.com//article/st-jude-medical-cyber-idUSL1N1CN15F?type=companyNews,0.9561,0.055,0.818,0.127
95,"  Abbott Laboratories, which is in the process of buying St. Jude Medical Inc for $25 billion, said the companies would sell some of their medical devices to Japan-based Terumo Corp for about $1.12 billion.Abbott said on Tuesday the deal is an important step toward completion of the St. Jude acquisition, which is scheduled to close by the year-end.The deal is subject to the successful completion of Abbott's acquisition of St. Jude and other approvals.The divestiture was a nice win for the companies as it signaled that the deal remained on track to close before the year-end and the price seems ""extremely lucrative"", Canaccord Genuity analysts wrote in a client note. St. Jude's shares rose 1.93 percent, their biggest intraday percentage jump since the deal with Abbott was announced in April, to $79.16. Abbott's shares gained about 1 percent to $40.96.     St. Jude has been under pressure after short-seller Muddy Waters and research firm MedSec Holdings alleged in August that the company's heart devices were riddled with defects that make them vulnerable to cyber hacks. St. Jude has denied the allegations and sued both companies.The company said last week it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. The all-cash transaction will include St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath, the companies said on Tuesday. Abbott said it would retain its vascular closure products. Abbott has been divesting to focus on its cardiovascular devices and diagnostics business, selling its medical optics division to Johnson & Johnson for $4.3 billion last month. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2016-10-18,STJ,"Tue Oct 18, 2016 | 11:03am EDT",St. Jude and Abbott to sell some medical devices for $1.12 billion,http://www.reuters.com//article/us-st-jude-medical-m-a-abbott-idUSKCN12I1G2?type=companyNews,0.8126,0.04,0.896,0.065
96,"  Abbott Laboratories, which is in the process of buying St. Jude Medical Inc for $25 billion, said the companies would sell some of their medical devices to Japan-based Terumo Corp for about $1.12 billion.Abbott said on Tuesday the deal is an important step toward completion of the St. Jude acquisition, which is scheduled to close by the year-end.The deal is subject to the successful completion of Abbott's acquisition of St. Jude and other approvals.The divestiture was a nice win for the companies as it signaled that the deal remained on track to close before the year-end and the price seems ""extremely lucrative"", Canaccord Genuity analysts wrote in a client note. St. Jude's shares rose 1.93 percent, their biggest intraday percentage jump since the deal with Abbott was announced in April, to $79.16. Abbott's shares gained about 1 percent to $40.96.     St. Jude has been under pressure after short-seller Muddy Waters and research firm MedSec Holdings alleged in August that the company's heart devices were riddled with defects that make them vulnerable to cyber hacks. St. Jude has denied the allegations and sued both companies.The company said last week it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. The all-cash transaction will include St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath, the companies said on Tuesday. Abbott said it would retain its vascular closure products. Abbott has been divesting to focus on its cardiovascular devices and diagnostics business, selling its medical optics division to Johnson & Johnson for $4.3 billion last month. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2016-10-18,STJ,"Tue Oct 18, 2016 | 11:03am EDT",UPDATE 2-St. Jude and Abbott to sell some medical devices for $1.12 bln,http://www.reuters.com//article/st-jude-medical-ma-abbott-idUSL4N1CO3VC?type=companyNews,0.8126,0.04,0.896,0.065
97,"  Oct 18 St. Jude Medical Inc* St. Jude Medical, FDA and top pediatric cardiology experts announce new clinical trial to treat congenital heart defects  * St. Jude Medical, FDA and top pediatric cardiology experts announce new clinical trial to treat congenital heart defects  Source text for Eikon:  Further company coverage: ",2016-10-18,STJ,"Tue Oct 18, 2016 | 9:28am EDT","BRIEF-St. Jude Medical, FDA and top pediatric cardiology experts announce new clinical trial to treat congenital heart defects",http://www.reuters.com//article/idUSASC09BKQ?type=companyNews,0.3818,0.094,0.749,0.157
98,"  Oct 18 Abbott Laboratories -* St. Jude Medical and Abbott to sell portion of vascular closure and electrophysiology businesses to Terumo Corporation* Deal for purchase price of approximately $1.12 billion * Abbott, St. Jude Medical and Terumo are bound by terms of an exclusivity agreement* Divestiture is an all-cash transaction * Abbott expects to mitigate any impact to its adjusted earnings per share projections related to sale of these assets to Terumo * Abbott to retain vascular closure products* Transaction is subject to successful completion of Abbott's acquisition of St. Jude Medical and antitrust regulatory approvals  Source text for Eikon:  Further company coverage:",2016-10-18,STJ,"Tue Oct 18, 2016 | 8:42am EDT",BRIEF-St. Jude and Abbott to divest two businesses to Terumo Corp,http://www.reuters.com//article/idUSASC09BJL?type=companyNews,0.7717,0.0,0.926,0.074
99,"  Oct 18 Abbott Laboratories and St. Jude Medical Inc   said they would sell some of their medical devices to Japan-based Terumo Corp for about $1.12 billion.The all-cash transaction will include St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath.  Abbott said the deal is an important step toward completion of its acquisition of St. Jude Medical, which is expected to close by the year-end.    (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila) ",2016-10-18,STJ,"Tue Oct 18, 2016 | 8:20am EDT",St. Jude and Abbott to sell some medical devices for $1.12 bln,http://www.reuters.com//article/st-jude-medical-ma-abbott-idUSL4N1CO3TC?type=companyNews,0.2023,0.0,0.977,0.023
100,"   By Ransdell Pierson and Natalie Grover  Abbott Laboratories said on Wednesday it was pushing ahead to complete its planned purchases of medical device maker St. Jude Medical Inc and diagnostics company Alere Inc despite lingering questions about product safety and government investigations.Abbott Chief Executive Officer Miles White on a conference call with analysts said he hoped to acquire St. Jude by the end of the year and praised the smaller company's handling of claims by short-seller Muddy Waters that its implantable heart devices posed cyber security risks.Although White said Abbott was pursuing all necessary regulatory approvals to acquire Alere, he did not go so far as to predict the deal would be approved. ""We'll work through regulatory approvals and see what happens,"" White said on the call.Shares of Abbott fell 2.7 percent to $40.04 while Alere rose 2.3 percent to $43.36 and St. Jude dipped 0.6 percent to $79, all on the New York Stock Exchange.Stifel Nicolaus analyst Rick Wise attributed Abbott's  decline to lingering uncertainty about the St. Jude and Alere deals, and worries about declining overseas sales of Abbott's baby formulas.""There's a lot of concern and noise,"" he said. ""Any hint of anything is making people anxious."" Abbott agreed in February to buy Alere for $5.8 billion, to acquire its diagnostic tests performed at home and in doctors' offices and hospitals. Just two months later it agreed to pay $25 billion for St. Jude, a leading maker of heart devices. The combined price of the two deals amounted to half of Abbott's market valuation.The relationship between Abbott and Alere cooled after the target company failed to file financial statements and disclosed probes into billing and foreign sales practices. Moreover, in July, at the request of the Food and Drug Administration, Alere recalled its INRatio device used to monitor levels of the widely used blood thinner warfarin because it was found to generate faulty results. In August, Alere filed a lawsuit accusing Abbott of dragging its feet on key antitrust submissions to sabotage the deal.Separately on Wednesday, Abbott reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.Excluding items, Abbott earned 59 cents per share on sales of $5.30 billion in the third quarter.Analysts, on average, expected earnings of 58 cents per share on revenue of $5.29 billion, according to Thomson Reuters I/B/E/S. Global sales of nutritional products, including baby formula Similac and Ensure for adults, fell 2 percent to $1.76 billion. Sales of the products outside the United States dropped 9.4 percent, largely due to declines in China, which is requiring manufacturers to reregister their baby formulas with the government to greater ensure their safety.""The situation in China is leading to a lot of unusually high (price) discounting,"" Stifel Nicolaus' Wise said.In the longer term, however, he said Abbott could benefit as many rival makers of infant formula vanish from the Chinese market due to stricter regulations.Also on Wednesday St. Jude reported its quarterly adjusted profit was 99 cents, missing the average estimate by 2 cents.St. Jude is facing multiple problems, including an investigation by the FDA over claims its heart devices have defects that make them vulnerable to fatal cyber hacks. The company has sued short-seller Muddy Waters and cyber research firm MedSec Holdings after they claimed flaws in the cyber security of Abbott's devices.St. Jude CEO Michael Rousseau said on a conference call on Wednesday he expected Muddy Waters to continue to ""mislead"" investors and patients about the cyber safety of its devices.Muddy Waters released several videos on Wednesday morning that claimed to be demonstrations of how attacks could be launched on St. Jude's implanted heart devices. Reuters was unable to independently confirm claims in the videos, which were posted on a new website set up by Muddy Waters, www.profitsoverpatients.com.A St. Jude spokeswoman said the company had not verified the claims in the videos.In an unrelated matter last week, St. Jude said it will recall some of its 400,000 implanted heart devices due to the risk of premature battery depletion, a condition linked to two deaths in Europe.St. Jude and Abbott on Tuesday announced a $1.12 billion deal to sell some of their devices to Japan-based Terumo Corp, an important step toward completing their tie-up.     (Reporting by Ransdell Pierson in New York and Natalie Grover in Bengaluru; Additional reporting by Jim Finkle in Boston and Bill Berkrot in New York; Editing by Martina D'Couto and Jeffrey Benkoe)",2016-10-19,STJ,"Wed Oct 19, 2016 | 12:48pm EDT","Abbott moves ahead on St. Jude, Alere deals, but investors fret",http://www.reuters.com//article/us-abbott-results-idUSKCN12J1DE?type=companyNews,0.9661,0.047,0.876,0.077
101,"  Oct 19 Abbott, in conference call with analysts:* Says continues to believe Alere Inc would be good strategic, long term fit, for Abbott* Says expects fourth quarter EPS of 64 cents to 66 cents per share, excluding special items * Says deal to purchase St. Jude to close, and probably by the end of 2016* Says cyber security allegations will not affect closing of St. Jude deal or overall business, based on current information * Abbott CEO says St. Jude has handled Muddy Waters cyber security allegations ""well and thoroughly"" * Abbott CEO says St. Jude has taken cyber security allegations relating to its heart devices ""seriously""* Further company coverage:     (Reporting by Ransdell Pierson)",2016-10-19,STJ,"Wed Oct 19, 2016 | 10:06am EDT",BRIEF-Abbott says pursuing all necessary regulatory approvals to buy Alere,http://www.reuters.com//article/idUSL1N1CP0NE?type=companyNews,0.9485,0.0,0.84,0.16
102,"  Oct 19 Abbott Laboratories, which is in the process of acquiring St. Jude Medical Inc, reported a nearly 3 percent rise in quarterly sales, fueled by strength in its generic drug and medical device businesses.Net loss from continuing operations was $329 million, or 24 cents per share, primarily due to an adjustment of 66 cents per share associated with Abbott's equity investment in Mylan NV . Abbott sold its generic drugs business catering to developed markets to Mylan in 2014. Abbott earned $580 million, or 39 cents per share, a year earlier.  Net sales rose to $5.30 billion from $5.15 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)",2016-10-19,STJ,"Wed Oct 19, 2016 | 8:03am EDT",Abbott's third-quarter revenue rises nearly 3 percent,http://www.reuters.com//article/abbott-results-idUSL4N1CO4GB?type=companyNews,0.7579,0.02,0.894,0.086
103,"  Oct 19 St. Jude Medical Inc -* St. Jude Medical reports third quarter 2016 results* Q3 adjusted earnings per share $0.99* Q3 earnings per share $0.73* Q3 sales $1.499 billion versus i/b/e/s view $1.5 billion * Q3 earnings per share view $1.01 -- Thomson Reuters I/B/E/S* St. Jude Medical Inc qtrly total CRM sales were $378 million for Q3 of 2016, a 7 percent decline on both a reported and constant currency basis * Due to planned merger with Abbott, st. Jude Medical withdrew financial guidance for fiscal year 2016* Total cardiovascular sales were $313 million for Q3 of 2016, an increase of 8 percent compared to prior year quarter * In q3 company recognized net after-tax charges of $74 million, or $0.26 per diluted share* After-tax charges in Q3 related to amortization of intangible assets, product field action costs, litigation costs, acquisition-related costs* St. Jude Medical Inc continues to expect Abbott transaction to close in Q4 of 2016  Source text for Eikon:  Further company coverage:",2016-10-19,STJ,"Wed Oct 19, 2016 | 7:41am EDT",BRIEF-St. Jude Medical Q3 earnings per share $0.73,http://www.reuters.com//article/idUSASC09BRC?type=companyNews,0.6369,0.036,0.892,0.073
104,"   By Jim Finkle  Short-selling firm Muddy Waters said in a legal filing on Monday that outside experts it hired validated its claims that St. Jude Medical Inc cardiac implants are vulnrable to potentially life-threatening cyber attacks.U.S. regulators responded by reiterating previous advice that patients should keep using the devices, and a St. Jude spokeswoman said the company would respond ""through appropriate legal channels.""Muddy Waters released a 53-page report from boutique cyber security firm Bishop Fox as part of a legal filing in federal court in Minnesota in its defense against a suit brought by St. Jude. Bishop Fox said in the report it validated the claims with help from well-known specialists in cryptography, computer hardware hacking, forensics and wireless communications, and cyber research firm MedSec Holdings that St. Jude cardiac implants are susceptible to hacking.St. Paul, Minnesota-based St. Jude has strongly disputed those claims, which are under investigation by the U.S. Food and Drug Administration.One of the world's biggest makers of implantable cardiac devices, St. Jude filed a lawsuit against San Francisco-based Muddy Waters, Miami-based MedSec and individuals affiliated with those firms on Sept. 7.St. Jude accused them of intentionally disseminating false information about its heart devices to manipulate its stock price, which fell 5 percent the day they went public with their claims. The FDA said in a statement it had no comment on the litigation but that based on information obtained to date it urged patients to continue using devices as directed by their physicians.""The benefits of the devices far outweigh any potential cyber security vulnerabilities,"" the FDA said of St. Jude's cardiac implants, which the company said have been implanted in hundreds of thousands of patients.St. Jude spokeswoman Candace Steele Flippin said the company's lawyers were reviewing the documents from Muddy Waters and MedSec.""We continue to feel this lawsuit is the best course of action to make sure those looking to profit by trying to frighten patients and caregivers are held accountable for their actions,"" she said in an email. St. Jude in April agreed to sell itself for $25 billion to Abbott Laboratories.Short sellers like Muddy Waters make bets that stock prices will fall, selling borrowed shares so they can buy them at a lower price and profit from the difference.The defendants said that St. Jude's lawsuit is without merit, reiterating their prior claim that St. Jude's heart devices have ""significant security vulnerabilities."" ""Muddy Waters' and MedSec's statements regarding security issues in the St. Jude Medical implant ecosystem were, by and large, accurate,"" Bishop Fox Partner Carl Livitt said in the report.The report said the wireless communications in St. Jude cardiac devices are vulnerable to hacking, making it possible for hackers to convert the company's Merlin@home patient monitoring devices into ""weapons"" that can cause cardiac implants to stop providing care and deliver shocks to patients.Bishop Fox said it conducted successful test attacks from 10 feet (3 meters) away, but that the range might be extended to as far as 100 feet (30 meters) with an antenna and a specialized device known as a software defined radio.The report said Bishop Fox confirmed that several different types of hacks were possible. In one instance, it said, a hacker could remotely turn off the therapeutic functions of an  implantable cardioverter defibrillator (ICD), then send a T-wave shock to a patient's heart, causing ventricular fibrillation, would could lead to cardiac arrest.Bishop Fox said its clients include Fortune 500 firms,  global financial firms, medical institutions and law firms.Shares in St. Jude were little changed in afternoon trading.",2016-10-24,STJ,"Mon Oct 24, 2016 | 3:40pm EDT",Hired experts back claims St. Jude heart devices can be hacked,http://www.reuters.com//article/st-jude-medical-cyber-muddywaters-idUSL1N1CU15H?type=companyNews,0.9761,0.059,0.843,0.099
105,"   By Jim Finkle  Short-selling firm Muddy Waters said in a legal filing on Monday that outside experts it hired validated its claims that St. Jude Medical Inc  cardiac implants are vulnerable to potentially life-threatening cyber attacks.U.S. regulators responded by reiterating previous advice that patients should keep using the devices, and a St. Jude spokeswoman said the company would respond ""through appropriate legal channels.""Muddy Waters released a 53-page report from boutique cyber security firm Bishop Fox as part of a legal filing in federal court in Minnesota in its defense against a suit brought by St. Jude. Bishop Fox said in the report it validated the claims with help from well-known specialists in cryptography, computer hardware hacking, forensics and wireless communications, and cyber research firm MedSec Holdings that St. Jude cardiac implants are susceptible to hacking. St. Paul, Minnesota-based St. Jude has strongly disputed those claims, which are under investigation by the U.S. Food and Drug Administration. One of the world's biggest makers of implantable cardiac devices, St. Jude filed a lawsuit against San Francisco-based Muddy Waters, Miami-based MedSec and individuals affiliated with those firms on Sept. 7.St. Jude accused them of intentionally disseminating false information about its heart devices to manipulate its stock price, which fell 5 percent the day they went public with their claims.The FDA said in a statement it had no comment on the litigation but that based on information obtained to date it urged patients to continue using devices as directed by their physicians. ""The benefits of the devices far outweigh any potential cyber security vulnerabilities,"" the FDA said of St. Jude's cardiac implants, which the company said have been implanted in hundreds of thousands of patients.St. Jude spokeswoman Candace Steele Flippin said the company's lawyers were reviewing the documents from Muddy Waters and MedSec.""We continue to feel this lawsuit is the best course of action to make sure those looking to profit by trying to frighten patients and caregivers are held accountable for their actions,"" she said in an email.St. Jude in April agreed to sell itself for $25 billion to Abbott Laboratories. Short sellers like Muddy Waters make bets that stock prices will fall, selling borrowed shares so they can buy them at a lower price and profit from the difference.The defendants said that St. Jude's lawsuit is without merit, reiterating their prior claim that St. Jude's heart devices have ""significant security vulnerabilities.""""Muddy Waters' and MedSec's statements regarding security issues in the St. Jude Medical implant ecosystem were, by and large, accurate,"" Bishop Fox Partner Carl Livitt said in the report. The report said the wireless communications in St. Jude cardiac devices are vulnerable to hacking, making it possible for hackers to convert the company's Merlin@home patient monitoring devices into ""weapons"" that can cause cardiac implants to stop providing care and deliver shocks to patients. Bishop Fox said it conducted successful test attacks from 10 feet (3 meters) away, but that the range might be extended to as far as 100 feet (30 meters) with an antenna and a specialized device known as a software defined radio. The report said Bishop Fox confirmed that several different types of hacks were possible. In one instance, it said, a hacker could remotely turn off the therapeutic functions of an  implantable cardioverter defibrillator (ICD), then send a T-wave shock to a patient's heart, causing ventricular fibrillation, would could lead to cardiac arrest.Bishop Fox said its clients include Fortune 500 firms,  global financial firms, medical institutions and law firms.Shares in St. Jude were little changed in afternoon trading. (Reporting by Jim Finkle; Editing by Will Dunham)",2016-10-24,STJ,"Mon Oct 24, 2016 | 3:31pm EDT",Hired experts back claims St. Jude heart devices can be hacked,http://www.reuters.com//article/us-st-jude-medical-cyber-muddywaters-idUSKCN12O1O1?type=companyNews,0.9749,0.06,0.843,0.097
106,"   By Jim Finkle  Short-selling firm Muddy Waters said in a legal filing on Monday that outside experts it hired validated its claims that St. Jude Medical Inc  cardiac implants are vulnerable to potentially life-threatening cyber attacks.U.S. regulators responded by reiterating previous advice that patients should keep using the devices, and a St. Jude spokeswoman said the company would respond ""through appropriate legal channels.""Muddy Waters released a 53-page report from boutique cyber security firm Bishop Fox as part of a legal filing in federal court in Minnesota in its defense against a suit brought by St. Jude. Bishop Fox said in the report it validated the claims with help from well-known specialists in cryptography, computer hardware hacking, forensics and wireless communications, and cyber research firm MedSec Holdings that St. Jude cardiac implants are susceptible to hacking. St. Paul, Minnesota-based St. Jude has strongly disputed those claims, which are under investigation by the U.S. Food and Drug Administration. One of the world's biggest makers of implantable cardiac devices, St. Jude filed a lawsuit against San Francisco-based Muddy Waters, Miami-based MedSec and individuals affiliated with those firms on Sept. 7.St. Jude accused them of intentionally disseminating false information about its heart devices to manipulate its stock price, which fell 5 percent the day they went public with their claims.The FDA said in a statement it had no comment on the litigation but that based on information obtained to date it urged patients to continue using devices as directed by their physicians. ""The benefits of the devices far outweigh any potential cyber security vulnerabilities,"" the FDA said of St. Jude's cardiac implants, which the company said have been implanted in hundreds of thousands of patients.St. Jude spokeswoman Candace Steele Flippin said the company's lawyers were reviewing the documents from Muddy Waters and MedSec.""We continue to feel this lawsuit is the best course of action to make sure those looking to profit by trying to frighten patients and caregivers are held accountable for their actions,"" she said in an email.St. Jude in April agreed to sell itself for $25 billion to Abbott Laboratories. Short sellers like Muddy Waters make bets that stock prices will fall, selling borrowed shares so they can buy them at a lower price and profit from the difference.The defendants said that St. Jude's lawsuit is without merit, reiterating their prior claim that St. Jude's heart devices have ""significant security vulnerabilities.""""Muddy Waters' and MedSec's statements regarding security issues in the St. Jude Medical implant ecosystem were, by and large, accurate,"" Bishop Fox Partner Carl Livitt said in the report. The report said the wireless communications in St. Jude cardiac devices are vulnerable to hacking, making it possible for hackers to convert the company's Merlin@home patient monitoring devices into ""weapons"" that can cause cardiac implants to stop providing care and deliver shocks to patients. Bishop Fox said it conducted successful test attacks from 10 feet (3 meters) away, but that the range might be extended to as far as 100 feet (30 meters) with an antenna and a specialized device known as a software defined radio. The report said Bishop Fox confirmed that several different types of hacks were possible. In one instance, it said, a hacker could remotely turn off the therapeutic functions of an  implantable cardioverter defibrillator (ICD), then send a T-wave shock to a patient's heart, causing ventricular fibrillation, would could lead to cardiac arrest.Bishop Fox said its clients include Fortune 500 firms,  global financial firms, medical institutions and law firms.Shares in St. Jude were little changed in afternoon trading. (Reporting by Jim Finkle; Editing by Will Dunham)",2016-10-24,STJ,"Mon Oct 24, 2016 | 3:31pm EDT",UPDATE 3-Hired experts back claims St. Jude heart devices can be hacked,http://www.reuters.com//article/st-jude-medical-cyber-muddywaters-idUSL1N1CU132?type=companyNews,0.9749,0.06,0.843,0.097
107,"  (Corrects spelling of last name of Bishop Fox partner in paragraph 7, Livitt instead of Livit)By Jim FinkleOct 24 Short-selling firm Muddy Waters said in a legal brief filed on Monday that outside cyber security experts it hired have validated its claim that St. Jude Medical Inc  cardiac implants are vulnerable to potentially life-threatening cyber attacks.Boutique cyber security firm Bishop Fox disclosed its findings in a 53-page report that was attached to a legal brief filed on Monday in U.S. district court in Minnesota on behalf of the short-sellers, who hired the firm to perform the work as they defend themselves in a lawsuit filed by St. Jude.A representative for St. Jude was not immediately available for comment. St. Jude filed the suit on Sept. 7 against Muddy Waters, cyber research firm MedSec Holdings and individuals affiliated with those companies. The suit accused the group of intentionally disseminating false information about St. Jude heart devices to manipulate its stock price, which fell 5 percent on the day they revealed their claims.The defendants said in a filing released on Monday that the lawsuit is without merit, reiterating their claim that St. Jude Medical's heart devices have ""significant security vulnerabilities."" The report from Bishop Fox said the firm was able to validate those claims.""I found that Muddy Waters' and MedSec's statements regarding security issues in the St. Jude Medical implant ecosystem were, by and large, accurate,"" Bishop Fox Partner Carl Livitt said in an introduction to the report. The report said that the wireless communications protocol used in St. Jude cardiac devices is vulnerable to hacking, making it possible for hackers to convert the company's Merlin@home patient monitoring devices into ""weapons"" that can cause cardiac implants to stop providing care and deliver shocks to patients.Bishop Fox tested the attacks from 10 feet (3 meters) away, but said that might be extended to 45 feet (13.7 meters) with an antenna, or 100 feet (30.5 meters) with a transmitting device known as a software defined radio.(Reporting by Jim Finkle; Editing by Will Dunham)",2016-10-24,STJ,"Mon Oct 24, 2016 | 1:15pm EDT",CORRECTED-UPDATE 1-Hired experts support claims St. Jude heart devices can be hacked,http://www.reuters.com//article/st-jude-medical-cyber-muddywaters-correc-idUSL1N1CU0MK?type=companyNews,0.1491,0.042,0.911,0.047
108,"  BOSTON Oct 24 Short-selling firm Muddy Waters said in a legal brief filed on Monday that that it hired outside cyber security experts, who found that St Jude Medical Inc  heart devices can be hacked. Muddy Waters submitted a 53-page report from those experts in a legal filing in Minnesota U.S. District. It is also published on a Muddy Waters' website, www.profitsoverpatients.com.   (Reporting by Jim Finkle Editing by W Simon)  ",2016-10-24,STJ,"Mon Oct 24, 2016 | 9:46am EDT",Muddy Waters says outside experts found St Jude devices can be hacked,http://www.reuters.com//article/st-jude-medical-cyber-muddywaters-idUSL1N1CU0J3?type=companyNews,0.1779,0.039,0.883,0.078
109,  Oct 24 St. Jude Medical Inc : * St. Jude medical announces data to be presented as late-breaking clinical trials and highlights its latest cardiovascular portfolio at the 2016 TCT conference  Source text for Eikon:  Further company coverage:  ,2016-10-24,STJ,"Mon Oct 24, 2016 | 8:40am EDT",BRIEF-St. Jude Medical announces data to be presented as late-breaking clinical trials,http://www.reuters.com//article/idUSASC09CHN?type=companyNews,0.0,0.0,1.0,0.0
110,"  Oct 26 St. Jude Medical Inc -* St. Jude Medical shareholders approve merger with Abbott * Companies continue to expect transaction to close by end of year  * Based on preliminary vote results, about 99 percent of voting St. Jude medical shareholders cast their vote in favor of merger  Source text for Eikon:  Further company coverage:",2016-10-26,STJ,"Wed Oct 26, 2016 | 4:56pm EDT",BRIEF-St. Jude Medical shareholders approve merger with Abbott,http://www.reuters.com//article/idUSASC09DDA?type=companyNews,0.4019,0.0,0.952,0.048
111,"   By Bill Berkrot  Medical device maker St. Jude Medical Inc said on Friday it has notified doctors to stop implants of one of its cardiac pacemakers, citing reports of problems with electronic data reporting caused by a battery malfunction that could put patients at risk.The affected device is the Nanostim leadless cardiac pacemaker (LCP). St. Jude, which is being acquired by Abbott Laboratories, said it had seven reports of lost telemetry and heart pacing output from the devices.Of a total of 1,423 Nanostim devices implanted worldwide, 1,397 remain in service and represent a potential risk to patients, the company warned.There have been no reports of patient injury associated with the malfunction, St. Jude said.""We are currently working to ensure our physician partners worldwide have the information they need to effectively manage their patients,"" St. Jude Chief Medical Officer Mark Carlson said in a statement, adding that the company remains committed to developing leadless pacing technology. In a letter to doctors, St. Jude said they should not implant any Nanostim pacemakers they might have in stock and instead return them to the company. It said device replacement is recommended, with priority given to patients with implants of the longest duration.Pacemakers are used to keep a patient's heart beating at a normal healthy rate. The seven reports of problems occurred between 29 and 37 months after implant, St. Jude said.Two of the affected patients received replacement LCPs, three received more traditional pacemakers and two are awaiting replacement devices, it said. The company said it will analyze returned LCPs.The LCP issue follows other recent problems with St. Jude  heart devices. Earlier this month, the company announced a recall of some of its other implanted heart devices due to risk of premature battery depletion, which was linked to two deaths in Europe. That recall involved ICDs and CRT-Ds that are used to shock a dangerously racing heart back to its normal rhythm, or to help maintain a normal heart rhythm. ICDs are implantable cardioverter defibrillators, while CRT-D stands for cardiac resynchronization therapy defibrillator. St. Jude shares were off 71 cents, or nearly 1 percent, at $78.30 on the New York Stock Exchange. (Reporting by Bill Berkrot in New York; Editing by Matthew Lewis and Dan Grebler)",2016-10-28,STJ,"Fri Oct 28, 2016 | 1:55pm EDT","St. Jude halts pacemaker implants due to data, battery issues",http://www.reuters.com//article/us-st-jude-medical-pacemaker-idUSKCN12S24J?type=companyNews,-0.9274,0.086,0.87,0.044
112,"   By Bill Berkrot  Medical device maker St. Jude Medical Inc said on Friday it has notified doctors to stop implants of one of its cardiac pacemakers, citing reports of problems with electronic data reporting caused by a battery malfunction that could put patients at risk.The affected device is the Nanostim leadless cardiac pacemaker (LCP). St. Jude, which is being acquired by Abbott Laboratories, said it had seven reports of lost telemetry and heart pacing output from the devices.Of a total of 1,423 Nanostim devices implanted worldwide, 1,397 remain in service and represent a potential risk to patients, the company warned.There have been no reports of patient injury associated with the malfunction, St. Jude said.""We are currently working to ensure our physician partners worldwide have the information they need to effectively manage their patients,"" St. Jude Chief Medical Officer Mark Carlson said in a statement, adding that the company remains committed to developing leadless pacing technology. In a letter to doctors, St. Jude said they should not implant any Nanostim pacemakers they might have in stock and instead return them to the company. It said device replacement is recommended, with priority given to patients with implants of the longest duration.Pacemakers are used to keep a patient's heart beating at a normal healthy rate. The seven reports of problems occurred between 29 and 37 months after implant, St. Jude said.Two of the affected patients received replacement LCPs, three received more traditional pacemakers and two are awaiting replacement devices, it said. The company said it will analyze returned LCPs.The LCP issue follows other recent problems with St. Jude  heart devices. Earlier this month, the company announced a recall of some of its other implanted heart devices due to risk of premature battery depletion, which was linked to two deaths in Europe. That recall involved ICDs and CRT-Ds that are used to shock a dangerously racing heart back to its normal rhythm, or to help maintain a normal heart rhythm. ICDs are implantable cardioverter defibrillators, while CRT-D stands for cardiac resynchronization therapy defibrillator. St. Jude shares were off 71 cents, or nearly 1 percent, at $78.30 on the New York Stock Exchange. (Reporting by Bill Berkrot in New York; Editing by Matthew Lewis and Dan Grebler)",2016-10-28,STJ,"Fri Oct 28, 2016 | 1:55pm EDT","UPDATE 1-St. Jude halts pacemaker implants due to data, battery issues",http://www.reuters.com//article/st-jude-medical-pacemaker-idUSL1N1CY1BA?type=companyNews,-0.9274,0.086,0.87,0.044
113,"  The U.S. Food and Drug Administration today approved St. Jude Medical Inc's device to prevent recurrent strokes in certain patients.The device, amplatzer PFO occluder, has been approved for patients who previously had a stroke due to a blood clot that passed through a small hole in the heart and then traveled to the brain. (bit.ly/2eVlgo2)    (Reporting by Dipika Jain in Bengaluru; Editing by Shounak Dasgupta)",2016-10-28,STJ,"Fri Oct 28, 2016 | 1:49pm EDT",FDA approves St. Jude device to prevent recurring strokes in some patients,http://www.reuters.com//article/us-st-jude-medical-fda-idUSKCN12S2C3?type=companyNews,0.7783,0.0,0.868,0.132
114,  Oct 28 U.S. FDA: * FDA - approves St. Jude Medical's Amplatzer PFO Occluder device for prevention of recurrent strokes in certain patients  Source text bit.ly/2eVlgo2 Further company coverage:  ,2016-10-28,STJ,"Fri Oct 28, 2016 | 1:45pm EDT",BRIEF-U.S. FDA approves St. Jude Medical's device for prevention of recurring strokes,http://www.reuters.com//article/idUSFWN1CY1FL?type=companyNews,0.5859,0.0,0.839,0.161
115,"  Oct 28 Medical device maker St. Jude Medical Inc  said on Friday it has paused implanting of one of its cardiac pacemakers due to problems with electronic data reporting.The affected device is the Nanostim leadless cardiac pacemaker (LCP). St. Jude, which is being acquired by Abbott Laboratories, said it had seven reports of lost telemetry and heart pacing output from the devices.There had been no reports of patient injury associated with the malfunction, the company said. ""We are currently working to ensure our physician partners worldwide have the information they need to effectively manage their patients,"" St. Jude Chief Medical Officer Mark Carlson said in a statement, adding that the company remains committed to developing leadless pacing technology. Implanted pacemakers are used to keep a patient's heart beating at a normal healthy rate. (Reporting by Bill Berkrot in New York; Editing by Matthew Lewis)",2016-10-28,STJ,"Fri Oct 28, 2016 | 12:28pm EDT",St. Jude halts certain pacemaker implants over data issue,http://www.reuters.com//article/st-jude-medical-pacemaker-idUSL1N1CY188?type=companyNews,-0.5106,0.094,0.84,0.066
116,"  Oct 28 St. Jude Medical Inc :* Has paused implants of Nanostim leadless cardiac pacemaker due to 7 reports of lost telemetry and pacing output from pacemaker  * There have been no reports of patient injury associated with lost telemetry, pacing output from its leadless cardiac pacemaker  Further company coverage: ",2016-10-28,STJ,"Fri Oct 28, 2016 | 12:03pm EDT",BRIEF-St Jude pauses implants of cardiac pacemaker due to reports of lost telemetry,http://www.reuters.com//article/idUSFWN1CY1D1?type=companyNews,-0.6249,0.171,0.766,0.062
117,  Nov 1 St. Jude Medical Inc :* analysis of RESPECT trial showed Amplatzer PFO Occluder reduced risk of recurrent stroke by 45% over guideline-directed medical therapy alone  * long-term follow-up treatment with Amplatzer PFO Occluder was more effective than medical therapy alone in reducing risk for recurrent stroke  Source text for Eikon:  Further company coverage: ,2016-11-01,STJ,"Tue Nov 1, 2016 | 1:07pm EDT",BRIEF-St. Jude Medical reports long-term data from RESPECT trial,http://www.reuters.com//article/idUSFWN1D20RW?type=companyNews,0.6732,0.126,0.708,0.165
118,"  BRUSSELS Medical device maker Abbott Laboratories (ABT.N) has offered concessions in an attempt to secure EU antitrust approval for its $25 billion bid for St Jude Medical Inc (STJ.N), according to the European Commision.The move pushed back the European Commission's decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer's website on Thursday. It did not provide details.The Commission can either accept the offer, demand more or open an investigation which can take up to five months. Abbott and St Jude last month announced the sale of some of their medical devices worth about $1.12 billion to Japanese company Terumo Corp (4543.T) as part of their deal. The deal comes as medical equipment makers come under pressure to offer a wider range of products to hospital customers.  (Reporting by Foo Yun Chee; Editing by Alexandra Hudson)",2016-11-03,STJ,"Thu Nov 3, 2016 | 12:46pm EDT",Abbott offers EU concessions over $25 billion St. Jude deal,http://www.reuters.com//article/us-st-jude-medical-m-a-abbott-eu-idUSKBN12Y26P?type=companyNews,0.743,0.025,0.909,0.066
119,"  BRUSSELS Medical device maker Abbott Laboratories (ABT.N) has offered concessions in an attempt to secure EU antitrust approval for its $25 billion bid for St Jude Medical Inc (STJ.N), according to the European Commision.The move pushed back the European Commission's decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer's website on Thursday. It did not provide details.The Commission can either accept the offer, demand more or open an investigation which can take up to five months. Abbott and St Jude last month announced the sale of some of their medical devices worth about $1.12 billion to Japanese company Terumo Corp (4543.T) as part of their deal. The deal comes as medical equipment makers come under pressure to offer a wider range of products to hospital customers.  (Reporting by Foo Yun Chee; Editing by Alexandra Hudson)",2016-11-03,STJ,"Thu Nov 3, 2016 | 12:46pm EDT",Abbott offers EU concessions over $25 bln St Jude deal,http://www.reuters.com//article/st-jude-medical-ma-abbott-eu-idUSL8N1D47ZN?type=companyNews,0.743,0.025,0.909,0.066
120,  Nov 7 St. Jude Medical Inc * st. Jude medical gains CE mark approval for MRI labeling of its quadra allure mp cardiac resynchronization therapy pacemaker  Source text for Eikon:  Further company coverage:  ,2016-11-07,STJ,"Mon Nov 7, 2016 | 8:16am EST",BRIEF-St. Jude Medical gains CE mark approval for MRI labeling of its Quadra Allure MP cardiac Resynchronization Therapy Pacemaker,http://www.reuters.com//article/idUSFWN1D80RW?type=companyNews,0.6705,0.0,0.841,0.159
121,"   By Foo Yun Chee  EU antitrust regulators are expected to give conditional clearance to U.S. medical device maker Abbott Laboratories' (ABT.N) $25 billion bid for rival St. Jude Medical Inc (STJ.N), a person familiar with the matter said on Tuesday.A spokesman for the European Commission, which is due to decide on the deal by Nov. 23, declined to comment. Abbott, which also makes prescription drugs and diagnostics, had no immediate comment. St. Jude officials could not be reached for comment.Abbott Chief Executive Miles White in October said he hoped to acquire St. Jude by the end of the year, despite lingering questions about the safety of its implantable heart devices.The suburban Chicago company announced the St. Jude deal in April to expand its heart device business and help it compete against larger rivals Medtronic Plc (MDT.N) and Boston Scientific Corp (BSX.N).The companies offered concessions to address the European Commission's concerns on Oct. 31 but did not disclose details.  However, two weeks before that, they announced the sale of some of their medical devices worth about $1.12 billion to Japanese company Terumo Corp (4543.T), saying the move was part of their deal.The all-cash transaction included St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath.St. Jude is facing multiple problems, including an investigation by the U.S. Food and Drug Administration over claims its heart devices have defects that make them vulnerable to fatal cyber hacks. The company sued short-seller Muddy Waters and its investment partner, cyber research firm MedSec Holdings, after they claimed flaws in the cyber security of its devices. MedSec warned the alleged flaws could cause implanted devices to pace at potentially dangerous rates or have their batteries drained.After Abbott reported stronger than expected earnings on Oct. 19, White praised the way St. Jude has handled Muddy Waters' allegations. In an unrelated matter last month, St. Jude said it will recall some of its 400,000 implanted heart devices due to the risk of premature battery depletion, a condition linked to two deaths in Europe.Shares of Abbott and St. Jude both closed 1.6 percent higher on Tuesday amid moderate gains for the broad stock market.Mergers in the sector have underscored the pressure felt by medical equipment makers to scale up and offer a wider range of products to hospital customers. (Reporting by Foo Yun Chee in Brussels; Additional reporting by Natalie Grover in Bengaluru and Ransdell Pierson in New York; Editing by Ruth Pitchford and Matthew Lewis)",2016-11-15,STJ,"Tue Nov 15, 2016 | 5:52pm EST","Exclusive: EU regulators seen clearing $25 billion Abbott, St Jude deal: source",http://www.reuters.com//article/us-st-jude-m-a-abbott-eu-idUSKBN13A2J3?type=companyNews,-0.815,0.066,0.878,0.056
122,"  (Adds Viacom, Abbott, Valeant, updates Lundin)Nov 15 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:** EU antitrust regulators are expected to give conditional clearance to U.S. medical device maker Abbott Laboratories'  bid for peer St Jude Medical Inc, a person familiar with the matter said on Tuesday.** South Korea's Hyundai Heavy Industries is being split into four companies, with its non-shipbuilding businesses being spun off to improve management efficiency and competitiveness, the shipbuilder said.** International Data Group, a pioneer in technology publishing and owner of such venerable names as PCWorld and the market research firm IDC, is in talks to sell itself for more than $1 billion to a Chinese investor group headed by IDG of Greater China chairman Hugo Shong, according to people familiar with the matter.** Canada's Lundin Mining Corp is hopeful that the sale of its stake in the Tenke Fungurume copper-cobalt mine in the Democratic Republic of Congo will not be challenged by the country's state-owned miner, Lundin's chief executive said.** Cosmetics maker Estee Lauder Cos Inc agreed to buy makeup brand Too Faced for about $1.45 billion in its biggest-ever deal, adding products such as Better than Sex mascara and Melted Matte lipsticks that are popular among millennials.** U.S. cigarette maker Reynolds American Inc is seeking a higher price from British American Tobacco Plc  after rejecting its $47 billion takeover offer, a source familiar with the situation told Reuters. ** Kirkland Lake Gold shares rose sharply on Monday on speculation there might be another bid for the Canadian gold miner which has rejected three offers, but at least one potential buyer said it would not jump into the fray.** Grocery shopping center owner Regency Centers Corp  said on Monday it would buy Equity One Inc for about $4.6 billion, adding shopping centers in urban areas like New York and Los Angeles to its portfolio.** Russia's top oil producer Rosneft has offered 3,706.41 roubles ($56.74) per share for a mandatory buyout of minority shareholders in its mid-sized rival Bashneft, the company said in a regulatory filing. ** Britain's financial regulator approved interdealer broker Tullett Prebon's proposed acquisition of ICAP Plc's  hybrid voice broking business, removing a key regulatory hurdle in the path to create the world's largest voice broker.** EDF's board has formally approved an offer by the French state-owned power utility to acquire Areva's  reactor assets, a key plank in the troubled nuclear group's recovery plan, two sources said.**  Kazakhstan's two biggest lenders, Kazkommertsbank (KKB)  and Halyk Bank,, are discussing a merger to create a bank with assets of $27 billion that would dwarf its competitors, two sources familiar with the talks told Reuters.** French veterinary pharmaceuticals firm Ceva Sante Animale is raising a 600 million euro add-on term loan to finance two acquisitions and refinance expensive subordinated debt, banking sources said. **  Valeant Pharmaceuticals Inc, a heavily indebted Canadian drugmaker trying to sell non-core assets, has received offers for some core businesses, Chief Executive Joe Papa said.** General Electric Co said its software unit bought ServiceMax, a cloud-based provider of software used in inventory and workforce management, for $915 million.The company also acquired two tech startups to build its artificial intelligence capability, a move that helps it compete with IBM's Watson product.** Private equity firm Equistone Partners has put its controlling stake in Unither Pharmaceuticals up for sale, with investment firms Eurazeo and Wendel among possible bidders, sources with knowledge of the matter told Reuters. CVC Capital is also among potential buyers of the medical packaging maker, the sources said.** EU antitrust regulators are set to clear German container shipping line Hapag-Lloyd's merger with United Arab Shipping Company (UASC) after the latter agreed to withdraw from some vessel sharing agreements, two people familiar with the matter said.** Viacom Inc, the owner of Comedy Central, Nickelodeon and MTV, said it had bought Argentine broadcaster Television Federal SA (Telefe) from telecom carrier Telefonica SA TEF.MC for $345 million in cash.** French sovereign fund Bpifrance and Credit Agricole announced plans to sell a 1.85 percent stake in Schneider Electric through an accelerated book-building with institutional investors.    (Compiled by Komal Khettry and Aishwarya Venugopal in Bengaluru)",2016-11-15,STJ,"Tue Nov 15, 2016 | 4:07pm EST",Deals of the day - Mergers and acquisitions,http://www.reuters.com//article/idUSL4N1DG3MR?type=companyNews,0.995,0.016,0.878,0.107
123,"   By Bill Berkrot | NEW ORLEANS  NEW ORLEANS St. Jude Medical Inc's new, smaller HeartMate 3 heart pumping assist device proved superior to its older HeartMate II in advanced heart failure patients, according to the first data from a large trial presented on Wednesday.Six months after implantation, 86 percent of patients who received HeartMate 3 were still alive without a disabling stroke or need for reoperation to repair or replace the device. That compared with 77 percent for those who received the older device.HeartMate 3 was designed to prevent blood from clogging in the mechanism, a complication known as pump thrombosis that can lead to major surgery to replace the device.While survival and stroke rates were similar, there was no pump thrombosis with HeartMate 3 versus 18 cases in the older device, based on data from the first 294 patients in a study that intends to enroll more than 1,000.HeartMate 3 is approved in Europe. This trial aims to make the case for U.S. approval.The trial was designed to demonstrate that the new device is at least as safe as HeartMate II. ""We met not only non-inferiority, but also superiority. We're ecstatic with this,"" said Dr. Mandeep Mehra, the lead researcher who presented the data at the American Heart Association scientific meeting in New Orleans.""We are always looking for something that reduces the limitations of these devices,"" he said. ""We now have the HeartMate 3 that virtually eliminates one major complication that we see with left ventricular assistance.""Analysts have said if the data proves very positive it could  pressure a rival product from Medtronic Plc. The study included both patients who needed a short-term  option while awaiting a heart transplant or long-term support because they were not candidates for transplantation.Nearly 6 million Americans are living with heart failure, a leading cause of hospitalization, and a condition that causes shortness of breath and difficulty performing daily activities. These devices do the work of the left ventricle by pumping blood into the aorta. HeartMate 3 has wider blood passages and its rotor is suspended by magnetic forces to prevent damage to red blood cells. It also fits entirely inside the chest cavity, while the larger model must be placed below the diaphragm. And it appears to provide a benefit sure to cheer patients and payers.""If you have a pump that does not require a repeat surgery to replace it, that is a very clear health economic advantage,"" Mehra said. (Editing by Matthew Lewis)",2016-11-16,STJ,"Wed Nov 16, 2016 | 11:47am EST",New St. Jude heart pumping device proves superior to older model: study,http://www.reuters.com//article/us-heart-st-jude-medical-idUSKBN13B27B?type=companyNews,0.9565,0.056,0.84,0.104
124,"   By Bill Berkrot | NEW ORLEANS  NEW ORLEANS St. Jude Medical Inc's new, smaller HeartMate 3 heart pumping assist device proved superior to its older HeartMate II in advanced heart failure patients, according to the first data from a large trial presented on Wednesday.Six months after implantation, 86 percent of patients who received HeartMate 3 were still alive without a disabling stroke or need for reoperation to repair or replace the device. That compared with 77 percent for those who received the older device.HeartMate 3 was designed to prevent blood from clogging in the mechanism, a complication known as pump thrombosis that can lead to major surgery to replace the device.While survival and stroke rates were similar, there was no pump thrombosis with HeartMate 3 versus 18 cases in the older device, based on data from the first 294 patients in a study that intends to enroll more than 1,000.HeartMate 3 is approved in Europe. This trial aims to make the case for U.S. approval.The trial was designed to demonstrate that the new device is at least as safe as HeartMate II. ""We met not only non-inferiority, but also superiority. We're ecstatic with this,"" said Dr. Mandeep Mehra, the lead researcher who presented the data at the American Heart Association scientific meeting in New Orleans.""We are always looking for something that reduces the limitations of these devices,"" he said. ""We now have the HeartMate 3 that virtually eliminates one major complication that we see with left ventricular assistance.""Analysts have said if the data proves very positive it could  pressure a rival product from Medtronic Plc. The study included both patients who needed a short-term  option while awaiting a heart transplant or long-term support because they were not candidates for transplantation.Nearly 6 million Americans are living with heart failure, a leading cause of hospitalization, and a condition that causes shortness of breath and difficulty performing daily activities. These devices do the work of the left ventricle by pumping blood into the aorta. HeartMate 3 has wider blood passages and its rotor is suspended by magnetic forces to prevent damage to red blood cells. It also fits entirely inside the chest cavity, while the larger model must be placed below the diaphragm. And it appears to provide a benefit sure to cheer patients and payers.""If you have a pump that does not require a repeat surgery to replace it, that is a very clear health economic advantage,"" Mehra said. (Editing by Matthew Lewis)",2016-11-16,STJ,"Wed Nov 16, 2016 | 11:47am EST",New St. Jude heart pumping device proves superior to older model -study,http://www.reuters.com//article/heart-st-jude-medical-idUSL1N1DG237?type=companyNews,0.9565,0.056,0.84,0.104
125,"  BRUSSELS The European Commission on Wednesday said it has given its conditional approval to U.S. medical device maker Abbott Laboratories' (ABT.N) bid for peer St Jude Medical Inc (STJ.N).Reuters reported on Nov. 15 that the $25 billion deal was going to be cleared in Brussels.The European Commission, the mergers regulator, said in a statement that its approval was conditional on ""Abbott divesting two devices used in cardiovascular treatments.""    (Reporting by Gabriela Baczynska)",2016-11-23,STJ,"Wed Nov 23, 2016 | 12:24pm EST",EU regulator conditionally approves Abbott's purchase of St Jude,http://www.reuters.com//article/us-st-jude-m-a-abbott-eu-idUSKBN13I23X?type=companyNews,0.765,0.0,0.899,0.101
126,"  BRUSSELS The European Commission on Wednesday said it has given its conditional approval to U.S. medical device maker Abbott Laboratories' (ABT.N) bid for peer St Jude Medical Inc (STJ.N).Reuters reported on Nov. 15 that the $25 billion deal was going to be cleared in Brussels.The European Commission, the mergers regulator, said in a statement that its approval was conditional on ""Abbott divesting two devices used in cardiovascular treatments.""    (Reporting by Gabriela Baczynska)",2016-11-23,STJ,"Wed Nov 23, 2016 | 12:24pm EST",EU regulator conditionally approves Abbott's purchase of St Jude,http://www.reuters.com//article/st-jude-ma-abbott-eu-idUSL8N1DO57S?type=companyNews,0.765,0.0,0.899,0.101
127,  Jan 16   * S&P says Tractor Supply Co to replace Life Technologies Corpin S&P 500  * S&P says change to be made after close of trading on January 23  * S&P says Life Technologies is being acquired by Thermo Fisher Scientific Inc * S&P says Tractor Supply has a market capitalization that is more  representative of the large cap market space,2014-01-16,TSCO,"Thu Jan 16, 2014 | 5:20pm EST","BRIEF-S&P 500 to add Tractor Supply; index to drop Life Technologies, which is being acquired",http://www.reuters.com//article/sp500-brief-idUSWEN00C5K20140116?type=companyNews,0.0,0.0,1.0,0.0
128,"  Thomson Reuters April 28, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.                      - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  28 Apr     13:00           Apollo Commercial Real Estate Shareholders Meeting 28 Apr     13:00             CitiAnnual Shareholders Meeting 28 Apr     13:00        Fiesta Restaurant Annual Shareholders Meeting 28 Apr     13:00          Fortune Brands Home & Security Annual Shareholders Meeting 28 Apr     13:00           Home Properties Annual Shareholders Meeting 28 Apr     13:00          Vantiv Annual Shareholders Meeting 28 Apr     13:30           Federal Signal Corp Annual Shareholders Meeting 28 Apr     13:30        National Penn Bancshares Annual Shareholders Meeting 28 Apr     13:30           SunTrust Banks Annual Shareholders Meeting 28 Apr     13:30           Wells Fargo & Co Annual Shareholders Meeting 28 Apr     23:00           Bio Rad Laboratories Annual Shareholders Meeting 28 Apr     00:00           Principal Financial at Milken Institute Global Conf 28 Apr     12:00            Chubb Corp Annual Shareholders Meeting 28 Apr     12:00           Coca-Cola Enterprises Annual Shareholders Meeting 28 Apr     12:00           PerkinElmer Annual Shareholders Meeting 28 Apr     12:00           Teradata Corp Annual Shareholders Meeting 28 Apr     12:30           HanesBrands Annual Shareholders Meeting 28 Apr     14:00           AGL Resources Annual Shareholders Meeting 28 Apr     14:00        Capital City Bank Annual Shareholders Meeting 28 Apr     14:00           Exelon Corp Annual Shareholders Meeting 28 Apr     14:00           Hershey Co Annual Shareholders Meeting 28 Apr     14:00           Stepan Co Annual Shareholders Meeting 28 Apr     14:00           TAL International Annual Shareholders Meeting 28 Apr     14:00           Total System Services Annual Shareholders Meeting 28 Apr     14:00        UMB Financial Corp Annual Shareholders Meeting 28 Apr     14:00             United States Steel Corp Annual Shareholders Meeting 28 Apr     14:00           Weingarten Realty Investors Annual Shareholders Meeting 28 Apr     14:30           Apartment Investment and Management Shareholders Meeting 28 Apr     14:30        Charter Communications Annual Shareholders Meeting 28 Apr     14:30           Comerica Annual Shareholders Meeting 28 Apr     14:30        Cumberland Pharmaceuticals Annual Shareholders Meeting 28 Apr     14:30           Exterran Holdings Annual Shareholders Meeting 28 Apr     14:30           Noble Energy Annual Shareholders Meeting 28 Apr     15:00           AMC Entertainment Holdings Annual Shareholders Meeting 28 Apr     15:00           BB&T Corp Annual Shareholders Meeting 28 Apr     15:00           Centene Corp Annual Shareholders Meeting 28 Apr     15:00        Control4 Corp Annual Shareholders Meeting 28 Apr     15:00           First Horizon National Corp Annual Shareholders Meeting 28 Apr     15:00        Hancock Holding Co Annual Shareholders Meeting 28 Apr     15:00           International Business Machines Annual Shareholders Meeting 28 Apr     15:00           Kirby Corp Annual Shareholders Meeting 28 Apr     15:00           ManpowerAnnual Shareholders Meeting 28 Apr     15:00           PNC Financial Services Annual Shareholders Meeting 28 Apr     15:00            Praxair Annual Shareholders Meeting 28 Apr     15:00            Spectra Energy Corp Annual Shareholders Meeting 28 Apr     15:00        Washington Trust Bancorp Annual Shareholders Meeting 28 Apr     15:00        YRC Worldwide Annual Shareholders Meeting 28 Apr     15:30        First Financial Bankshares Annual Shareholders Meeting 28 Apr     15:30           Metlife Annual Shareholders Meeting 28 Apr     16:00           MDU Resources Annual Shareholders Meeting 28 Apr     16:15           Rollins Annual Shareholders Meeting 28 Apr     16:30           Principal Financial at Milken Institute Global Conf 28 Apr     17:00           PS Business Parks Annual Shareholders Meeting 28 Apr     18:00          Alexander & Baldwin Annual Shareholders Meeting 28 Apr     18:00        First Community Bancshares Annual Shareholders Meeting 28 Apr     18:00           FMC Corp Annual Shareholders Meeting 28 Apr     18:00         South State Corp Annual Shareholders Meeting 28 Apr     18:30        Renasant Corp Annual Shareholders Meeting 28 Apr     19:00        BOK Financial Corp Annual Shareholders Meeting 28 Apr     19:00           First Commonwealth Financial Corp Annual Shareholders Meeting 28 Apr     19:00        Trustmark Corp Annual Shareholders Meeting 28 Apr     19:00           Valmont Industries Annual Shareholders Meeting 28 Apr     07:30        Aquabounty Technologies Annual Shareholders Meeting 28 Apr     19:30           RPC Annual Shareholders Meeting 28 Apr     20:00        Cepheid Annual Shareholders Meeting 28 Apr     20:00        Earthlink Holdings Corp Annual Shareholders Meeting 28 Apr     20:00           Nautilus Annual Shareholders Meeting 28 Apr     21:00          Corelogic Annual Shareholders Meeting 28 Apr     21:30           Principal Financial at Milken Institute Global Conf 29 Apr     13:00           BorgWarner Annual Shareholders Meeting 29 Apr     13:00           CNA Financial Corp Annual Shareholders Meeting 29 Apr     13:00           Geo Annual Shareholders Meeting 29 Apr     13:00           Harsco Corp Annual Shareholders Meeting 29 Apr     13:00        Inficon Holding AG Annual Shareholders Meeting 29 Apr     13:00         SciQuest Annual Shareholders Meeting 29 Apr     13:00        Tecumseh Products Company Annual Shareholders Meeting 29 Apr     00:00           Ryland Annual Shareholders Meeting 29 Apr     12:00        Bloomin' Brands Annual Shareholders Meeting 29 Apr     14:00         Advanced Micro Devices Annual Shareholders Meeting 29 Apr     14:00           Ball Corp Annual Shareholders Meeting 29 Apr     14:00           Discover Financial Services Annual Shareholders Meeting 29 Apr     14:00        First Niagara Financial Annual Shareholders Meeting 29 Apr     14:00           Gannett Co Annual Shareholders Meeting 29 Apr     14:00           Marathon Petroleum Corp Annual Shareholders Meeting 29 Apr     14:30            Eversource Energy Annual Shareholders Meeting 29 Apr     15:00        Glacier Bancorp Annual Shareholders Meeting 29 Apr     15:00           Marathon Oil Corp Annual Shareholders Meeting 29 Apr     15:00          McGraw Hill Financial Annual Shareholders Meeting 29 Apr     15:00           MRC Global Annual Shareholders Meeting 29 Apr     15:00        Papa John's International Annual Shareholders Meeting 29 Apr     15:00            TECO Energy Annual Shareholders Meeting 29 Apr     15:00            The Coca-Cola Co Annual Shareholders Meeting 29 Apr     15:00            Under Armour Annual Shareholders Meeting 29 Apr     15:00           W W Grainger Annual Shareholders Meeting 29 Apr     15:00           Westwood Holdings Annual Shareholders Meeting 29 Apr     15:30           Fresh Del Monte Produce Annual Shareholders Meeting 29 Apr     15:30           Principal Financial at Milken Institute Global Conf 29 Apr     15:30           Tennant Co Annual Shareholders Meeting 29 Apr     16:00           Ameriprise Financial Annual Shareholders Meeting 29 Apr     16:00           DCT Industrial Trust Annual Shareholders Meeting 29 Apr     16:00        ReachLocal Annual Shareholders Meeting 29 Apr     17:00           Cambrex Corp Annual Shareholders Meeting 29 Apr     18:00        Retail Opportunity Investments Corp Annual Shareholders Meeting 29 Apr     18:00           Stryker Corp Annual Shareholders Meeting 29 Apr     19:00        Ares Capital Corp Annual Shareholders Meeting 29 Apr     19:00           Deluxe Corp Annual Shareholders Meeting 29 Apr     19:00          Douglas Dynamics Annual Shareholders Meeting 29 Apr     19:00           Duke Realty Corp Annual Shareholders Meeting 29 Apr     19:00        Selective Insurance Annual Shareholders Meeting 29 Apr     20:30           Prologis Annual Shareholders Meeting 30 Apr     13:00        Altra Industrial Motion Corp Annual Shareholders Meeting 30 Apr     13:00        BroadSoft Annual Shareholders Meeting 30 Apr     13:00           Cobalt International Energy Annual Shareholders Meeting 30 Apr     13:00           SCANA Corp Annual Shareholders Meeting 30 Apr     13:30           Energen Corp Annual Shareholders Meeting 30 Apr     13:30        RetailMeNot Annual Shareholders Meeting 30 Apr     22:00        Enterprise Financial Services Corp Annual Shareholders Meeting 30 Apr     12:00           American Axle & Manufacturing Annual Shareholders Meeting 30 Apr     12:00           Unisys Corp Annual Shareholders Meeting 30 Apr     12:30           Dana Holding Corp Annual Shareholders Meeting 30 Apr     14:00           Capital One Financial Corp Annual Shareholders Meeting 30 Apr     14:00        CenterState Banks Annual Shareholders Meeting 30 Apr     14:00           EMC Corp Annual Shareholders Meeting 30 Apr     14:00        Entegris Annual Shareholders Meeting 30 Apr     14:00           Fluor Corp Annual Shareholders Meeting 30 Apr     14:00           Mead Johnson Nutrition Co Annual Shareholders Meeting 30 Apr     14:00        MYR Annual Shareholders Meeting 30 Apr     14:00           Owens & Minor Annual Shareholders Meeting 30 Apr     14:00           Polaris Industries Annual Shareholders Meeting 30 Apr     14:00           South Jersey Industries Annual Shareholders Meeting 30 Apr     14:00       Southern Peru Copper Peru Branch Annual Shareholders Meeting 30 Apr     14:00           Vector Ltd Annual Shareholders Meeting 30 Apr     15:00        Bryn Mawr Bank Corp Annual Shareholders Meeting 30 Apr     15:00           Cincinnati Bell Annual Shareholders Meeting 30 Apr     15:00           Corning Annual Shareholders Meeting 30 Apr     15:00           Huntington Ingalls Industries Annual Shareholders Meeting 30 Apr     15:00           Kimberly-Clark Corp Annual Shareholders Meeting 30 Apr     15:00           Snap-On Annual Shareholders Meeting 30 Apr     15:00          Southern Copper Corp Annual Shareholders Meeting 30 Apr     15:00           Torchmark Corp Annual Shareholders Meeting 30 Apr     15:00           Valero Energy Corp Annual Shareholders Meeting 30 Apr     15:30           Hudson Valley Holding Corp Annual Shareholders Meeting 30 Apr     16:00        Enphase Energy Annual Shareholders Meeting 30 Apr     16:00        Kona Grill Annual Shareholders Meeting 30 Apr     16:30           HCP Annual Shareholders Meeting 30 Apr     17:00        EchoStar Corp Annual Shareholders Meeting 30 Apr     17:00        Entropic Special Meeting of Stockholders 30 Apr     17:00        Entropic Communications Annual Shareholders Meeting 30 Apr     17:00        Mobile Mini Annual Shareholders Meeting 30 Apr     17:30           Sunstone Hotel Investors Annual Shareholders Meeting 30 Apr     18:00      Itausa Investimentos Itau SA Annual Shareholders Meeting 30 Apr     18:00        Tessera Technologies Annual Shareholders Meeting 30 Apr     18:30          MSCI Annual Shareholders Meeting 30 Apr     19:00        Endurance International Holdings Annual Shareholders Meeting 30 Apr     19:00           HCA Holdings Annual Shareholders Meeting 30 Apr     20:00           EOG Resources Annual Shareholders Meeting 30 Apr     20:00           Public Storage Annual Shareholders Meeting 30 Apr     20:00        WSFS Financial Corp Annual Shareholders Meeting 01 May     13:00        ArcBest Corp Annual Shareholders Meeting 01 May     13:00           CMS Energy Corp Annual Shareholders Meeting 01 May     13:00          Realogy Holdings Corp Annual Shareholders Meeting 01 May     13:00           Yum! Brands Annual Shareholders Meeting 01 May     13:30            Alcoa Annual Shareholders Meeting 01 May     13:30           Babcock & Wilcox Co Annual Shareholders Meeting 01 May     22:00        FormFactor Annual Shareholders Meeting 01 May                     Lindsay Corp at Gabelli Omaha Research Trip 01 May                  Rentrak Corp at Gabelli Omaha Research Trip 01 May                     Safeguard Scientifics at Gabelli Omaha Research Trip 01 May                    TD Ameritrade Holding Corp at Gabelli Omaha Research Trip 01 May                     Union Pacific Corp at Gabelli Omaha Research Trip 01 May                     Valmont Industries at Gabelli Omaha Research Trip 01 May                  Werner Enterprises at Gabelli Omaha Research Trip 01 May     12:30        Alnylam Pharmaceuticals Annual Shareholders Meeting 01 May     14:00        Lincoln Educational Services Corp Annual Shareholders Meeting 01 May     14:00        Olympic Steel Annual Shareholders Meeting 01 May     14:00         Pilgrims Pride Corp Annual Shareholders Meeting 01 May     14:00        Primoris Services Corp Annual Shareholders Meeting 01 May     14:00             Ryder System Annual Shareholders Meeting 01 May     14:00         Sprouts Farmers Market Annual Shareholders Meeting 01 May     14:00           Zoetis Annual Shareholders Meeting 01 May     14:30           Louisiana-Pacific Corp Annual Shareholders Meeting 01 May     15:00           Allegheny Technologies Annual Shareholders Meeting 01 May     15:00        eBay Annual Shareholders Meeting 01 May     15:00         Magnetek Annual Shareholder Meeting 01 May     15:00           Teleflex Annual Shareholders Meeting 01 May     15:30           Occidental Petroleum Corp Annual Shareholders Meeting 01 May     15:30           RLJ Lodging Trust Annual Shareholders Meeting 01 May     16:00        Huron Consulting Annual Shareholders Meeting 01 May     17:30        CommScope Holding Company Annual Shareholders Meeting 01 May     18:00        Hawaiian Telcom Holdco Annual Shareholders Meeting 01 May     07:00           Rowan Companies PLC Annual Shareholders Meeting 01 May     19:00        Overstock.com Annual Shareholders Meeting 02 May     13:30        Cincinnati Financial Corp Annual Shareholders Meeting 02 May     20:45          Berkshire Hathaway Annual Shareholders Meeting 04 May     13:00          Tumi Holdings Annual Shareholders Meeting 04 May     13:30          Textura Corp Annual Shareholders Meeting 04 May     14:00           Aflac Annual Shareholders Meeting 04 May     14:00           Agree Realty Corp Annual Shareholders Meeting 04 May     14:00        Consolidated Communications Annual Shareholders Meeting 04 May     14:00        Exone Co Annual Shareholders Meeting 04 May     14:00           Masco Corp Annual Shareholders Meeting 04 May     14:00        MKS Instruments Annual Shareholders Meeting 04 May     14:00           Oasis Petroleum Annual Shareholders Meeting 04 May     14:00          STAG Industrial Annual Shareholders Meeting 04 May     14:30        Dot Hill Systems Corp Annual Shareholders Meeting 04 May     15:00        CyrusOne Annual Shareholders Meeting 04 May     15:00           Eli Lilly and Co Annual Shareholders Meeting 04 May     16:00           Clearwater Paper Corp Annual Shareholders Meeting 04 May     16:00         Potlatch Corp Annual Shareholders Meeting 04 May     17:00           Excel Trust Annual Shareholders Meeting 04 May     17:00           PG&E Corp. and Pacific Gas & Electric Co Annual Meeting 04 May     18:00           QTS Realty Trust Annual Shareholders Meeting 04 May     18:05           Noble Energy at Credit Suisse Offshore Technology Conf Tour 04 May     18:30         LKQ Corp Annual Shareholders Meeting 04 May     18:30           Peabody Energy Corp Annual Shareholders Meeting 04 May     19:30        First Merchants Corp Annual Shareholders Meeting 04 May     20:00           CBL & Associates Properties Annual Shareholders Meeting 04 May     20:00           E. W. Scripps Co Annual Shareholders Meeting 04 May     20:00           Stillwater Mining Co Annual Shareholders Meeting 04 May     20:05           Chevron Corp at Credit Suisse Offshore Technology Conf Tour 04 May     20:40           Halliburton Co at Credit Suisse Offshore Technology Conf Tour 05 May     13:00        Bravo Brio Restaurant Annual Shareholders Meeting 05 May     13:00           Citizens Financial Annual Shareholders Meeting 05 May     13:00           DiamondRock Hospitality Co Annual Shareholders Meeting 05 May     13:00           FMC Technologies at Credit Suisse Offshore Technology Conf Tour 05 May     13:00          Hubbell Annual Shareholders Meeting 05 May     13:00        Lumos Networks Corp Annual Shareholders Meeting 05 May     13:00           M/I Homes Annual Shareholders Meeting 05 May     13:00          NRG Yield Annual Shareholders Meeting 05 May     13:00           Ramco-Gershenson Properties Trust Annual Shareholders Meeting 05 May     13:00           Sturm Ruger & Co Annual Shareholders Meeting 05 May     13:15           Brady Corp at Wells Fargo Conf 05 May     13:15            Curtiss-Wright Corp at Wells Fargo Conf 05 May     13:15           Pulteat Wells Fargo Conf 05 May     13:30            Franklin Covey Co at Robert W. Baird Conf 05 May     13:30        Habit Restaurants at Robert W. Baird Conf 05 May     13:30        Houston Wire & Cable Co Annual Shareholders Meeting 05 May     13:30        Kraft Foods Annual Shareholders Meeting 05 May     13:30        Meridian Bioscience at Robert W. Baird Conf 05 May     13:30        PostRock Energy Corp Annual Shareholders Meeting 05 May     13:30           Superior Industries International Annual Shareholders Meeting 05 May     13:30           West Pharmaceutical Services Annual Shareholders Meeting 05 May     13:55           Caterpillar at Wells Fargo Conf 05 May     13:55           Dow Chemical Co at Wells Fargo Conf 05 May     13:55        Stock Building Supply Holdings at Wells Fargo Conf 05 May     22:00          LifeLock Annual Shareholders Meeting 05 May                  Adobe Systems at Robert W. Baird Conf 05 May     12:00           Albemarle Corp Annual Shareholders Meeting 05 May                     Ashford Hospitality Trust at Robert W. Baird Conf 05 May                  Asure Software at Credit Suisse Mexico Investment Ideas Conf 05 May                  First Cash Financial Services at Credit Suisse Conf 05 May                     Gap at Credit Suisse Mexico Investment Ideas Conf 05 May                     Monsanto Co at Wells Fargo Conf 05 May                  Nordson Corp at Wells Fargo Conf 05 May                     Pebblebrook Hotel Trust at Robert W. Baird Conf 05 May     12:00           Penske Automotive Annual Shareholders Meeting 05 May     12:00        Strayer Education Annual Shareholders Meeting 05 May                  TESARO at Citi Midwest Healthcare Access Day 05 May     12:00           Zimmer Holdings Annual Shareholders Meeting 05 May     12:30           Charles River Laboratories Annual Shareholders Meeting 05 May     12:30           Entercom Communications Corp Annual Shareholders Meeting 05 May     12:30           Gamco Investors Annual Shareholders Meeting 05 May     12:35           Ametek at Wells Fargo Conf 05 May     12:35           Harman International at Wells Fargo Conf 05 May     12:35           Rockwell Collins at Wells Fargo Conf 05 May     12:35           Tenneco at Wells Fargo Conf 05 May     14:00        Abraxas Petroleum Corp Annual Shareholders Meeting 05 May     14:00           Alon USA Energy Annual Shareholders Meeting 05 May     14:00        Argo International Holdings Ltd Annual Shareholders Meeting 05 May     14:00           Baxter International Annual Shareholders Meeting 05 May     14:00           Bristol-Myers Squibb Co Annual Shareholders Meeting 05 May     14:00        Capella Education Co Annual Shareholders Meeting 05 May     14:00        Fulton Financial Corp Annual Shareholders Meeting 05 May     14:00           Kimco Realty Corp Annual Shareholders Meeting 05 May     14:00           Manitowoc Company Annual Shareholders Meeting 05 May     14:00        NBT Bancorp Annual Shareholders Meeting 05 May     14:00        Progress Software Corp Annual Shareholders Meeting 05 May     14:00        Varonis Systems Annual Shareholders Meeting 05 May     14:00        VSE Corp. Annual Meeting of Stockholders 05 May     14:00           ZAIS Financial Corp Annual Shareholders Meeting 05 May     14:10        Blackbaud at Robert W. Baird Conf 05 May     14:10        Littelfuse at Robert W. Baird Conf 05 May     14:10        Paychex at Robert W. Baird Conf 05 May     14:10           United Parcel Service at Robert W. Baird Conf 05 May     14:30        Horsehead Holding Corp Annual Shareholders Meeting 05 May     14:35           Ball Corp at Wells Fargo Conf 05 May     14:35           Eastman Chemical Co at Wells Fargo Conf 05 May     14:35           Hovnanian Enterprises at Wells Fargo Conf 05 May     14:35        PACCAR at Wells Fargo Conf 05 May     14:45        Exlservice Holdings at Robert W. Baird Conf 05 May     14:45        Gentex Corp at Robert W. Baird Conf 05 May     14:45          Store Capital Corp at Robert W. Baird Conf 05 May     14:45          Zoe's Kitchen at Robert W. Baird Conf 05 May     15:00           Boston Scientific Corp Annual Shareholders Meeting 05 May     15:00           Cousins Properties Annual Shareholders Meeting 05 May     15:00           Great Plains Energy Annual Shareholders Meeting 05 May     15:00           Leggett & Platt Annual Shareholders Meeting 05 May     15:00        NIC Annual Shareholders Meeting 05 May     15:00           Oceaneering International at Credit Suisse Technology Conf Tour 05 May     15:00        O'Reilly Automotive Annual Shareholders Meeting 05 May     15:00        Raptor Pharmaceutical Corp Annual Shareholders Meeting 05 May     15:00        Sigma-Aldrich Corp Annual Shareholders Meeting 05 May     15:00        Thoratec Corp Annual Shareholders Meeting 05 May     15:00        Tractor Supply Co Annual Shareholders Meeting 05 May     15:15           AAR Corp at Wells Fargo Conf 05 May     15:15           FLY Leasing Ltd at Wells Fargo Conf 05 May     15:15           Huntsman Corp at Wells Fargo Conf 05 May     15:15            Owens Corning at Wells Fargo Conf 05 May     15:20        Broadcom Corp at Robert W. Baird Conf 05 May     15:20           Chipotle Mexican Grill at Robert W. Baird Conf 05 May     15:20        EnerNOC at Robert W. Baird Conf 05 May     15:20        Forward Air Corp at Robert W. Baird Conf 05 May     15:30           HNI Corp Annual Shareholders Meeting 05 May     15:30           NVR Annual Shareholders Meeting 05 May     15:30        Quidel Corp Annual Shareholders Meeting 05 May     15:35           Helix Energy Solutions at Credit Suisse Technology Conf Tour 05 May     15:55        Buffalo Wild Wings at Robert W. Baird Conf 05 May     15:55            DeVry Education at Robert W. Baird Conf 05 May     15:55         Silicon Graphics International Corp at Robert W. Baird Conf 05 May     16:00           Goodrich Petroleum Corp Annual Shareholders Meeting 05 May     16:00           Nuverra Environmental Solutions Annual Shareholders Meeting 05 May     16:00          Paycom Software Annual Shareholders Meeting 05 May     16:00           TETRA Technologies Annual Shareholders Meeting 05 May     16:30           Ecolab at Robert W. Baird Conf 05 May     16:30           Kilroy Realty Corp at Robert W. Baird Conf 05 May     16:30           Red Hat at Robert W. Baird Conf 05 May     16:30        Rocky Brands at Robert W. Baird Conf 05 May     17:00           Calgon Carbon Corp Annual Shareholders Meeting 05 May     17:15        LMI Aerospace at Wells Fargo Conf 05 May     17:15           RPM International at Wells Fargo Conf 05 May     17:15           Terex Corp at Wells Fargo Conf 05 May     17:15          Tower International at Wells Fargo Conf 05 May     17:40           Apartment Investment and Management Co at Robert W. Baird Conf 05 May     17:40        Dunkin' Brands at Robert W. Baird Conf 05 May     17:40        FARO Technologies at Robert W. Baird Conf 05 May     17:40        Power Solutions International at Robert W. Baird Conf 05 May     17:55          ADS Tactical at Wells Fargo Conf 05 May     17:55           Lennox International at Wells Fargo Conf 05 May     17:55           Sonoco Products Company at Wells Fargo Conf 05 May     17:55         TriMas Corp at Wells Fargo Conf 05 May     18:00            Knowles Corp Annual Shareholders Meeting 05 May     18:00           Nordstrom Annual Shareholders Meeting 05 May     18:15         Ignite Restaurant at Robert W. Baird Conf 05 May     18:15            La Quinta Holdings at Robert W. Baird Conf 05 May     18:15           Quanta Services at Robert W. Baird Conf 05 May     18:15        Xoom Corp at Robert W. Baird Conf 05 May     18:30           L-3 Communications Holdings Annual Shareholders Meeting 05 May     18:35           BorgWarner at Wells Fargo Conf 05 May     18:35           Crown Holdings at Wells Fargo Conf 05 May     18:35             Ryder System at Wells Fargo Conf 05 May     18:35           Stanley Black & Decker at Wells Fargo Conf 05 May     18:50           Armada Hoffler Properties at Robert W. Baird Conf 05 May     18:50        Hub at Robert W. Baird Conf 05 May     18:50           Krispy Kreme Doughnuts at Robert W. Baird Conf 05 May     19:00            Delek US Holdings Annual Shareholders Meeting 05 May     19:15           AK Steel Holding Corp at Wells Fargo Conf 05 May     19:15           Aptarat Wells Fargo Conf 05 May     19:15        US Ecology at Wells Fargo Conf 05 May     19:15           Watsco at Wells Fargo Conf 05 May     19:25        Constant Contact at Robert W. Baird Conf 05 May     19:25        GoPro at Robert W. Baird Conf 05 May     19:25        Plug Power at Robert W. Baird Conf 05 May     19:25        Stericycle at Robert W. Baird Conf 05 May     19:55           Myers Industries at Wells Fargo Conf 05 May     19:55           Olin Corp at Wells Fargo Conf 05 May     19:55           Ryerson Holding Corp at Wells Fargo Conf 05 May     19:55           TAL International at Wells Fargo Conf 05 May     20:00        Citrix Systems at Robert W. Baird Conf 05 May     20:00           Highwoods Properties at Robert W. Baird Conf 05 May     20:00           Neustar at Robert W. Baird Conf 05 May     20:50        NasdaqAkamai Technologies at Robert W. Baird Conf 05 May     21:00        East West Bancorp Annual Shareholders Meeting 05 May     21:00        IBERIABANK Corp Annual Shareholders Meeting 05 May     21:00           Plum Creek Timber Company Annual Shareholders Meeting      FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-04-28,TSCO,"Tue Apr 28, 2015 | 8:24am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL4N0XP5OQ20150428?type=companyNews,0.9995,0.001,0.935,0.064
129,"  Tractor Supply Co Inc has reached a settlement with U.S. regulators over allegations that the retailer imported and sold vehicles and engines from China that did not comply with clean air and emission information labeling rules. Tractor Supply will pay a penalty of $775,000 and implement a compliance plan, the U.S. Environmental Protection Agency and the Department of Justice said on Wednesday. (1.usa.gov/1GhDXrC) They said the company and its unit imported and sold 28,000 all-terrain vehicles, motorcycles and engines that did not comply with federal Clean Air Act certification and emission information labeling requirements.        (Reporting by Ankit Ajmera in Bengaluru; Editing by Kirti Pandey)",2015-09-30,TSCO,"Wed Sep 30, 2015 | 2:46pm EDT",Tractor Supply settles with regulators over clean air violations,http://www.reuters.com//article/us-tractor-supply-settlement-idUSKCN0RU2GN20150930?type=companyNews,0.2124,0.061,0.87,0.069
130,"  Sept 30 Tractor Supply Co Inc has reached a settlement with U.S. regulators over allegations that the retailer imported and sold vehicles and engines from China that did not comply with clean air and emission information labeling rules.Tractor Supply will pay a penalty of $775,000 and implement a compliance plan, the U.S. Environmental Protection Agency and the Department of Justice said on Wednesday. (1.usa.gov/1GhDXrC)  They said the company and its unit imported and sold 28,000 all-terrain vehicles, motorcycles and engines that did not comply with federal Clean Air Act certification and emission information labeling requirements.        (Reporting by Ankit Ajmera in Bengaluru; Editing by Kirti Pandey) ",2015-09-30,TSCO,"Wed Sep 30, 2015 | 2:30pm EDT",Tractor Supply settles with regulators over clean air violations,http://www.reuters.com//article/tractor-supply-settlement-idUSL3N1205MB20150930?type=companyNews,0.2124,0.06,0.871,0.068
131,  April 20 Tractor Supply Co* Tractor supply company reports first quarter results* Q1 earnings per share view $0.46 -- Thomson Reuters I/B/E/S * Q1 sales $1.47 billion versus i/b/e/s view $1.45 billion * Q1 earnings per share $0.50 * Tractor supply co qtrly comparable store sales increased 4.9% compared to a 5.7% increase in prior year period* Tractor supply co says  company is reiterating fiscal 2016 outlook  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780),2016-04-20,TSCO,"Wed Apr 20, 2016 | 4:26pm EDT",BRIEF-Tractor Supply Q1 earnings per share $0.50,http://www.reuters.com//article/idUSASD08EEA?type=companyNews,0.7783,0.0,0.887,0.113
132,"  May 3 Tractor Supply Co :* Tractor Supply Company announces senior management promotion  * Steve Barbarick has been promoted to president and chief merchandising officer, effective immediately  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-05-03,TSCO,"Tue May 3, 2016 | 5:08pm EDT",BRIEF-Tractor Supply promotes Steve Barbarick to president,http://www.reuters.com//article/idUSFWN180154?type=companyNews,0.8555,0.0,0.773,0.227
133,  May 3 Tractor Supply Co* Tractor supply company announces 20% dividend increase  * Sets quarterly cash dividend of $0.24 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-03,TSCO,"Tue May 3, 2016 | 8:16am EDT",BRIEF-Tractor supply announces 20 pct dividend increase,http://www.reuters.com//article/idUSASC08M72?type=companyNews,0.5423,0.0,0.857,0.143
134,"  NEW YORK Shares of farm supply retailer Tractor Supply Co could rise as much as 20 percent on solid earnings growth, according to a report in Barron's.The company is likely to improve its same-store sales this year, while most retailers are struggling, the article in the June 27 issue of the weekly newspaper said. Shares of Tractor Supply closed at $91.81 on the Nasdaq stock market on Friday.   (Reporting by Michael Erman; Editing by Sandra Maler)",2016-06-26,TSCO,"Sun Jun 26, 2016 | 4:24pm EDT",Tractor Supply shares could rise as much as 20 percent: Barron's,http://www.reuters.com//article/us-tractorsupply-stock-idUSKCN0ZC11O?type=companyNews,0.7533,0.037,0.826,0.138
135,  June 29 Tractor Supply Co :* Tractor Supply Company provides business update and announces webcast of second quarter 2016 results* Sees FY EPS $3.35 - $3.40* Sees FY net sales $6.8 billion - $6.9 billion* Q2 earnings per share view $1.26 -- Thomson Reuters I/B/E/S * FY2016 earnings per share view $3.49 -- Thomson Reuters I/B/E/S* FY2016 revenue view $6.94 billion -- Thomson Reuters I/B/E/S* Q2 sales $1.85 billion versus I/B/E/S view $1.93 billion * Sees Q2 earnings per share $1.15 to $1.16* Qtrly comparable store sales decreased 0.5 pct versus a 5.6 pct increase in prior year's Q2 * Company expects gross margin rate for Q2 2016 to be down 25 to 30 basis points* Sees fy 2016  net sales $6.8 billion - $6.9 billion* Q2 same store sales fell 0.5 percent* Sees FY 2016 comparable store sales between 2.5 pct - 3.5 pct  Source text for Eikon:  Further company coverage:,2016-06-29,TSCO,"Wed Jun 29, 2016 | 5:13pm EDT",BRIEF-Tractor Supply qtrly comparable store sales decreased 0.5 pct,http://www.reuters.com//article/idUSL8N19L69X?type=companyNews,0.8074,0.02,0.899,0.081
136,  Sept 7 Tractor Supply Co* Tractor supply company provides business update ahead of participation in goldman sachs global retailing conference* Sees Q3 earnings per share $0.65 to $0.67* Sees Q3 sales up about 4.2 to 5 percent* Sees Q3 sales $1.54 billion to $1.55 billion * Net sales for q3 are expected to increase approximately 4.2 percent to 5.0 percent to $1.54 billion to $1.55 billion* Sees Q3  comparable store sales ranging from flat to a decrease of 1.0 percent* Comparable store transaction counts in Q3 are expected to be slightly positive to flat in comparison to prior year Q3 * Expects net income per diluted share for Q3 to be in range of $0.65 to $0.67* Lowering its guidance for results of operations expected for fiscal 2016 * Sees full-year net sales $6.70 billion - $6.75 billion* Sees full-year comparable store sales 1.0% - 1.7%* Sees full-year earnings per diluted share $3.22 - $3.26*   Source text for Eikon:  Further company coverage:,2016-09-07,TSCO,"Wed Sep 7, 2016 | 4:11pm EDT",BRIEF-Tractor Supply forecasts Q3 earnings per share $0.65 to $0.67,http://www.reuters.com//article/idUSASC095MY?type=companyNews,0.8484,0.012,0.912,0.076
137,"  Sept 29 Tractor Supply Co :* Tractor supply company announces acquisition of petsense, a growth-oriented pet specialty retailer with 136 stores* Deal for $116 mln * Says acquisition was a cash transaction financed with cash-on-hand and revolver debt* Transaction, including transaction and integration costs, not expected to be material to tractor supply's net EPS for fiscal 2016 * Plans to continue to grow Petsense store base at a target rate of 15 pct to 20 pct, annually * Says Petsense will operate as a subsidiary of Tractor Supply Company* Will convert its two existing hometown pet stores to Petsense stores  Source text for Eikon:  Further company coverage:",2016-09-29,TSCO,"Thu Sep 29, 2016 | 4:11pm EDT",BRIEF-Tractor Supply Company reports of Petsense,http://www.reuters.com//article/idUSFWN1C50N0?type=companyNews,0.5423,0.0,0.966,0.034
138,"  Oct 4 Tractor Supply Co : * Winona Capital Management announces sale of Petsense, LLC to Tractor Supply Company  Source text for Eikon:  Further company coverage:  ",2016-10-04,TSCO,"Tue Oct 4, 2016 | 9:42am EDT",BRIEF-Winona Capital Management announces sale of Petsense to Tractor Supply Co,http://www.reuters.com//article/idUSASC09A4R?type=companyNews,0.0,0.0,1.0,0.0
139,"  Oct 19 Tractor Supply Co* Q3 earnings per share $0.67* Q3 sales $1.54 billion versus I/B/E/S view $1.54 billion* Q3 same store sales fell 0.6 percent * Q3 earnings per share view $0.66 -- Thomson Reuters I/B/E/S* Says sees fiscal 2016 net sales $6.70 billion - $6.75 billion * Tractor supply co sees fiscal 2016 comparable store sales 1.0 percent to 1.7 percent * Says sees fiscal 2016 capital expenditures $235 million to $245 million* Sees 2016 earnings per diluted share $3.22 - $3.26* FY2016 earnings per share view $3.24, revenue view $6.72 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-10-19,TSCO,"Wed Oct 19, 2016 | 4:05pm EDT",BRIEF-Tractor Supply Q3 earnings per share $0.67,http://www.reuters.com//article/idUSASC09BVN?type=companyNews,0.7783,0.0,0.916,0.084
140,"  Nov 1 Tractor Supply Co :* Tractor Supply -authorized a $1 billion increase to its existing share repurchase program, bringing total amount authorized to date under program to $3 billion * Tractor Supply Co says repurchase  program, established in February 2007, has also been extended through December 31, 2020 * Tractor Supply Co says board of directors declared a quarterly cash dividend of $0.24 per share of company's common stock * Tractor Supply Company declares quarterly dividend and authorizes $1 billion increase in its share repurchase program  Source text for Eikon:  Further company coverage:",2016-11-01,TSCO,"Tue Nov 1, 2016 | 8:09am EDT","BRIEF-Tractor Supply declares qtrly dividend of $0.24 per share, authorizes $1 bln increase to existing share repurchase program",http://www.reuters.com//article/idUSASC09EOP?type=companyNews,0.9136,0.0,0.848,0.152
141,  Nov 3 Tractor Supply Co : * Tractor Supply Company appoints Ram Krishnan to its board of directors  Source text for Eikon:  Further company coverage:  ,2016-11-03,TSCO,"Thu Nov 3, 2016 | 8:14am EDT",BRIEF-Tractor Supply Co appoints Ram Krishnan to its board,http://www.reuters.com//article/idUSASC09FTM?type=companyNews,0.0,0.0,1.0,0.0
142,"  Nov 17 Tractor Supply Co* Entered into a transition agreement with Anthony F. Crudele, company's executive vice president and chief financial officer  * Pursuant to transition agreement, Crudele has agreed to serve in his current capacity through March 3, 2017  Source text for Eikon:  Further company coverage: ",2016-11-17,TSCO,"Thu Nov 17, 2016 | 5:33pm EST",BRIEF-Tractor Supply entered into a transition agreement with CFO Anthony Crudele,http://www.reuters.com//article/idUSFWN1DI0T5?type=companyNews,0.8176,0.0,0.832,0.168
143,"  FRANKFURT Jan 14 U.S. aerospace components maker Transdigm and European buyout groups Cinven  and EQT are all exploring an acquisition of cargo handler Telair in a potential $700-800 million deal, two people familiar with the transaction said.Aviation support company AAR Corp has asked for final bids for its Germany-headquartered business by late January or early February, the sources said.U.S. industrial conglomerate Honeywell and aviation firm Triumph are also considering making final bids for Telair, one of the sources said.Telair has annual core earnings (EBITDA) of about $70 million and the company could fetch more than ten times that, the sources said. Previously, sources had said that Telair may be valued at up to $1 billion in a potential sale.Telair's workers fear that a sale to an industry  player may cause severe job cuts as seen after TransDigm's acquisition of a Telair unit in 2010, an employee representative said. Telair, Honeywell, Cinven and EQT declined to comment, while Transdigm and Triumph were not available for comment.Previously owned by Teleflex, Telair was sold to AAR along with Nordisk Aviation Products in 2011 for a combined $280 million. Telair designs, manufactures and supports on-board baggage and cargo systems, such as its ""Sliding Carpet"" device, for companies including Airbus and Boeing.Since the 2011 acquisition Telair has bought Germany's PFW Aerospace, boosting its loading-system assets.Telair's low capital expenditure and ability to free up cash quickly makes it attractive to private equity bidders, sources familiar with the asset have said.     (Reporting by Arno Schuetze; editing by Keith Weir)",2015-01-14,TDG,"Wed Jan 14, 2015 | 4:49am EST","U.S. groups, private equity line up bids for cargo handler Telair - sources",http://www.reuters.com//article/telair-ma-idUSL6N0US3P520150114?type=companyNews,0.9485,0.037,0.86,0.102
144,"  AAR Corp (AIR.N) said it would sell its cargo handling business, Telair Cargo Group, to TransDigm Group Inc (TDG.N) for $725 million in cash to focus on its aviation services business.AAR, which provides services to U.S. government and commercial clients, also said on Monday that it intended to sell its unprofitable precision systems manufacturing business.The company warned that results in the quarter ending Feb. 28 would be less than expected due to costs associated with the sale of Telair and with bids for large government contracts as well as fewer flying positions in its airlift operations.AAR said the quarter would include an impairment charge of about $40 million related to the discontinuation of the precision systems business. A fall in sales to defense customers led to AAR posting lower revenue in the year ended May 31, the first decline in four years.The company's revenue has missed market estimates for four of the past six quarter. Citi is AAR's financial adviser and Winston & Strawn LLP is its legal adviser. They will also serve as advisers on the sale of the precision systems manufacturing business.Shares of AAR had risen 8.37 pct in the last 12 months through Friday's close of $29.91. The shares were untraded premarket on Monday. TransDigm's shares were also untraded premarket on Monday from their Friday close of $213.73. (Reporting by Radhika Rukmangadhan in Bengaluru; Editing by Ted Kerr and Savio D'Souza)",2015-02-23,TDG,"Mon Feb 23, 2015 | 9:23am EST",AAR to sell cargo handling business to TransDigm for $725 million,http://www.reuters.com//article/us-aar-m-a-transdigm-group-idUSKBN0LR17L20150223?type=companyNews,0.25,0.027,0.933,0.04
145,"  Feb 23 AAR Corp said it would sell its cargo handling business, Telair Cargo Group, to TransDigm Group Inc for $725 million in cash to focus on its aviation services business.AAR, which provides services to U.S. government and commercial clients, also said on Monday that it intended to sell its unprofitable precision systems manufacturing business.The company warned that results in the quarter ending Feb. 28 would be less than expected due to costs associated with the sale of Telair and with bids for large government contracts as well as fewer flying positions in its airlift operations.AAR said the quarter would include an impairment charge of about $40 million related to the discontinuation of the precision systems business. A fall in sales to defense customers led to AAR posting lower revenue in the year ended May 31, the first decline in four years. The company's revenue has missed market estimates for four of the past six quarter.Citi is AAR's financial adviser and Winston & Strawn LLP is its legal adviser. They will also serve as advisers on the sale of the precision systems manufacturing business. Shares of AAR had risen 8.37 pct in the last 12 months through Friday's close of $29.91. The shares were untraded premarket on Monday.TransDigm's shares were also untraded premarket on Monday from their Friday close of $213.73.   (Reporting by Radhika Rukmangadhan in Bengaluru; Editing by Ted Kerr and Savio D'Souza)",2015-02-23,TDG,"Mon Feb 23, 2015 | 9:21am EST",UPDATE 1-AAR to sell cargo handling business to TransDigm for $725 mln,http://www.reuters.com//article/aar-ma-transdigm-group-idUSL4N0VX2X820150223?type=companyNews,0.4939,0.027,0.925,0.049
146,"  Feb 23 Aviation services provider AAR Corp  said it would sell its cargo handling business, Telair Cargo Group, to TransDigm Group Inc for $725 million in cash. AAR also said it intended to sell its money-losing precision systems manufacturing business and would record a related charge of about $40 million in the third quarter of 2015.     (Reporting by Radhika Rukmangadhan in Bengaluru; Editing by Ted Kerr)  ",2015-02-23,TDG,"Mon Feb 23, 2015 | 8:37am EST",AAR to sell cargo handling business to TransDigm for $725 mln,http://www.reuters.com//article/aar-ma-transdigm-group-idUSL4N0VX2V020150223?type=companyNews,0.0,0.0,1.0,0.0
147,"  May 10 Transdigm Group Inc* TransDigm Group Inc sees 2016 net sales to be in range of $3,151 million to $3,181 million* TransDigm Group Inc sees 2016 earnings per share to be in range of $9.89 to $10.13 per share based upon weighted average shares outstanding of 56.2 million* TransDigm Group Inc sees 2016 adjusted earnings per share to be in range of $11.04 to $11.28 per share * Fy2016 earnings per share view $10.82 -- Thomson Reuters I/B/E/S* TransDigm Group reports fiscal 2016 second quarter results * Q2 adjusted earnings per share $2.86 * Q2 earnings per share $2.47* Q2 sales $796.8 million versus I/B/E/S view $777.1 million* Q2 earnings per share view $2.58 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-10,TDG,"Tue May 10, 2016 | 7:25am EDT",BRIEF-TransDigm Group reports Q2 adj. earnings per share $2.86,http://www.reuters.com//article/idUSASC08ODA?type=companyNews,0.9628,0.0,0.833,0.167
148,"  Aircraft components maker TransDigm Group Inc (TDG.N) said on Tuesday it would buy ILC Holdings Inc from private equity firm Behrman Capital for $1 billion to expand its spare parts business.ILC is the parent of Data Device Corp (DDC), which supplies power control and databus products to the global military and commercial aerospace markets.Databuses help connect internal components of a computer. DDC's products are used in aircraft such as such as F-18 fighters, C-130 Hercules transports, Boeing's (BA.N) 787 and 777X passenger planes and Airbus's (AIR.PA) A350XWB. The company's main plant is in Bohemia, New York.TransDigm said DDC is expected to have revenue of more than $200 million in 2016, with about 75 percent coming from the defense market and the rest from the commercial aircraft market. Cleveland-based TransDigm makes cockpit security components and systems, aircraft audio systems and ignition systems for military and commercial aircraft. The deal is expected to close before the end of fiscal 2016, TransDigm said. (Reporting by Ankit Ajmera in Bengaluru; Editing by Ted Kerr)",2016-05-24,TDG,"Tue May 24, 2016 | 8:53am EDT",Aircraft parts maker TransDigm to buy ILC Holdings for $1 billion,http://www.reuters.com//article/us-ilc-holdings-m-a-transdigm-group-idUSKCN0YF1MN?type=companyNews,0.7717,0.007,0.942,0.051
149,"  Aircraft components maker TransDigm Group Inc (TDG.N) said on Tuesday it would buy ILC Holdings Inc from private equity firm Behrman Capital for $1 billion to expand its spare parts business.ILC is the parent of Data Device Corp (DDC), which supplies power control and databus products to the global military and commercial aerospace markets.Databuses help connect internal components of a computer. DDC's products are used in aircraft such as such as F-18 fighters, C-130 Hercules transports, Boeing's (BA.N) 787 and 777X passenger planes and Airbus's (AIR.PA) A350XWB. The company's main plant is in Bohemia, New York.TransDigm said DDC is expected to have revenue of more than $200 million in 2016, with about 75 percent coming from the defense market and the rest from the commercial aircraft market. Cleveland-based TransDigm makes cockpit security components and systems, aircraft audio systems and ignition systems for military and commercial aircraft. The deal is expected to close before the end of fiscal 2016, TransDigm said. (Reporting by Ankit Ajmera in Bengaluru; Editing by Ted Kerr)",2016-05-24,TDG,"Tue May 24, 2016 | 8:53am EDT",UPDATE 1-Aircraft parts maker TransDigm to buy ILC Holdings for $1 bln,http://www.reuters.com//article/ilc-holdings-ma-transdigm-group-idUSL3N18L3ST?type=companyNews,0.7717,0.007,0.942,0.051
150,  May 24 Transdigm Group Inc : * Behrman Capital to sell portfolio company Data Device Corporation to TransDigm group for $1 billion  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-24,TDG,"Tue May 24, 2016 | 8:26am EDT",BRIEF-Behrman Capital to sell Data Device Corp to TransDigm for $1 bln,http://www.reuters.com//article/idUSFWN18L056?type=companyNews,0.0,0.0,1.0,0.0
151,"  May 24 Aircraft components maker TransDigm Group Inc said on Tuesday it would buy ILC Holdings Inc from private equity firm Behrman Capital for $1 billion in cash. ILC Holdings is the parent of Data Device Corp, which supplies databus and power supply products to the global military and commercial aerospace markets.    (Reporting by Ankit Ajmera in Bengaluru; Editing by Ted Kerr)  ",2016-05-24,TDG,"Tue May 24, 2016 | 8:19am EDT",TransDigm to buy ILC Holdings for $1 bln,http://www.reuters.com//article/ilc-holdings-ma-transdigm-group-idUSL3N18L3RO?type=companyNews,0.0,0.0,1.0,0.0
152,"  May 24 Transdigm Group Inc :* Expects to finance acquisition through a combination of cash on hand, existing availability under our revolving credit facility and new debt * DDC revenues are anticipated to be over $200 million for fiscal year ending December 2016 * Total purchase price of $1.0 billion in cash * Transdigm to acquire data device corporation  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-05-24,TDG,"Tue May 24, 2016 | 8:16am EDT",BRIEF-Transdigm to acquire Data Device Corporation,http://www.reuters.com//article/idUSASC08R0B?type=companyNews,0.7783,0.034,0.838,0.128
153,"  May 25 TransDigm Group Inc :* Transdigm Group announces proposed private offering of $950 million senior subordinated notes * Transdigm Group Inc says its unit is planning, to offer $950 million aggregate principal amount of senior subordinated notes due 2026  * Transdigm Group Inc says intends to use a portion of net proceeds from offering of notes and term loans to fund purchase price for DDC acquisition  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-05-25,TDG,"Wed May 25, 2016 | 8:28am EDT",BRIEF-Transdigm group announces proposed private offering of $950 million senior subordinated notes,http://www.reuters.com//article/idUSASC08R7H?type=companyNews,0.5423,0.0,0.954,0.046
154,"  May 27 S&P Dow Jones Indices : * Transdigm Group Inc will replace Baxalta Inc in the S&P 500 after the close of trading on Thursday, June 2  Source text - bit.ly/22roP74    (Bengaluru Newsroom: +1 646 223 8780)  ",2016-05-27,TDG,"Fri May 27, 2016 | 5:24pm EDT",BRIEF-S&P Dow Jones Indices says Transdigm Group will replace Baxalta Inc in the S&P 500,http://www.reuters.com//article/idUSFWN18O0DU?type=companyNews,0.0,0.0,1.0,0.0
155,"  June 9 Transdigm Group Inc* Unit received funding of an additional term loan of $500 million maturing in 2023 at a current rate of 3.75% * Unit received commitments of a delayed draw term loan of $450 million , converted $790 million of existing tranche c term loans into tranche f term loans * Portion of proceeds will be used to fund purchase price of acquisition of ilc holdings, inc. * Transdigm group completes successful additional term loan and notes offering  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom; +1 646 223 8780)",2016-06-09,TDG,"Thu Jun 9, 2016 | 5:36pm EDT",BRIEF-Transdigm Group says its Unit received funding of an additional term loan of $500 mln,http://www.reuters.com//article/idUSASC08TJD?type=companyNews,0.5267,0.021,0.919,0.059
156,  Sept 6 Transdigm Group Inc * Transdigm to acquire Young & Franklin Inc. And Tactair Fluid Controls Inc.  Source text for Eikon:  Further company coverage:  ,2016-09-06,TDG,"Tue Sep 6, 2016 | 4:37pm EDT",BRIEF-TransDigm to acquire Young & Franklin and Tactair Fluid Controls,http://www.reuters.com//article/idUSFWN1BI0J9?type=companyNews,0.0,0.0,1.0,0.0
157,"  Oct 4 TransDigm Group Inc :* TransDigm announces proposed new term loan, considers paying special dividend and provides update on estimated fiscal 2016 results* Considering paying a cash dividend in range of $1.1 billion to $1.5 billion with proceeds of proposed new term loan * Expects fiscal 2016 EBITDA as defined to be at or modestly above midpoint of previously stated guidance range * Based on preliminary expectations, August 9, 2016 guidance still appears to be materially correct * Seeking to increase its existing term loan facility by an additional $650 million term loan* Expects fiscal 2016 net sales to be at or slightly below low end of guidance range  Source text for Eikon:  Further company coverage:",2016-10-04,TDG,"Tue Oct 4, 2016 | 8:42am EDT",BRIEF-TransDigm reports proposed new term loan,http://www.reuters.com//article/idUSASC09A44?type=companyNews,0.7703,0.015,0.913,0.072
158,"  Oct 6 Transdigm Group Inc : * TransDigm announces retirement of Gregory Rufus, current senior executive vice president and former chief financial officer, effective October 1, 2016  Source text for Eikon:  Further company coverage:  ",2016-10-06,TDG,"Thu Oct 6, 2016 | 8:47am EDT",BRIEF-Transdigm reports retirement of Gregory Rufus,http://www.reuters.com//article/idUSASC09AE3?type=companyNews,0.4767,0.0,0.906,0.094
159,"  Oct 13 Transdigm Group Inc :* Transdigm Group announces tender offer for any and all of its 7.50 pct senior subordinated notes due 2021 * ""Total consideration"" for each $1,000 principal amount of notes validly tendered, and not validly withdrawn, is $1060.50 * Tender offer to purchase will expire on November 10, 2016 * Co's unit Transdigm has commenced cash tender offer for any and all of its outstanding 7.50 pct senior subordinated notes due 2021  Source text for Eikon:  Further company coverage:",2016-10-13,TDG,"Thu Oct 13, 2016 | 2:02pm EDT",BRIEF-Transdigm announces tender offer for its 7.50% senior subordinated notes due 2021,http://www.reuters.com//article/idUSASC09B3H?type=companyNews,0.8402,0.0,0.895,0.105
160,  Oct 14 Transdigm Group Inc * Transdigm group declares a special cash dividend of $24.00 per share and announces successful completion of incremental term loan  Source text for Eikon:  Further company coverage:  ,2016-10-14,TDG,"Fri Oct 14, 2016 | 4:25pm EDT",BRIEF-Transdigm declares a special cash dividend of $24.00 per share,http://www.reuters.com//article/idUSASC09B8F?type=companyNews,0.8271,0.0,0.756,0.244
161,"  Nov 23 Transdigm Group Inc * Transdigm-Entered new $500 million interest rate swap at a fixed rate of 1.9%, new $450 million interest rate cap at a fixed rate of 2.5% - SEC filing  Source text: [bit.ly/2g3hitx] Further company coverage:  ",2016-11-23,TDG,"Wed Nov 23, 2016 | 9:26am EST",BRIEF-Transdigm entered new $500 mln interest rate swap at a fixed rate of 1.9 pct,http://www.reuters.com//article/idUSFWN1DO0DR?type=companyNews,0.7184,0.0,0.85,0.15
